,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2023-01-08,69.33184051513672,2023-01-15,69.60603332519531,0.003954789141920045,U1,[],"{""assetTurnoverTTM"": 0.4578, ""bookValue"": 37037, ""cashRatio"": 0.23451108660099645, ""currentRatio"": 0.8593, ""ebitPerShare"": 0.7013, ""eps"": 0.5776, ""ev"": 244754.5601, ""fcfMargin"": 0.1645, ""fcfPerShareTTM"": 4.6696, ""grossMargin"": 0.7843, ""inventoryTurnoverTTM"": 1.2744, ""longtermDebtTotalAsset"": 0.238, ""longtermDebtTotalCapital"": 0.3465, ""longtermDebtTotalEquity"": 0.6201, ""netDebtToTotalCapital"": 0.3481, ""netDebtToTotalEquity"": 0.6228, ""netMargin"": 0.0804, ""operatingMargin"": 0.0976, ""pb"": 5.9856, ""peTTM"": 67.444, ""pfcfTTM"": 30.6327, ""pretaxMargin"": 0.0694, ""psTTM"": 4.9986, ""quickRatio"": 0.6806, ""receivablesTurnoverTTM"": 4.3987, ""roaTTM"": 0.0339, ""roeTTM"": 0.091, ""roicTTM"": 0.0499, ""rotcTTM"": 0.057, ""salesPerShare"": 7.184, ""sgaToSale"": 0.2157, ""totalDebtToEquity"": 0.7893, ""totalDebtToTotalAsset"": 0.303, ""totalDebtToTotalCapital"": 0.4411, ""totalRatio"": 1.623, ""period"": ""2022-12-31""}"
1,2023-01-15,69.60603332519531,2023-01-22,67.71605682373047,-0.027152481059148803,D3,[],"{""assetTurnoverTTM"": 0.4578, ""bookValue"": 37037, ""cashRatio"": 0.23451108660099645, ""currentRatio"": 0.8593, ""ebitPerShare"": 0.7013, ""eps"": 0.5776, ""ev"": 244754.5601, ""fcfMargin"": 0.1645, ""fcfPerShareTTM"": 4.6696, ""grossMargin"": 0.7843, ""inventoryTurnoverTTM"": 1.2744, ""longtermDebtTotalAsset"": 0.238, ""longtermDebtTotalCapital"": 0.3465, ""longtermDebtTotalEquity"": 0.6201, ""netDebtToTotalCapital"": 0.3481, ""netDebtToTotalEquity"": 0.6228, ""netMargin"": 0.0804, ""operatingMargin"": 0.0976, ""pb"": 5.9856, ""peTTM"": 67.444, ""pfcfTTM"": 30.6327, ""pretaxMargin"": 0.0694, ""psTTM"": 4.9986, ""quickRatio"": 0.6806, ""receivablesTurnoverTTM"": 4.3987, ""roaTTM"": 0.0339, ""roeTTM"": 0.091, ""roicTTM"": 0.0499, ""rotcTTM"": 0.057, ""salesPerShare"": 7.184, ""sgaToSale"": 0.2157, ""totalDebtToEquity"": 0.7893, ""totalDebtToTotalAsset"": 0.303, ""totalDebtToTotalCapital"": 0.4411, ""totalRatio"": 1.623, ""period"": ""2022-12-31""}"
2,2023-01-22,67.71605682373047,2023-01-29,64.1711196899414,-0.0523500230235906,D5+,[],{}
3,2023-01-29,64.1711196899414,2023-02-05,62.12446212768555,-0.03189374865429795,D4,"[{""date"": ""2023-01-29"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""U.S. Appeals Court Sides With Drugmakers on Discount Program"", ""summary"": ""The court ruled that drugmakers can limit their shipments of federally discounted drugs to pharmacies, in a blow to hospitals and clinics.""}, {""date"": ""2023-01-30"", ""headline"": ""UPDATE 1-Drugmakers prevail in dispute over U.S. discount drug program"", ""summary"": ""Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.  The ruling from a three-judge panel of the 3rd U.S. Circuit Court of Appeals based in Philadelphia is a victory for Sanofi SA, Novo Nordisk AS and AstraZeneca PLc .  The companies had sued the U.S. Department of Health and Human Services (HHS) after it ordered them to stop restricting sales of discounted drugs to so-called contract pharmacies.""}, {""date"": ""2023-01-30"", ""headline"": ""Drugmakers prevail in dispute over U.S. discount drug program"", ""summary"": ""(Reuters) -Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.  The ruling from a three-judge panel of the 3rd U.S. Circuit Court of Appeals based in Philadelphia is a victory for Sanofi SA, Novo Nordisk AS and AstraZeneca PLc.  The companies had sued the U.S. Department of Health and Human Services (HHS) after it ordered them to stop restricting sales of discounted drugs to so-called contract pharmacies.""}, {""date"": ""2023-01-30"", ""headline"": ""15 Biggest Neuroscience Companies in the World"", ""summary"": ""In this article, we will discuss the 15 Biggest Neuroscience Companies in the World. You can skip our industry overview and go directly to the 5 Biggest Neuroscience Companies in the World. As the name suggests, neuroscience concerns itself with the development, structure, and functions of the nervous system, intending to enhance neurological health. According [\u2026]""}, {""date"": ""2023-01-30"", ""headline"": ""Merck (MRK) to Report Q4 Earnings: What's in the Cards?"", ""summary"": ""Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.""}, {""date"": ""2023-01-30"", ""headline"": ""Is AstraZeneca PLC (AZN) a High Growth Stock?"", ""summary"": ""Baron Funds, an investment management company, released its \u201cBaron Health Care Fund\u201d fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P [\u2026]""}, {""date"": ""2023-01-30"", ""headline"": ""Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""AstraZeneca begins late-stage trial of datopotamab, Keytruda combo for NSC lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""Cantor biotech/biopharma analysts hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""WHO maintains public health emergency on COVID but sees `inflexion point` ahead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""Diabetes drug developer Structure Therapeutics sets terms for $125M US IPO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-01"", ""headline"": ""Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints"", ""summary"": ""Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.""}, {""date"": ""2023-02-01"", ""headline"": ""3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023"", ""summary"": ""Top dividend stocks are capable of delivering above-average returns returns in any type of market.  Which dividend stocks are no-brainer buys for retail investors right now?  AstraZeneca (NASDAQ: AZN), Merck (NYSE: MRK), and Medtronic (NYSE: MDT) are three elite income stocks that have recession-proof businesses, strong growth prospects, and ample free cash flows.""}, {""date"": ""2023-02-01"", ""headline"": ""AZN Crosses Below Key Moving Average Level"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-02"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $63.15, moving -0.65% from the previous trading session.""}, {""date"": ""2023-02-02"", ""headline"": ""GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod"", ""summary"": ""GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.""}, {""date"": ""2023-02-02"", ""headline"": ""TEZSPIRE\u00ae approved for self-administration in the US with a new pre-filled pen"", ""summary"": ""WILMINGTON, Del., February 02, 2023--AstraZeneca and Amgen\u2019s TEZSPIRE\u00ae (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1""}]",{}
4,2023-02-05,62.12446212768555,2023-02-12,67.45165252685547,0.08575028606639434,U5+,"[{""date"": ""2023-02-05"", ""headline"": ""PRESS DIGEST-British Business - Feb 6"", ""summary"": ""The following are the top stories on the business pages of British newspapers.  The Times - The UK is losing out on investment from AstraZeneca Plc to more competitive countries, Tom Keith-Roach, the head of the company, warned.  - A British semiconductor company, IQE Plc could move overseas unless the government sets out its strategy for the sector in the next six months, its chief executive said.""}, {""date"": ""2023-02-06"", ""headline"": ""Hutchmed: We Explore Pharma In China"", ""summary"": ""HUTCHMED (China) being a part of CK Hutchison Holdings, a huge conglomerate, is developing well. Read more on HCM stock here.""}, {""date"": ""2023-02-07"", ""headline"": ""AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?"", ""summary"": ""Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.""}, {""date"": ""2023-02-07"", ""headline"": ""AstraZeneca says Forxiga approved in EU for heart failure"", ""summary"": ""AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.""}, {""date"": ""2023-02-08"", ""headline"": ""AstraZeneca Swung to 4Q Profit, But Covid-19 Shot Decline Hit Revenue -- Update"", ""summary"": ""By Cecilia Butini AstraZeneca PLC on Thursday posted a swing to fourth-quarter profit, though it reported lower revenue due to declining sales of its...""}, {""date"": ""2023-02-08"", ""headline"": ""AstraZeneca Q4 core earnings beat estimates despite easing COVID vaccine demand"", ""summary"": ""By Scott Kanowsky""}, {""date"": ""2023-02-08"", ""headline"": ""AstraZeneca PLC 4Q EPS 58c"", ""summary"": ""Corrections &amp; Amplifications This headline was corrected at 0928 GMT to reflect AstraZeneca 4Q Adj EPS $1.38, not 4Q Adj Loss/Shr $17.00 By Cecilia...""}, {""date"": ""2023-02-08"", ""headline"": ""PepsiCo, AstraZeneca, PayPal earnings: 3 things to watch"", ""summary"": ""By Liz Moyer""}, {""date"": ""2023-02-08"", ""headline"": ""AstraZeneca Expected to Swing to 4Q Profit -- Earnings Preview"", ""summary"": ""By Cecilia Butini AstraZeneca PLC is scheduled to report results for the fourth quarter on Feb 9. Here is what you need to know: SALES FORECAST: Sales at the...""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca Plc (AZN) Q4 2022 Earnings Call Transcript"", ""summary"": ""Before I hand the call over to AstraZeneca, I'd like to read the safe harbor statement.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.  Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.""}, {""date"": ""2023-02-09"", ""headline"": ""As Brits reel from a cost-of-living crisis, the UK stock market quietly booms to an all-time high"", ""summary"": ""The FTSE 100 has hit three all-time highs over the last week, despite continued gloom on the U.K. economy and amid a cost-of-living crisis. ""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca Hits Its Stride On Upbeat Guidance With 'Desirable' Growth"", ""summary"": ""AstraZeneca's earnings topped forecasts Thursday, but sales came in light. AZN stock rose on its upbeat 2023 guidance.""}, {""date"": ""2023-02-09"", ""headline"": ""Garage demolition underway at AstraZeneca\u2019s future Kendall Square home"", ""summary"": ""It's the first step on a years-long, billion-dollar path to build a new research center for the life sciences giant.""}, {""date"": ""2023-02-09"", ""headline"": ""Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates"", ""summary"": ""Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.""}, {""date"": ""2023-02-09"", ""headline"": ""Omicron strains remain dominant globally, and the WHO is monitoring four closely"", ""summary"": ""The omicron strain of the coronavirus that causes COVID and its descendent lineages are still dominant globally, and XBB.1.5 is under monitoring.""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca snubs Britain over \u00a3320m drug factory amid \u2018discouraging\u2019 taxes"", ""summary"": ""AstraZeneca overlooked Britain for a new $400m (\u00a3320m) drug factory because of its \u201cdiscouraging\u201d tax regime, chief executive Pascal Soriot has said.""}, {""date"": ""2023-02-09"", ""headline"": ""Market check: Google stock falls, AstraZeneca stock trades higher amid earnings"", ""summary"": ""Yahoo Finance Live\u2019s Brad Smith breaks down how stocks are moving in intraday trading.""}, {""date"": ""2023-02-09"", ""headline"": ""2 Top Biotech Stocks to Buy Right Now"", ""summary"": ""For today, let's highlight two high-quality pharmaceutical stocks that investors may want to consider buying and holding for the long run.  With over 83,000 employees throughout the world, AstraZeneca (NASDAQ: AZN) is a truly global business.  As you would expect from a large-cap pharmaceutical company, AstraZeneca boasts world-class products.""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade"", ""summary"": ""AstraZeneca Plc (NASDAQ: AZN) has reported Q4 core EPS of $1.38, down 17% Y/Y (-5% constant currency). The company clocked Q4 sales of $11.21 billion, -7% (+1% CC), in line with the consensus. The core gross margin of 77% in the fourth quarter was impacted by inventory write-downs and manufacturing termination fees for Evusheld, its COVID-19 treatment. Fourth-quarter revenue was also hurt by a decline in sales of AstraZeneca's COVID-19 vaccine Vaxzevria. \""In 2023, we expect to see another year o""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca Has a Covid Sales Problem. Its Stock Doesn\u2019t."", ""summary"": ""The Anglo-Swedish pharma major reported 1% revenue growth as cancer and cardiovascular therapies offset a decline in sales of its Vaxzevria vaccine.""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca (AZN) Q4 Earnings Beat, Sales Hurt by COVID Jab"", ""summary"": ""AstraZeneca (AZN) beats fourth-quarter estimates for earnings while missing the same for sales.""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca chief says industry should not pay for NHS Covid costs"", ""summary"": ""AstraZeneca\u2019s chief executive said the pharmaceuticals industry should not be made to pay for the \u201cexplosion\u201d of NHS costs related to the Covid pandemic, as drugmakers ramp up their criticism of the UK government.  Pascal Soriot said the pricing agreement reached with the industry in 2019 \u2014 which stated the NHS would not have to pay more than a 2 per cent increase each year for branded drugs, however much it buys \u2014 did not take account of soaring demand from treating Covid patients.  The UK health department\u2019s clawback rose from about 5-10 per cent before the pandemic to 26.5 per cent this year, prompting other pharmaceutical chief executives to warn that it could hit life sciences investment in the UK.""}, {""date"": ""2023-02-09"", ""headline"": ""UPDATE 2-European shares gain as upbeat earnings ease recession fears"", ""summary"": ""The pan-European STOXX 600 ended up 0.6%, after hitting a near one-year high earlier in the session.  Industrials were the biggest to boost to the index, bolstered by a 6.7% gain in Siemens after the builder of trains and industrial software reported better-than-expected earnings and raised its full-year sales and profit guidance.  AstraZeneca Plc rose 4.1% after the British drugmaker projected growth in 2023 and beyond.""}, {""date"": ""2023-02-09"", ""headline"": ""How To Allocate $5,000 Among 5 Dividend Income And Dividend Growth Stocks And ETFs"", ""summary"": ""In this article, I will show you a portfolio that consists of 5 picks that provide you with Dividend Income and Dividend Growth. Read more here.""}, {""date"": ""2023-02-09"", ""headline"": ""FTSE 100: Astrazeneca swings into profit amid double-digit revenue rise"", ""summary"": ""AstraZeneca posted adjusted earnings of $1.38 per share on revenue of $12.2bn.""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca Beat Expectations on 4Q Profit, But Revenue Is a Miss -- Earnings Review"", ""summary"": ""By Cecilia Butini AstraZeneca PLC reported fourth-quarter results on Thursday. Here is what we watched. REVENUE: Sales at the Anglo-Swedish pharma major...""}, {""date"": ""2023-02-09"", ""headline"": ""As demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023"", ""summary"": ""Demand for Covid-19 vaccines has dropped, but AstraZeneca has \""blockbuster\"" projects in development that are set to make billions of dollars, according to its CFO.""}, {""date"": ""2023-02-09"", ""headline"": ""AstraZeneca goes for growth with new drugs as COVID sales wane"", ""summary"": ""AstraZeneca on Thursday said it was poised to grow in 2023 and beyond, banking on its burgeoning line-up of cancer, metabolic and rare disease drugs to pick up the pace from dwindling COVID product sales.  CEO Pascal Soriot said the firm was on a path to deliver at least 15 new medicines this decade and said it expects to kick off at least thirty new late-stage clinical trials in 2023.  But like many other industries and its own peers, AstraZeneca has grappled with higher costs linked to the war in Ukraine and the lingering effects of the pandemic in 2022.""}, {""date"": ""2023-02-10"", ""headline"": ""Super Bowl ads boost sales of drugs, yet only two companies advertising this year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""AstraZeneca PLC (NASDAQ:AZN) Q4 2022 Earnings Call Transcript"", ""summary"": ""AstraZeneca PLC (NASDAQ:AZN) Q4 2022 Earnings Call Transcript February 9, 2023 Operator: Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe and good evening to those listening in Asia. Welcome, ladies and gentlemen, to AstraZeneca\u2019s Full Year and Q4 2022 Results Conference Call for investors and [\u2026]""}, {""date"": ""2023-02-10"", ""headline"": ""Sunak is putting Britain\u2019s life sciences success at risk, warns Covid jab creator"", ""summary"": ""Rishi Sunak risks squandering Britain's post-pandemic lead in life sciences, one of the creators of the Oxford Covid-19 vaccine has warned, as ministers are hit with an industry backlash over \""discouraging\"" tax policies.""}, {""date"": ""2023-02-10"", ""headline"": ""Jeremy Hunt has made Britain a no-go area for investment"", ""summary"": ""The timing couldn\u2019t be more perfect. On Friday, Rishi Sunak and Jeremy Hunt hosted a summit of more than 200 prominent business figures as part of efforts to drum up fresh investment into Britain. And what better backdrop than one of the biggest snubs this Government has ever suffered? AstraZeneca\u2019s usually restrained boss Sir Pascal Soriot confirmed that the pharma giant had chosen to build a new state-of-the-art factory in Dublin rather than the north-west of England because of the Treasury\u2019s""}, {""date"": ""2023-02-10"", ""headline"": ""IN THE KNOW: AstraZeneca late-stage pipeline impresses Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO"", ""summary"": ""AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.""}, {""date"": ""2023-02-10"", ""headline"": ""LONDON MARKET CLOSE: Rate worries keep European stocks in check"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""AZN June 16th Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""AstraZeneca PLC 2022 Q4 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by AstraZeneca PLC in conjunction with their 2022 Q4 earnings call.""}, {""date"": ""2023-02-10"", ""headline"": ""GLOBAL BROKER RATINGS: LBBW raises Siemens; Jefferies cuts Adidas"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: AstraZeneca (AZN), AbbVie (ABBV)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""Medicare mulls rebates in 2025 for drug prices rising faster than inflation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-10"", ""headline"": ""UPDATE: Hunt disappointed UK loses new AstraZeneca factory to Ireland"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""AstraZeneca (AZN) Declares $0.98 Dividend"", ""summary"": """"}, {""date"": ""2023-02-12"", ""headline"": ""AstraZeneca: Strong 2022 Growth Bodes Well"", ""summary"": ""AstraZeneca's stock might have sagged in January, but it got a boost recently after its 2022 earnings release. Click here to read why I\u00e2\u0080\u0099d buy AZN.""}, {""date"": ""2023-02-12"", ""headline"": ""AstraZeneca's (LON:AZN) Dividend Will Be $1.45"", ""summary"": ""AstraZeneca PLC ( LON:AZN ) will pay a dividend of $1.45 on the 27th of March. Based on this payment, the dividend...""}]",{}
5,2023-02-12,67.45165252685547,2023-02-19,67.539794921875,0.0013067492302645256,U1,"[{""date"": ""2023-02-12"", ""headline"": ""AstraZeneca (AZN) Declares $0.98 Dividend"", ""summary"": """"}, {""date"": ""2023-02-12"", ""headline"": ""AstraZeneca: Strong 2022 Growth Bodes Well"", ""summary"": ""AstraZeneca's stock might have sagged in January, but it got a boost recently after its 2022 earnings release. Click here to read why I\u00e2\u0080\u0099d buy AZN.""}, {""date"": ""2023-02-12"", ""headline"": ""AstraZeneca's (LON:AZN) Dividend Will Be $1.45"", ""summary"": ""AstraZeneca PLC ( LON:AZN ) will pay a dividend of $1.45 on the 27th of March. Based on this payment, the dividend...""}, {""date"": ""2023-02-13"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR advanced 1.20% to $69.71 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-13"", ""headline"": ""AstraZeneca rises Monday, still underperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.28% to \u00a3114.22 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-02-13"", ""headline"": ""AstraZeneca, SOPHiA team up to use AI, machine learning in cancer drugs development"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Sophia  expands deal with AstraZeneca to include MM approaches to oncology"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""LONDON BROKER RATINGS: Bryan Garnier starts Unilever with 'neutral'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.90% higher to $70.34 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-14"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.84% to \u00a3115.18 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-02-14"", ""headline"": ""SVB Securities Sticks to Their Buy Rating for AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Compugen: Rilvegostomig expected to progress into Phase 3 this year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""UK drug pricing watchdog declines to recommend AstraZeneca`s COVID therapy Evusheld"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR shed 0.92% to $69.69 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-15"", ""headline"": ""Novo Nordisk: Attractive Market But Likely No Margin Of Safety"", ""summary"": ""Novo Nordisk is the only pure-play and a market leader in the diabetes and obesity care space. Click here to read my most recent analysis of NVO stock.""}, {""date"": ""2023-02-15"", ""headline"": ""Medicare mulls limiting per month costs for generic drugs at $2"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Panel backs moving opioid antidote Narcan over the counter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""AstraZeneca rises Wednesday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.43% to \u00a3115.68 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-02-15"", ""headline"": ""AstraZeneca's Evusheld not recommended by NHS for vulnerable people"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""GLOBAL BROKER RATINGS: HBSC cuts Michelin; Bryan Garnier likes Danone"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slipped 2.50% to $67.95 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-16"", ""headline"": ""AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium"", ""summary"": ""WILMINGTON, Del., February 16, 2023--Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-resistant prostate cancer (mCRPC) showed LYNPARZA\u00ae (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada in combination with abiraterone and prednisone or prednisolone demonstrated median OS of 42.1 months versus 34.7 months for abiraterone plus placebo. This result re""}, {""date"": ""2023-02-16"", ""headline"": ""Moderna, Pfizer, BioNTech Covid jab patent dispute heads to 2024 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""U.K. stocks rise for fourth session"", ""summary"": ""U.K. stocks finished up Thursday, with the FTSE 100 Index rising 0.18% at 8,012.53. Of the FTSE 100 constituents, major international banks company Standard...""}, {""date"": ""2023-02-16"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC shed 1.78% to \u00a3113.62 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-02-16"", ""headline"": ""AstraZeneca, Merck present final results from Phase III PROpel trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""Merck, AstraZeneca present final results from Phase 3 PROpel trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""3 Stocks To Buy As U.S. Inflation Stays Sticky"", ""summary"": ""There was good news and bad news on the US inflation front for January 2023. Read more to see 3 stocks to buy in the current situation.""}, {""date"": ""2023-02-16"", ""headline"": ""Pfizer, GSK to face FDA AdCom meetings for RSV vaccines from late February"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""AstraZeneca: Reiterate Our Growth Pick"", ""summary"": ""AstraZeneca, profit beats expectations, but revenues are down due to lower COVID-19 sales. See why we recommend a buy on AZN stock.""}, {""date"": ""2023-02-16"", ""headline"": ""MannKind: The Continuing Saga Of What They Say Vs. What They Do"", ""summary"": ""As we approach another pivotal point for MannKind I thought it might be good to review the history of the company. See why I rate MNKD stock a Hold now.""}, {""date"": ""2023-02-17"", ""headline"": ""COVID vaccine sales to see decline through end of decade as pandemic eases"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Steven Cohen\u2019s Point72 Hedge Fund Backs Salesforce, Broadcom And Meta While Cutting Palo Alto And Workday Stakes"", ""summary"": """"}, {""date"": ""2023-02-17"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR advanced 1.50% to $68.97 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-02-17"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC advanced 1.09% to \u00a3114.86 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-02-17"", ""headline"": ""UK dividends calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""10 Sectors Likely To Generate Good Returns In The Next Decade"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""This chart offers one reason that European stocks may continue to outperform U.S. equities"", ""summary"": ""One of the stories for markets this year has been the outperformance of European stocks to U.S. ones""}, {""date"": ""2023-02-17"", ""headline"": ""9 February Inflation-Busting Ideal Dividend Dogs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Campbell & CO Investment Adviser LLC Buys 1, Sells 4 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
6,2023-02-19,67.539794921875,2023-02-26,65.9370346069336,-0.023730606774796437,D3,"[{""date"": ""2023-02-20"", ""headline"": ""AstraZeneca reports protection against RSV in infants with Beyfortus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-20"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.47% to \u00a3115.40 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-02-21"", ""headline"": ""TOP NEWS: AstraZeneca wins three approvals in EU for cancer drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""AstraZeneca`s blood cancer drug Calquence`s tablet form gets approval in EU"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""AstraZeneca Imfinzi, Imjudo combo gets approval in EU to treat liver, lung cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.90% higher to $69.59 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-02-21"", ""headline"": ""AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.26% to \u00a3115.70 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-02-21"", ""headline"": ""Ex-Dividend Reminder: AstraZeneca, STERIS and Baxter International"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""BRIDGER MANAGEMENT, LLC Buys 1, Sells 4 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""Top 5 4th Quarter Trades of HOWE & RUSLING INC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""LONDON BROKER RATINGS: BoA cuts DS Smith; Jefferies likes JTC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""AstraZeneca to pay KYM $63M upfront in license deal for potential gastric cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""AstraZeneca signs USD63 million agreement to address gastric cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""AstraZeneca Signs License Agreement With KYM Biosciences for Gastric Cancer Therapy"", ""summary"": ""By Michael Susin AstraZeneca PLC said Thursday that it has entered into an agreement with KYM Biosciences Inc. regarding an exclusive license agreement for a...""}, {""date"": ""2023-02-22"", ""headline"": ""LONDON MARKET EARLY CALL: Stocks to rise after uneventful Fed minutes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 1.06% to $68.85 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-22"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.61% to \u00a3115.00 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE...""}, {""date"": ""2023-02-22"", ""headline"": ""UK dividends calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""AstraZeneca reports Imfinzi plus Imjudo approved in EU for NSCLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""AstraZeneca says Calquence tablet formulation approved in EU for CLL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""ADRs End Higher; Alibaba, AstraZeneca Trade Actively"", ""summary"": ""By Denny Jacob International stocks trading in New York closed higher on Thursday. The S&P/BNY Mellon index of American depositary receipts edged up 0.5% to...""}, {""date"": ""2023-02-23"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.71% to $67.40 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-23"", ""headline"": ""Top Research Reports for Exxon Mobil, Coca-Cola & AstraZeneca"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), The Coca-Cola Company (KO) and AstraZeneca PLC (AZN).""}, {""date"": ""2023-02-23"", ""headline"": ""Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down"", ""summary"": ""Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.""}, {""date"": ""2023-02-23"", ""headline"": ""Interesting AZN Put And Call Options For April 6th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC shed 1.12% to \u00a3112.10 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-02-23"", ""headline"": ""LONDON MARKET CLOSE: FTSE 100 struggles, but European peers rise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""AstraZeneca announces license agreement with KYM Biosciences for CMG901"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""AstraZeneca PLC ADR outperforms market despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR shed 1.53% to $66.37 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-02-24"", ""headline"": ""Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo"", ""summary"": ""FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.""}, {""date"": ""2023-02-24"", ""headline"": ""AstraZeneca prices two EUR750 million fixed-rate notes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""SVB Securities Reaffirms Their Buy Rating on AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.98% to \u00a3111.00 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE...""}, {""date"": ""2023-02-24"", ""headline"": ""TOP NEWS: AstraZeneca closes CinCor buy; Enhertu wins Chinese approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""The Zacks Analyst Blog Highlights ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard"", ""summary"": ""ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard are included in this Analyst Blog.""}, {""date"": ""2023-02-24"", ""headline"": ""Ambrx Biopharma drops 17% to end rally ahead of investor day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""AstraZeneca completes acquisition of CinCor Pharma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""AstraZeneca reports Enhertu approved in China for metastatic breast cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca"", ""summary"": ""Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca. Read more here...""}, {""date"": ""2023-02-26"", ""headline"": ""Baron International Growth Fund Q4 2022 Quarterly Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Baron Health Care Fund Q4 2022 Quarterly Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
7,2023-02-26,65.9370346069336,2023-03-05,64.774658203125,-0.017628581733130644,D2,"[{""date"": ""2023-02-26"", ""headline"": ""Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca"", ""summary"": ""Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca. Read more here...""}, {""date"": ""2023-02-26"", ""headline"": ""Baron International Growth Fund Q4 2022 Quarterly Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Baron Health Care Fund Q4 2022 Quarterly Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-27"", ""headline"": ""Are You Looking for a High-Growth Dividend Stock?"", ""summary"": ""Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.""}, {""date"": ""2023-02-27"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.65% higher to $66.80 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-02-27"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.02% to \u00a3110.98 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2023-02-28"", ""headline"": ""50 Biggest Public Companies in the World"", ""summary"": ""In this article, we will be taking a look at the 50 biggest public companies in the world. To skip our detailed analysis, you can go directly to see the 10 biggest public companies in the world. While much maligned, and often rightly so, the biggest public companies in the world aren\u2019t just intrinsically linked [\u2026]""}, {""date"": ""2023-02-28"", ""headline"": ""11 Most Promising Cancer Stocks According to Analysts"", ""summary"": ""In this article, we discuss 11 most promising cancer stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Cancer Stocks According to Analysts. The market for community oncology services worldwide is projected to experience substantial growth, with an estimated increase from $47.95 billion in 2022 [\u2026]""}, {""date"": ""2023-02-28"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 2.43% to $65.18 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-28"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slipped 1.96% to \u00a3108.80 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-02-28"", ""headline"": ""Merck Keytruda combo fails lung cancer trial, sees another setback in prostate cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""Valneva COVID shot shelf life extended; gets EMA nod for booster; shows efficacy in trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""The AstraZeneca PLC ADR inched 0.05% higher to $65.21 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-03-01"", ""headline"": ""IN BRIEF: AstraZeneca prices three tranche global bond offering"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.59% to \u00a3108.16 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-03-01"", ""headline"": ""FBI Director says novel coronavirus likely originated from China lab leak"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023"", ""summary"": ""WILMINGTON, Del., March 02, 2023--Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological diseases at the American Academy of Neurology (AAN) Annual Meeting, April 22-27, 2023. The company will present 19 abstracts, including eight oral presentations, across generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), Wilson disease and dermatomyositis.""}, {""date"": ""2023-03-02"", ""headline"": ""Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program"", ""summary"": ""As previously announced, Valneva SE (NASDAQ: VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new partnership. However, it is completing the remaining clinical studies and submissions. Last week, the Committee for Medicinal Products for Human Use of the European Medicines Agency backed VLA2001 approval in adults as a booster dose after at least seven months following primary vaccination with VLA2001 (homologous booster dose) or with an adenoviral vector""}, {""date"": ""2023-03-02"", ""headline"": ""AstraZeneca PLC ADR underperforms Thursday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slid 0.17% to $65.10 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-02"", ""headline"": ""UPDATE 1-U.S. FDA panel to review expanded use of Merck-AstraZeneca's cancer drug"", ""summary"": ""Merck & Co Inc and British drugmaker AstraZeneca PLC said on Thursday that an independent committee of advisers to the U.S. health regulator will review the companies' application for the expanded use of their drug Lynparza to treat an advanced form of prostate cancer.  The U.S. Food and Drug Administration's (FDA) committee is scheduled to meet on April 28.  The companies' are seeking approval of the drug Lynparza in combination with other medications \u2013 biraterone and prednisone or prednisolone \u2013for the treatment of a type of treatment-resistant prostate cancer in adult patients.""}, {""date"": ""2023-03-02"", ""headline"": ""US FDA to discuss AstraZeneca and Merck's Lynparza cancer drug combo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.44% to \u00a3108.64 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-03-02"", ""headline"": ""AstraZeneca (AZN) Receives a Buy from SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""AstraZeneca (AZN) Shares Cross Below 200 DMA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""AstraZeneca, Merck provide regulatory update on Lynparza sNDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Prenetics announces formation of scientific advisory board"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-03"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.15% higher to $65.20 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-03"", ""headline"": ""AstraZeneca's Trading Range Makes This Options Trade Appealing"", ""summary"": ""AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are going to be in a sideways grind, punishing speculation and...""}, {""date"": ""2023-03-03"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.74% to \u00a3107.84 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-03-04"", ""headline"": ""Lexicon Pharma: Advancing A Worthwhile Pipeline But Commercialization Remains A Key Risk"", ""summary"": ""Lexicon is getting closer to FDA approval for sotagliflozin. Click here to read my analysis of LXRX stock.""}, {""date"": ""2023-03-04"", ""headline"": ""Pharma R&D funding soared to a new record in 2022 as oncology candidates dominate pipelines"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""Those who invested in AstraZeneca (LON:AZN) five years ago are up 159%"", ""summary"": ""When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...""}]",{}
8,2023-03-05,64.774658203125,2023-03-12,63.77125549316406,-0.015490667767236954,D2,"[{""date"": ""2023-03-04"", ""headline"": ""Lexicon Pharma: Advancing A Worthwhile Pipeline But Commercialization Remains A Key Risk"", ""summary"": ""Lexicon is getting closer to FDA approval for sotagliflozin. Click here to read my analysis of LXRX stock.""}, {""date"": ""2023-03-05"", ""headline"": ""AstraZeneca, Daiichi Sankyo`s Enhertu shows promise in multiple cancer types in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""TOP NEWS: AstraZeneca hails Enhertu phase 2 trial results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""LONDON BRIEFING: Stocks called flat; AstraZeneca positive test results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""Those who invested in AstraZeneca (LON:AZN) five years ago are up 159%"", ""summary"": ""When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...""}, {""date"": ""2023-03-06"", ""headline"": ""Genomic Vision launches FiberSmart\u00ae, AI-powered software for automating genomic analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting"", ""summary"": ""AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) reported high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase 2 trial of Enhertu (trastuzumab deruxtecan) The study met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients. Related: AstraZeneca-Daiichi Sankyo's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer. En""}, {""date"": ""2023-03-06"", ""headline"": ""AstraZeneca PLC ADR underperforms Monday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.98% to $64.56 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-03-06"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.39% to \u00a3107.42 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE...""}, {""date"": ""2023-03-06"", ""headline"": ""ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial"", ""summary"": ""WILMINGTON, Del., March 06, 2023--Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo\u2019s ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients.""}, {""date"": ""2023-03-06"", ""headline"": ""4 AI Stocks That Are Revolutionizing Healthcare"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""AstraZeneca says cancer drug Enhertu showed positive results"", ""summary"": ""Enhertu--trastuzumab deruxtecan, which it is jointly developing and commercializing with Daiichi Sankyo--had met prespecified criteria for objective response rate and duration of response.""}, {""date"": ""2023-03-06"", ""headline"": ""AstraZeneca, Daiichi Sankyo announce Enhertu met the prespecified target for ORR"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""AstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slid 0.42% to $64.29 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-07"", ""headline"": ""Ionis, AstraZeneca eplontersen application accepted by FDA for nerve damage disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rallied 1.01% to \u00a3108.50 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-03-07"", ""headline"": ""Lexicon initiated at buy at Jefferies on uptake of heart failure candidate sotagliflozin"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study"", ""summary"": ""AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.""}, {""date"": ""2023-03-07"", ""headline"": ""Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Ionis: FDA to Review Eplontersen in ATTRv-PN >IONS"", ""summary"": ""By Colin Kellaher Ionis Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration will review its application seeking approval of its...""}, {""date"": ""2023-03-07"", ""headline"": ""Biden to announce plan to keep Medicare solvent beyond 2050"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Mineralys Therapeutics initiated with an Outperform at Evercore ISI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""AstraZeneca Tagrisso improves overall survival in lung cancer patients in phase 3 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""AstraZeneca`s Imfinzi shows event-free survival benefit in lung cancer patients in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""AstraZeneca Imfinzi Phase 3 Trial Returns Positive Results"", ""summary"": ""By Joe Hoppe AstraZeneca PLC said Thursday that a Phase 3 trial showed that its Imfinzi product significantly improved event-free survival in patients with...""}, {""date"": ""2023-03-08"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.26% to $64.12 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-08"", ""headline"": ""Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race"", ""summary"": ""Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies.""}, {""date"": ""2023-03-08"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.26% to \u00a3108.22 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-03-08"", ""headline"": ""Roche: Ongoing Pipeline Issues Sap Growth And Increase M&A Likelihood"", ""summary"": ""Roche hasn't scored the sort of big wins that change investment theses or drive lasting changes in sentiment. Find out our recommendation on RHHBY stock.""}, {""date"": ""2023-03-08"", ""headline"": ""3 No-Brainer Stocks to Buy With $400 Right Now"", ""summary"": ""A reasonably small amount of money can go a long way when it's invested in innovative businesses.""}, {""date"": ""2023-03-08"", ""headline"": ""Genprex's Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer"", ""summary"": ""Genprex has a strong financial position with zero debt and a cash balance of $29.52 million. Check out why I'm bullish on GNPX stock.""}, {""date"": ""2023-03-08"", ""headline"": ""Genprex`s Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Full Year 2022 Sophia Genetics SA Earnings Call"", ""summary"": ""Full Year 2022 Sophia Genetics SA Earnings Call""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZeneca (AZN) Receives a Buy from SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.03% to $64.10 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings"", ""summary"": ""AstraZeneca Plc (NASDAQ: AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The study included the adjuvant treatment of patients with early-stage (IB, II, and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. In May 2020, AstraZeneca anno""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients"", ""summary"": ""In a trial, lung cancer patients treated with AstraZeneca plc's (NASDAQ: AZN) immunotherapy Imfinzi (durvalumab) pre- and post-surgery lived significantly longer without the disease progressing or recurring than those treated with chemotherapy. The late-stage study compared patients with resectable, early-stage, non-small cell lung cancer treated with Imfinzi and chemotherapy before surgery and as monotherapy after surgery to patients treated with chemotherapy pre-surgery. Topline results from a""}, {""date"": ""2023-03-09"", ""headline"": ""5 Large Drug Stocks to Watch as Sector Picks Up in 2023"", ""summary"": ""Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.""}, {""date"": ""2023-03-09"", ""headline"": ""TAGRISSO\u00ae (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer"", ""summary"": ""WILMINGTON, Del., March 09, 2023--Positive high-level results from the ADAURA Phase III trial showed AstraZeneca\u2019s TAGRISSO\u00ae (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.""}, {""date"": ""2023-03-09"", ""headline"": ""IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer"", ""summary"": ""WILMINGTON, Del., March 09, 2023--Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo-controlled trial showed that treatment with AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy alone followed by surgery for patients with resecta""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZeneca announces ADAURA trial meets secondary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZeneca announces AEGEAN trial demonstrated statistical significance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZeneca says Tagrisso showed `strong` overall survival benefit in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZeneca says Imfinzi significantly improved event-free survival in AEGEAN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""AstraZeneca hails trial results of cancer drugs Imfinzi and Tagrisso"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-10"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.14% higher to $64.19 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-10"", ""headline"": ""AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies"", ""summary"": ""Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.""}, {""date"": ""2023-03-10"", ""headline"": ""AstraZeneca falls Friday, still outperforms market"", ""summary"": ""Shares of AstraZeneca PLC dropped 1.55% to \u00a3106.98 Friday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-03-10"", ""headline"": ""Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi"", ""summary"": ""J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.""}, {""date"": ""2023-03-10"", ""headline"": ""Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript"", ""summary"": ""Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen\u2019s Fourth Quarter and Full Year 2022 Results Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the Investors section [\u2026]""}]",{}
9,2023-03-12,63.77125549316406,2023-03-19,65.18199157714844,0.022121817628878215,U3,"[{""date"": ""2023-03-13"", ""headline"": ""Silence Therapeutics: Breaking The Silence On An Under-The-Radar Mid-Stage SiRNA Platform"", ""summary"": ""Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Read why we rate SLN stock a speculative Buy.""}, {""date"": ""2023-03-13"", ""headline"": ""Astrazeneca (AZN) Gains As Market Dips: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $65.18, moving +1.54% from the previous trading session.""}, {""date"": ""2023-03-13"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.54% to $65.18 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-13"", ""headline"": ""AstraZeneca outperforms market despite losses on the day"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.11% to \u00a3106.86 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE...""}, {""date"": ""2023-03-14"", ""headline"": ""AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-14"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR sank 0.14% to $65.09 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-14"", ""headline"": ""AstraZeneca remains steady Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC were unchanged Tuesday at \u00a3106.86 , on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2023-03-15"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.78% to $64.58 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-15"", ""headline"": ""Astrazeneca (AZN) Could Be a Great Choice"", ""summary"": ""Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.""}, {""date"": ""2023-03-15"", ""headline"": ""AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?"", ""summary"": ""AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER.""}, {""date"": ""2023-03-15"", ""headline"": ""AstraZeneca falls Wednesday, still outperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.39% to \u00a3106.44 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE...""}, {""date"": ""2023-03-15"", ""headline"": ""GLOBAL BROKER RATINGS: HSBC says 'hold' Terna and Snam, 'buy' Enel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-15"", ""headline"": ""FOCUS-How GSK plans to replenish its depleted medicine cabinet"", ""summary"": ""GSK's chief scientist says an overhaul of the drugmaker's R&D unit has begun delivering results - citing an RSV vaccine and promising hepatitis B and asthma treatments - and pledged a tighter focus than his predecessor on infectious disease and HIV.  Tony Wood only took the helm of R&D last August.""}, {""date"": ""2023-03-15"", ""headline"": ""LONDON BROKER RATINGS: Jefferies rates Future at 'hold'; Spirent upped"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 2.17% to $65.98 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-16"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC advanced 1.45% to \u00a3107.98 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2023-03-16"", ""headline"": ""JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-17"", ""headline"": ""Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know"", ""summary"": ""In the latest trading session, Astrazeneca (AZN) closed at $65.61, marking a -0.56% move from the previous day.""}, {""date"": ""2023-03-17"", ""headline"": ""AstraZeneca PLC ADR falls Friday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.56% to $65.61 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-17"", ""headline"": ""2 Steady Stocks to Buy and Hold Forever"", ""summary"": ""There is nothing like a bear market to emphasize the importance of investing in solid, reliable, and steady companies that can deliver consistent revenue and earnings for a long time.  Two such companies are AstraZeneca (NASDAQ: AZN) and Visa (NYSE: V).  U.K.-based AstraZeneca is a drugmaker with a vast, diversified portfolio of over three-dozen products across six major segments.""}, {""date"": ""2023-03-17"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.15% to \u00a3108.14 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-03-17"", ""headline"": ""Is AstraZeneca PLC (AZN) a Solid Prospective Investment?"", ""summary"": ""Artisan Partners, an investment management company, released its \u201cArtisan Global Equity Fund\u201d fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, its Investor Class fund ARTHX returned 15.95%, Advisor Class fund APDHX posted a return of 15.98%, and Institutional Class fund APHHX returned 16.04%, compared to a [\u2026]""}]",{}
10,2023-03-19,65.18199157714844,2023-03-26,67.46698760986328,0.03505563388639876,U4,"[{""date"": ""2023-03-20"", ""headline"": ""AstraZeneca PLC ADR rises Monday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.72% to $66.74 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-20"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.22% to \u00a3107.90 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2023-03-21"", ""headline"": ""Oppenheimer emerging biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-21"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.37% higher to $66.99 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-03-21"", ""headline"": ""AstraZeneca rises Tuesday, still underperforms market"", ""summary"": ""AstraZeneca PLC shares advanced 1.06% to \u00a3109.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-03-22"", ""headline"": ""White House seeking alternative supply chains for pharmaceutical ingredients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.63% to $66.57 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-22"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.66% to \u00a3109.76 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-03-22"", ""headline"": ""UK dividends calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""Here's What is Driving Amgen (AMGN) Stock's Outperformance"", ""summary"": ""Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.""}, {""date"": ""2023-03-23"", ""headline"": ""Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session.""}, {""date"": ""2023-03-23"", ""headline"": ""BOE: Discounted Global Covered Call Fund"", ""summary"": ""BlackRock Enhanced Global Dividend Trust shares some similarities with BDJ but has a sizeable portion of its portfolio outside the US. See why BOE CEF is a Buy.""}, {""date"": ""2023-03-23"", ""headline"": ""7 Blue-Chip Stocks to Buy for Capital Preservation"", ""summary"": ""The financial sector-driven panic sent investors to the refuge of safe assets, including blue-chip stocks. In general, blue-chip stocks have a low beta and this supports capital preservation. Additionally, most blue-chip stocks have an attractive dividend yield. So, today, my focus is on names that are undervalued. Even if there is a meaningful correction in the broad markets, these blue-chip stocks are likely to remain resilient. Once market sentiments reverse, these stocks can deliver healthy""}, {""date"": ""2023-03-23"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR advanced 1.04% to $67.26 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-03-23"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.20% to \u00a3109.98 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-03-23"", ""headline"": ""These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar"", ""summary"": ""Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.""}, {""date"": ""2023-03-23"", ""headline"": ""3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030"", ""summary"": ""These historically profitable dividend-paying stocks are ideal for risk-averse investors wanting to take advantage of a bear market discount.""}, {""date"": ""2023-03-23"", ""headline"": ""AstraZeneca says Calquence conditionally approved in China for first indication"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""AstraZeneca`s blood cancer drug Calquence gets conditional approval in China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""TOP NEWS: AstraZeneca's Calquence receives first approval in China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%"", ""summary"": ""Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.""}, {""date"": ""2023-03-24"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""The AstraZeneca PLC ADR inched 0.97% higher to $67.91 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-03-24"", ""headline"": ""U.K. stocks continue losing streak, fall for second day"", ""summary"": ""U.K. stocks finished lower Friday, with the FTSE 100 Index falling 1.26% at 7,405.45. Among FTSE 100 constituents, major international banks company Standard...""}, {""date"": ""2023-03-24"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.75% to \u00a3110.80 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-03-24"", ""headline"": ""FDA draft guidance impacts companies using accelerated approval for oncology drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
11,2023-03-26,67.46698760986328,2023-04-02,68.95720672607422,0.022088122932482523,U3,"[{""date"": ""2023-03-26"", ""headline"": ""TOP NEWS: AstraZeneca hails eplontersen; Enhertu wins another approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-26"", ""headline"": ""LONDON BRIEFING: Stocks called higher as banking crisis fears ease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review"", ""summary"": ""Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's (NASDAQ: AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) that leads to peripheral nerve damage and motor disability. At 66 weeks, patients treated with eplontersen demonstrated a statistically significant and clinically meaningful change from baseline versus an external placebo group on t""}, {""date"": ""2023-03-27"", ""headline"": ""AstraZeneca PLC ADR rises Monday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.21% to $68.73 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-03-27"", ""headline"": ""Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study"", ""summary"": ""Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).""}, {""date"": ""2023-03-27"", ""headline"": ""Oppenheimer emerging biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks"", ""summary"": ""WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1""}, {""date"": ""2023-03-27"", ""headline"": ""Ionis, AstraZeneca report positive outcomes from eplontersen trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 0.19% to $68.60 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-03-28"", ""headline"": ""WHO updates COVID vaccine guidance; low priority for children and adolescents"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""LONDON BRIEFING: Stocks add to rebound; SSE ups earnings guidance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""AstraZeneca Completes KYM Solid Tumors Treatment Deal"", ""summary"": ""By Michael Susin AstraZeneca PLC said Thursday that it has completed an exclusive global license agreement with KYM Biosciences over the CMG901 treatment for...""}, {""date"": ""2023-03-29"", ""headline"": ""Astrazeneca (AZN) Gains But Lags Market: What You Should Know"", ""summary"": ""In the latest trading session, Astrazeneca (AZN) closed at $68.64, marking a +0.06% move from the previous day.""}, {""date"": ""2023-03-29"", ""headline"": ""Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively"", ""summary"": ""Pieris Pharmaceuticals Inc (NASDAQ: PIRS) reported Q4 earnings and provided updates across its pipeline. The investors are reacting to the further pushback of the timeline for the readout from the Phase 2a study of elarekibep to mid-2024 from prior guidance of the third quarter of 2023. Pieris is collaborating with AstraZeneca Plc (NASDAQ: AZN) to develop elarekibep for asthma patients. AstraZeneca has communicated that completion of the Phase 2a study remains an important priority and that addi""}, {""date"": ""2023-03-29"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.06% higher to $68.64 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-03-30"", ""headline"": ""AstraZeneca PLC ADR underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""The AstraZeneca PLC ADR inched 0.82% higher to $69.20 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-03-30"", ""headline"": ""7 Growth Stocks That Pay Generous Dividends"", ""summary"": ""When it comes to dividend-paying growth stocks, it can be difficult to find names that are both high-growth and high-yield. This makes sense, given that companies with high dividend yields are typically paying out a large portion of their earnings as a dividend, leaving little capital to fund growth. That said, there are quite a few stocks that, while not exactly \u201chigh-yield,\u201d have annual yields above that of the S&P 500 (1.69%), plus offer the opportunity for growth. Hitting this \u201csweet spot,\u201d""}, {""date"": ""2023-03-30"", ""headline"": ""AstraZeneca completes agreement with KYM Biosciences for CMG901"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-30"", ""headline"": ""AstraZeneca, KYM Biosciences complete licensing deal for cancer drug CMG901"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-30"", ""headline"": ""AstraZeneca signs exclusive global license deal with KYM Biosciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-31"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.30% higher to $69.41 Friday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-03-31"", ""headline"": ""This is Why  Astrazeneca (AZN) is a Great Dividend Stock"", ""summary"": ""Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.""}, {""date"": ""2023-03-31"", ""headline"": ""AstraZeneca Ultomiris gets EMA backing for expanded use"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-31"", ""headline"": ""Samsung Bioepis` biosimilar to AstraZeneca`s Soliris backed for EU approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-01"", ""headline"": ""Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript"", ""summary"": ""Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Hello and welcome to the Pieris Pharmaceuticals, Inc. Year-End 2022 Conference Call and Webcast. . A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to turn the call over to [\u2026]""}]","{""assetTurnoverTTM"": 0.4567, ""bookValue"": 35789, ""cashRatio"": 0.25068382944489137, ""currentRatio"": 0.8957, ""ebitPerShare"": 1.634, ""eps"": 1.1558, ""ev"": 247282.019, ""fcfMargin"": 0.1529, ""fcfPerShareTTM"": 3.8914, ""grossMargin"": 0.8362, ""inventoryTurnoverTTM"": 1.3059, ""longtermDebtTotalAsset"": 0.2784, ""longtermDebtTotalCapital"": 0.4, ""longtermDebtTotalEquity"": 0.7521, ""netDebtToTotalCapital"": 0.3755, ""netDebtToTotalEquity"": 0.7061, ""netMargin"": 0.1657, ""operatingMargin"": 0.2343, ""payoutRatioTTM"": 1.2896, ""pb"": 6.2033, ""peTTM"": 47.1962, ""pfcfTTM"": 36.8116, ""pretaxMargin"": 0.2079, ""psTTM"": 5.0642, ""quickRatio"": 0.6959, ""receivablesTurnoverTTM"": 4.6214, ""roaTTM"": 0.049, ""roeTTM"": 0.1308, ""roicTTM"": 0.0714, ""rotcTTM"": 0.0824, ""salesPerShare"": 6.9737, ""sgaToSale"": 0.1638, ""totalDebtToEquity"": 0.8802, ""totalDebtToTotalAsset"": 0.3258, ""totalDebtToTotalCapital"": 0.4682, ""totalRatio"": 1.5877, ""period"": ""2023-03-31""}"
12,2023-04-02,68.95720672607422,2023-04-09,71.86808013916016,0.042212751230616075,U5,"[{""date"": ""2023-04-02"", ""headline"": ""TOP NEWS: AstraZeneca's ultomiris recommended for EU approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-02"", ""headline"": ""Harbor Capital Appreciation Fund Buys AstraZeneca, Ups Nvidia Holding"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-02"", ""headline"": ""AstraZeneca's Ultomiris Recommended for Marketing Authorization in EU"", ""summary"": ""By Michael Susin AstraZeneca PLC said Monday that its treatment for patients with neuromyelitis optica spectrum disorder has been recommended for marketing...""}, {""date"": ""2023-04-03"", ""headline"": ""AstraZeneca PLC ADR rises Monday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.72% higher to $69.91 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-04-03"", ""headline"": ""AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease"", ""summary"": ""CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.""}, {""date"": ""2023-04-03"", ""headline"": ""Arvinas appoints Page as SVP, Global Head of Oncology Strategy, Program Leader"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-03"", ""headline"": ""AstraZeneca says Ultomiris recommended for approval in EU for NMOSD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""AstraZeneca Imfinzi, Lynparza combo improves progression-free survival in ovarian cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""What You Missed On Wall Street On Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""AstraZeneca's Lynparza, Imfinzi Ovarian Cancer Treatment Met Primary Endpoint in Phase 3 Trial"", ""summary"": ""By Joe Hoppe AstraZeneca PLC said Wednesday that its Lynparza and Imfinzi combination met its endpoint in the treatment of patients with advanced ovarian...""}, {""date"": ""2023-04-04"", ""headline"": ""Astrazeneca (AZN) Gains As Market Dips: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $70.25, moving +0.49% from the previous trading session.""}, {""date"": ""2023-04-04"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors despite daily gains"", ""summary"": ""The AstraZeneca PLC ADR inched 0.49% higher to $70.25 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-05"", ""headline"": ""GSK ordered by UK court to pay more royalties to AstraZeneca on Zejula sales - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""LONDON MARKET OPEN: European stocks edge higher in cautious trade"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""TOP NEWS: AstraZeneca's cancer drug Lynparza approved by NHS England"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""WHO chief expects COVID emergency to end this year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Unusual Call Option Trade in AstraZeneca (AZN)  Worth $1,645.00K"", ""summary"": """"}, {""date"": ""2023-04-05"", ""headline"": ""Medical Behemoth AstraZeneca Flirts With Breakout On Fresh Hope In Ovarian Cancer"", ""summary"": ""AstraZeneca said Wednesday a combination of its drugs Lynparza and Imfinzi met the goal of a key study, leading AZN stock to surge.""}, {""date"": ""2023-04-05"", ""headline"": ""Top Analyst Reports for Mastercard, AstraZeneca & Philip Morris"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AstraZeneca PLC (AZN) and Philip Morris International Inc. (PM).""}, {""date"": ""2023-04-05"", ""headline"": ""IN THE KNOW: AstraZeneca needs competitor data for context - Shore"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 2.56% to $72.05 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-04-05"", ""headline"": ""AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal"", ""summary"": ""Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.""}, {""date"": ""2023-04-05"", ""headline"": ""UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula"", ""summary"": ""A UK court on Wednesday ordered GSK's Tesaro to pay rival AstraZeneca royalties on total sales of ovarian cancer drug Zejula, in a win for the Anglo-Swedish drugmaker.  Tesaro had argued the royalty was payable only on sales that are for uses claimed or covered by the licensed patents, after AstraZeneca filed a UK lawsuit against GSK in 2021, asking for a bigger share of sales from Zejula.  In October 2012, Tesaro entered into license agreements with AstraZeneca, giving it exclusive rights to certain methods of treating patients with Zejula, developed by Tesaro with help from technology licensed from AstraZeneca.""}, {""date"": ""2023-04-05"", ""headline"": ""AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study"", ""summary"": ""AstraZeneca Plc (NASDAQ: AZN) announced topline data from a planned interim analysis of the DUO-O Phase 3 trial of a combination of Lynparza (olaparib), Imfinzi (durvalumab), chemotherapy, and bevacizumab. The combo therapy improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Also Read: AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients. In an additional arm, Imfinzi, chemotherapy plu""}, {""date"": ""2023-04-05"", ""headline"": ""U.K. stocks climb Wednesday"", ""summary"": ""U.K. stocks climbed Wednesday, as the FTSE 100 Index finished up 0.37% at 7,662.94. Of the FTSE 100 constituents, general mining company Polymetal...""}, {""date"": ""2023-04-05"", ""headline"": ""LONDON MARKET CLOSE: Risk-off mood prevails but FTSE 100 outperforms"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Drug giant AstraZeneca teams up with Hong Kong Science Park to drive biotech, medical research growth"", ""summary"": ""AstraZeneca, one of the world's leading pharmaceutical companies, has signed a second collaboration agreement with Hong Kong Science and Technology Parks (HKSTP) as the city moves to position itself as a trailblazer in life science innovation. Along with the wider Greater Bay Area, Hong Kong aims to attract the best health talent and drive growth in the fields of medical research, drug development, and clinical trials. The collaboration will involve AstraZeneca and HKSTP supporting and providing""}, {""date"": ""2023-04-05"", ""headline"": ""RPT-UPDATE 1-AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial"", ""summary"": ""AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.  Lynparza, jointly developed with U.S.-based Merck & Co , was approved last year by the U.S. Food and Drug Administration as a treatment for early-stage breast cancer with certain mutations.""}, {""date"": ""2023-04-05"", ""headline"": ""UPDATE 1-AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial"", ""summary"": ""AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.  Lynparza, jointly developed with U.S.-based Merck & Co , was approved last year by the U.S. Food and Drug Administration as a treatment for early-stage breast cancer with certain mutations.""}, {""date"": ""2023-04-05"", ""headline"": ""AstraZeneca says Lynparza/Imfinzi combo met endpoint in ovarian cancer study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""AstraZeneca receives positive interim trial results for Imfinzi drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""Catalyst Watch: Eyes on inflation data, big bank earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""McDonald's, U.K. Pharma Giant Hit New Highs"", ""summary"": ""Dow Jones component McDonald's hit new highs Wednesday while U.K. pharma giant AstraZeneca scored a breakout. In addition, MCD stock broke out from a 281.77 buy point, according to MarketSmith. Shares formed a 97-day consolidation and powered higher last month, up nine days in a row before pulling back this week.""}, {""date"": ""2023-04-06"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.40% higher to $72.34 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-04-06"", ""headline"": ""Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates"", ""summary"": ""J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.""}, {""date"": ""2023-04-06"", ""headline"": ""LONDON MARKET CLOSE: Stocks end shortened week on positive note"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""FDA forces pre-term birth drug off the market after 12 years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""The Zacks Analyst Blog Highlights Mastercard, AstraZeneca, Philip Morris, TJX and Citigroup"", ""summary"": ""Mastercard, AstraZeneca, Philip Morris, TJX and Citigroup are included in this Analyst Blog.""}, {""date"": ""2023-04-06"", ""headline"": ""Pfizer posts 82% efficacy for maternal RSV vaccine in full data release"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: AstraZeneca (AZN), Sanofi (SNY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""7 Very Undervalued Penny Stocks to Buy in April 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-07"", ""headline"": ""Steven Cohen Loads Up on Esperion Therapeutics as Shares Slide"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-07"", ""headline"": ""2 Top Biotech Stocks to Buy Right Now"", ""summary"": ""Pharmaceutical companies can be great long-term investments.  Because of the major industry risk that comes with patent expirations, investors need to be sure that they are picking pharmaceutical companies with strong product pipelines.  Here are two big pharma stocks with robust product portfolios and pipelines for long-term income investors to consider for their portfolios.""}, {""date"": ""2023-04-07"", ""headline"": ""Estimating The Fair Value Of AstraZeneca PLC (LON:AZN)"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, AstraZeneca fair value estimate is UK\u00a3139 AstraZeneca's UK\u00a3117...""}]","{""assetTurnoverTTM"": 0.4567, ""bookValue"": 35789, ""cashRatio"": 0.25068382944489137, ""currentRatio"": 0.8957, ""ebitPerShare"": 1.634, ""eps"": 1.1558, ""ev"": 247282.019, ""fcfMargin"": 0.1529, ""fcfPerShareTTM"": 3.8914, ""grossMargin"": 0.8362, ""inventoryTurnoverTTM"": 1.3059, ""longtermDebtTotalAsset"": 0.2784, ""longtermDebtTotalCapital"": 0.4, ""longtermDebtTotalEquity"": 0.7521, ""netDebtToTotalCapital"": 0.3755, ""netDebtToTotalEquity"": 0.7061, ""netMargin"": 0.1657, ""operatingMargin"": 0.2343, ""payoutRatioTTM"": 1.2896, ""pb"": 6.2033, ""peTTM"": 47.1962, ""pfcfTTM"": 36.8116, ""pretaxMargin"": 0.2079, ""psTTM"": 5.0642, ""quickRatio"": 0.6959, ""receivablesTurnoverTTM"": 4.6214, ""roaTTM"": 0.049, ""roeTTM"": 0.1308, ""roicTTM"": 0.0714, ""rotcTTM"": 0.0824, ""salesPerShare"": 6.9737, ""sgaToSale"": 0.1638, ""totalDebtToEquity"": 0.8802, ""totalDebtToTotalAsset"": 0.3258, ""totalDebtToTotalCapital"": 0.4682, ""totalRatio"": 1.5877, ""period"": ""2023-03-31""}"
13,2023-04-09,71.86808013916016,2023-04-16,73.378173828125,0.02101202211107922,U3,"[{""date"": ""2023-04-10"", ""headline"": ""TOP NEWS: Sanofi wins US drug control from AstraZeneca in Sobi deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""Sanofi to get commercial control of RSV therapy nirsevimab in US, AstraZeneca to record $0.7B gain"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""AstraZeneca upgraded to Overweight from Equal Weight at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""LONDON BRIEFING: Harbour Energy, BP to team up on carbon capture"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""Sanofi Gets Full Commercial Control on Virus Medication From AstraZeneca in U.S."", ""summary"": ""By Cecilia Butini Sanofi SA and AstraZeneca PLC said Monday that Sanofi would retain full commercial control on an antibody treatment for respiratory...""}, {""date"": ""2023-04-10"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed at $72.07 in the latest trading session, marking a -0.37% move from the prior day.""}, {""date"": ""2023-04-10"", ""headline"": ""AstraZeneca PLC ADR underperforms Monday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slid 0.37% to $72.07 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-04-10"", ""headline"": ""The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer"", ""summary"": ""J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.""}, {""date"": ""2023-04-10"", ""headline"": ""U.S. launches $5B program to speed up development of next-gen COVID vaccines"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market"", ""summary"": ""GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here.""}, {""date"": ""2023-04-10"", ""headline"": ""GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""Fusion Pharmaceuticals receives IND clearance for Alpha therapy FPI-2068"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms"", ""summary"": ""AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.""}, {""date"": ""2023-04-11"", ""headline"": ""12 Best Covid Treatment Stocks to Buy Today"", ""summary"": ""In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there\u2019s one thing that can be said for sure, it\u2019s that the coronavirus pandemic has changed the world. The deadly disease, [\u2026]""}, {""date"": ""2023-04-11"", ""headline"": ""AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023"", ""summary"": ""WILMINGTON, Del., April 11, 2023--AstraZeneca will showcase five real-world evidence (RWE) studies from its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio, reinforcing its commitment to advancing science in chronic kidney disease (CKD) and hyperkalemia (HK), at the National Kidney Foundation (NKF) Spring Clinical Meeting April 11-15, 2023.""}, {""date"": ""2023-04-11"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""AstraZeneca updates arrangements with Sobi, Sanofi for nirsevimab in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""LONDON BROKER RATINGS: Redburn likes Shell; Barclays raises Persimmon"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""SK Bioscience Rallies After Clinical Trials of Covid-19 Vaccine Booster"", ""summary"": ""By Kwanwoo Jun SK Bioscience Co Ltd.'s shares rallied Thursday after the global phase 3 clinical trials confirmed the efficacy and safety of its Covid-19...""}, {""date"": ""2023-04-12"", ""headline"": ""Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy"", ""summary"": ""Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the clearance of investigational new drug (IND) applications for [225Ac]-FPI-2068 (FPI-2068) and corresponding imaging analogue [111In]-FPI-2107 (FPI-2107) to the U.S. Food and Drug Administration (FDA). Fusion is jointly developing FPI-2068 with AstraZeneca (LSE/STO/Nasdaq: AZN) under the companies' multi-asset collabora""}, {""date"": ""2023-04-12"", ""headline"": ""Fusion Pharma Shares Edge Up 4.3% on FDA Clearance of FPI-2068"", ""summary"": ""By Denny Jacob Fusion Pharmaceuticals Inc. shares edged up 4.3% to $4.35 in aftermarket trading Wednesday after it said the U.S. Food and Drug Administration...""}, {""date"": ""2023-04-12"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rallied 2.19% to $73.76 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-12"", ""headline"": ""These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar"", ""summary"": ""Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.""}, {""date"": ""2023-04-12"", ""headline"": ""AstraZeneca COVID shot production is expected to resume in India"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""TOP NEWS: AstraZeneca Covid antibody neutralises variants of concern"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.37% to $74.77 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-13"", ""headline"": ""AstraZeneca Stock Sees Relative Strength Rating Rise To 85"", ""summary"": ""AstraZeneca  now clears that threshold, with a jump from 80 to 85 Thursday.  When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.  AstraZeneca ADR is still within a buy range after breaking past a 72.22 buy point in a flat base.""}, {""date"": ""2023-04-13"", ""headline"": ""Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy"", ""summary"": ""Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.""}, {""date"": ""2023-04-13"", ""headline"": ""AZN June 2nd Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""AstraZeneca price target raised to $85 from $75 at Argus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-14"", ""headline"": ""FTC Alerts Nearly 700 Companies About Potential Penalties for Misleading Claims"", ""summary"": ""Marketers will likely review their practices to avoid risking penalties that could stretch into the hundreds of millions of dollars""}, {""date"": ""2023-04-14"", ""headline"": ""AstraZeneca PLC ADR falls Friday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR shed 1.22% to $73.86 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-14"", ""headline"": ""IXJ: Healthcare Dashboard For April"", ""summary"": ""Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Learn why IXJ ETF is a global alternative to XLV.""}, {""date"": ""2023-04-14"", ""headline"": ""New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy"", ""summary"": ""ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET\u2122) imaging agent and radiopharmaceutical therapies (RPT) announces a poster presentation at AACR 2023 (# 3577 / 2 Poster PET, MRI, and CT Imaging April 18, 2023) of an independent analysis undertaken by AstraZeneca (LSE/STO/Nasdaq: AZN), on data from ImaginAb's IAB-CD8-201 'iCorrelate' Phase II study. The analysis shows baseline and early on-treatment CD8 ImmunoPET/CT may be able to distinguish resp""}, {""date"": ""2023-04-14"", ""headline"": ""3 Best Stocks to Buy Now, 4/14/2023, According to Top Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-14"", ""headline"": ""Ghana 1st in world to approve new malaria vaccine by Oxford"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""AstraZeneca presents results from AEGEAN Phase III trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial"", ""summary"": ""WILMINGTON, Del., April 16, 2023--Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC).""}]","{""assetTurnoverTTM"": 0.4567, ""bookValue"": 35789, ""cashRatio"": 0.25068382944489137, ""currentRatio"": 0.8957, ""ebitPerShare"": 1.634, ""eps"": 1.1558, ""ev"": 247282.019, ""fcfMargin"": 0.1529, ""fcfPerShareTTM"": 3.8914, ""grossMargin"": 0.8362, ""inventoryTurnoverTTM"": 1.3059, ""longtermDebtTotalAsset"": 0.2784, ""longtermDebtTotalCapital"": 0.4, ""longtermDebtTotalEquity"": 0.7521, ""netDebtToTotalCapital"": 0.3755, ""netDebtToTotalEquity"": 0.7061, ""netMargin"": 0.1657, ""operatingMargin"": 0.2343, ""payoutRatioTTM"": 1.2896, ""pb"": 6.2033, ""peTTM"": 47.1962, ""pfcfTTM"": 36.8116, ""pretaxMargin"": 0.2079, ""psTTM"": 5.0642, ""quickRatio"": 0.6959, ""receivablesTurnoverTTM"": 4.6214, ""roaTTM"": 0.049, ""roeTTM"": 0.1308, ""roicTTM"": 0.0714, ""rotcTTM"": 0.0824, ""salesPerShare"": 6.9737, ""sgaToSale"": 0.1638, ""totalDebtToEquity"": 0.8802, ""totalDebtToTotalAsset"": 0.3258, ""totalDebtToTotalCapital"": 0.4682, ""totalRatio"": 1.5877, ""period"": ""2023-03-31""}"
14,2023-04-16,73.378173828125,2023-04-23,75.10681915283203,0.023558031421660353,U3,"[{""date"": ""2023-04-15"", ""headline"": ""AstraZeneca presents results from AEGEAN Phase III trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""GRAIL, AstraZeneca present new data on methylation assay"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""LONDON BRIEFING: Possible offers for Network International, John Wood"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""AstraZeneca reports positive results for lung cancer drug combination"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial"", ""summary"": ""WILMINGTON, Del., April 16, 2023--Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC).""}, {""date"": ""2023-04-17"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Astrazeneca (AZN) closed at $73.63, marking a -0.31% move from the previous day.""}, {""date"": ""2023-04-17"", ""headline"": ""Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting"", ""summary"": ""Shanghai Cellular Biopharmaceutical Group Ltd. (the Company, or Shanghai Cellular Bio), a company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today presented data from the First-in-Human (FIH) Phase I trial evaluating C-CAR031 at the 2023 American Association for Cancer Research (AACR) Annual Meeting.""}, {""date"": ""2023-04-17"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slid 0.31% to $73.63 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-17"", ""headline"": ""GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research (AACR) Annual Meeting 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Astrazeneca (AZN) is a Top Dividend Stock Right Now: Should You Buy?"", ""summary"": ""Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.""}, {""date"": ""2023-04-17"", ""headline"": ""Pfizer Vs. AstraZeneca: Which Is Better For Long-Term Investors?"", ""summary"": """"}, {""date"": ""2023-04-18"", ""headline"": ""Why AstraZeneca Shares Are Trading Higher Today?"", ""summary"": ""AstraZeneca plc's (NASDAQ: AZN) vaccine head highlighted the confidence that the company's new COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. Laboratory studies show that the antibody, dubbed AZD3152, neutralizes all known variants of COVID-19. AstraZeneca has support from regulators to make the treatment available by the end of this year, Reuters reported citing Iskra Reic's interview. Depending on additional encouraging data and regulator""}, {""date"": ""2023-04-18"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR advanced 1.89% to $75.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-18"", ""headline"": ""AstraZeneca confident new COVID antibody protects against known variants"", ""summary"": ""AstraZeneca is confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants, its vaccines head said.  Laboratory studies show the antibody, called AZD3152, neutralizes all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment available by the end of this year, Iskra Reic said in an interview on Tuesday.  AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023.""}, {""date"": ""2023-04-18"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Relay Therapeutics (RLAY) and 23andMe Holding (ME)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-19"", ""headline"": ""Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""In the latest trading session, Astrazeneca (AZN) closed at $74.84, marking a -0.24% move from the previous day.""}, {""date"": ""2023-04-19"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.24% to $74.84 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-19"", ""headline"": ""Citigroup, Ryanair Bemoan Lingering Brexit Woes: New Economy"", ""summary"": ""(Bloomberg) -- The new Brexit Deal for Northern Ireland between the UK and the European Union represents progress but isn\u2019t enough to fully eliminate disruption caused by Britain\u2019s exit from the bloc, business leaders said at the Bloomberg New Economy Gateway Europe event near Dublin.Most Read from BloombergWorthless Degrees Are Creating an Unemployable Generation in IndiaAirline Blunder Sells $10,000 Asia-US Business Class Tickets for $300India Passes China as World\u2019s Most Populous Nation, UN S""}, {""date"": ""2023-04-19"", ""headline"": ""Could This Rare-Disease Drug Candidate Become a Blockbuster?"", ""summary"": ""This drug candidate could be a great treatment option for patients with a potentially deadly disease.""}, {""date"": ""2023-04-20"", ""headline"": ""AstraZeneca PLC ADR outperforms market despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.41% to $74.53 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-20"", ""headline"": ""Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick"", ""summary"": ""Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.""}, {""date"": ""2023-04-21"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""The AstraZeneca PLC ADR rose 1.44% to $75.60 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-21"", ""headline"": ""Mineralys: New IPO And A Leader In The Hypertension Drug Development Space"", ""summary"": """"}, {""date"": ""2023-04-21"", ""headline"": ""Merck (MRK) to Report Q1 Earnings: What's in the Cards?"", ""summary"": ""Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q1 earnings.""}, {""date"": ""2023-04-21"", ""headline"": ""Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""UK earnings, trading statements calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""UK shareholder meetings calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""ClearBridge International Value Strategy Q1 2023 Portfolio Manager Commentary"", ""summary"": """"}]",{}
15,2023-04-23,75.10681915283203,2023-04-30,72.74234771728516,-0.031481448185623484,D4,"[{""date"": ""2023-04-24"", ""headline"": ""EU outlines plan to take control of medicine production in health crises"", ""summary"": ""Proposal for compulsory licensing risks ire of pharmaceutical groups keen to protect patents and revenue""}, {""date"": ""2023-04-24"", ""headline"": ""AstraZeneca PLC ADR rises Monday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.28% higher to $75.81 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-04-24"", ""headline"": ""Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1?"", ""summary"": ""Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs.""}, {""date"": ""2023-04-24"", ""headline"": ""NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks"", ""summary"": ""WILMINGTON, Del., April 24, 2023--Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis\u2019 eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.1""}, {""date"": ""2023-04-24"", ""headline"": ""AstraZeneca/Sanofi`s RSV preventing therapy Beyfortus gets approval in Canada"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-24"", ""headline"": ""AstraZeneca, Ionis announce eplontersen trial met all endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-25"", ""headline"": ""AstraZeneca PLC ADR outperforms market despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.20% to $75.66 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-25"", ""headline"": ""AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?"", ""summary"": ""Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.""}, {""date"": ""2023-04-25"", ""headline"": ""UK shareholder meetings calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""LONDON BRIEFING: AstraZeneca revenue dips as Covid medicines decline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""AstraZeneca 1Q Revenue Consensus Was $10.60B"", ""summary"": ""By Cecilia Butini AstraZeneca PLC on Thursday reported a rise in profit for the first quarter, but said a decline in sales of its Covid-19 medicines hurt...""}, {""date"": ""2023-04-26"", ""headline"": ""LONDON MARKET EARLY CALL: Lower call as US bank sector worries weigh"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""GET READY: Astra, Barclays, LSEG, Schroders and Unilever at 0700 BST"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""AstraZeneca beats Q1 top and bottom line estimates; reaffirms FY23 outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Aspen Tech plunges to 9-month low on Q3 results; William Blair downgrades stock"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""European markets open lower; banks choppy after results beat expectations"", ""summary"": ""European markets opened lower Thursday, with concerns over the global banking sector still casting a shadow over investor sentiment.""}, {""date"": ""2023-04-26"", ""headline"": ""GLOBAL BRIEFING: Samsung posts weakest profit in 14 years in Q1"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""7 Low-Risk Stocks to Buy if You Only Want to Beat Inflation"", ""summary"": ""If you\u2019re looking for some low-risk stocks for inflation-proofing, investing in historically stable companies with robust cash flows and dividends is the best bet right now. A recession is on the cards later this year, and if you are only worried about protecting what you have while having returns that can beat inflation, I would not recommend investing in many of the hotter growth stocks this year. Now don\u2019t get me wrong \u2014 growth names are an essential part of your portfolio and they can substa""}, {""date"": ""2023-04-26"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slid 2.66% to $73.65 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-26"", ""headline"": ""Why AstraZeneca (AZN) Might Surprise This Earnings Season"", ""summary"": ""AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.""}, {""date"": ""2023-04-26"", ""headline"": ""Pfizer, BioNTech hit new 52-week lows"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""LONDON MARKET CLOSE: Tech shines but tepid trade elsewhere"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""U.K. stocks extend losing streak for third session"", ""summary"": ""U.K. stocks finished lower Wednesday, with the FTSE 100 Index dropping 0.49% at 7,852.64. Among FTSE 100 constituents, technical services company...""}, {""date"": ""2023-04-26"", ""headline"": ""Will AstraZeneca Q1 results bring positive surprise?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Merck, AstraZeneca dip as FDA reviews cancer drug ahead of AdCom meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""UK earnings, trading statements calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Notable earnings before Thursday`s open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""EU publishes proposed reforms for pharma industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Novartis` iptacopan improves hemoglobin levels in rare blood disorder trial full data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""AstraZeneca's 1Q Sales Expected to Dip -- Earnings Preview"", ""summary"": ""By Cecilia Butini AstraZeneca PLC is scheduled to report results for the first quarter on Thursday. Here's what you need to know: SALES: The Anglo-Swedish...""}, {""date"": ""2023-04-26"", ""headline"": ""Novartis iptacopan improves hemoglobin levels in rare blood disorder trial full data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Europe stocks markets set for higher open as earnings boost sentiment"", ""summary"": ""European stock markets are set to open higher on Friday as investors digest corporate earnings. ""}, {""date"": ""2023-04-27"", ""headline"": ""FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting"", ""summary"": ""The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC). In 2017, AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) collaborated to co-develop and co-commercialise Lynparza and Koselugo (selumetinib) for multiple cancer types. Ahead of the meeting, the""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales"", ""summary"": ""AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca chief warns high tax Britain now \u2018very unattractive\u2019"", ""summary"": ""High taxes are making Britain \""very unattractive\"" for business, the boss of the country's biggest drugmaker has warned, as he said that China was likely to shape the medicines of the future.""}, {""date"": ""2023-04-27"", ""headline"": ""Drugmakers scout for deals, ramp up research spending"", ""summary"": ""Drugmakers including Merck & Co, AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.  Several top drugs such as AbbVie flagship Humira have begun to face competition from new rivals or are expected to lose patent protections in the next few years, and deals could be a quick fix to address the loss of revenue from older therapies.  Merck recently announced a $10.8 billion deal to buy Prometheus Biosciences Inc.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues"", ""summary"": ""AstraZeneca Plc (NASDAQ: AZN) has reported Q1 FY23 core EPS of $1.92, up 1% Y/Y (+6% on constant currency), better than the consensus of $1.07. The company clocked Q1 sales of $10.88 billion, -4% (flat CC), beating the consensus of $10.75 billion. The company said that total revenue was stable, despite a decline of $1.46 billion from COVID-19 medicines. Excluding COVID-19 medicines, revenue increased by 15%, and product sales increased by 16% Core Gross margin of 83%, up four percentage points,""}, {""date"": ""2023-04-27"", ""headline"": ""Trending tickers: Meta | Unilever | AstraZeneca | Taylor Wimpey"", ""summary"": ""The latest investor updates on stocks that are trending on Thursday.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca hunts for more China deals after signing partnerships"", ""summary"": ""AstraZeneca is exploring potential deals in China, declaring the market \u201ccompletely open\u201d to foreign drugmakers.  Pascal Soriot, AstraZeneca\u2019s chief executive, has just returned from two weeks in the country, where the Anglo-Swedish drugmaker has signed three licensing partnerships in recent months.  AstraZeneca is the largest foreign pharmaceutical company by sales in China.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca's Profit, Revenue Beat Expectations Despite Covid-19 Slump -- Earnings Review"", ""summary"": ""By Cecilia Butini AstraZeneca PLC reported first-quarter results on Thursday. Here is what we watched. REVENUE: Revenue declined to $10.88 billion from...""}, {""date"": ""2023-04-27"", ""headline"": ""Unusually active option classes on open April 27th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca (AZN) Receives a Buy from SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""GLOBAL BROKER RATINGS: Berenberg cuts Dassault; HSBC cuts S&N"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""3 Best Stocks to Buy Now, 4/27/2023, According to Top Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""UPDATE 2-AstraZeneca first quarter profit, revenue beat expectations"", ""summary"": ""AstraZeneca on Thursday beat expectations for its first -quarter profit and revenue, helped by sales of its roster of drugs in emerging markets.  AstraZeneca's performance in emerging markets was particularly strong, CEO Pascal Soriot said in a statement.  Excluding sales of its COVID-19 products, sales grew 22% to $3.1 billion in emerging markets on a constant currency basis.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca beats estimates on strong emerging market sales as COVID wanes"", ""summary"": ""LONDON (Reuters) -AstraZeneca on Thursday beat expectations for first-quarter profit and revenue, as buoyant sales of cancer treatment Imfinzi and strong demand for its roster of drugs in emerging markets helped to offset dwindling COVID product sales.  The company's sales and outlook highlight the rapid decline of its COVID vaccine, its best-selling product in 2021 at the height of the pandemic, which has struggled to compete with rival shots developed by Pfizer and Moderna.  AstraZeneca's current strategy is focused on areas such as cancer, cardiovascular, kidney, rare and respiratory diseases.""}, {""date"": ""2023-04-27"", ""headline"": ""Analysts` Opinions Are Mixed on These Healthcare Stocks: AstraZeneca (AZN), BioMarin Pharmaceutical (BMRN) and Sanofi (SNY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Astrazeneca: Q1 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca sees FY23 core EPS up high single to low double-digit percentage"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca reports Q1 core EPS $1.92, consensus $1.07"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""TOP NEWS: AstraZeneca profit jumps despite Covid-19 sales decline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""AstraZeneca Q1 sales boosted by cancer drugs amid COVID products wane"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""LONDON MARKET OPEN: Stocks lower amid worries for health of US economy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""AstraZeneca Plc (AZN) Q1 2023 Earnings Call Transcript"", ""summary"": ""Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.  The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.""}, {""date"": ""2023-04-28"", ""headline"": ""Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study"", ""summary"": ""Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.""}, {""date"": ""2023-04-28"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 0.76% to $73.22 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-04-28"", ""headline"": ""Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised"", ""summary"": ""Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.""}, {""date"": ""2023-04-28"", ""headline"": ""GLOBAL BROKER RATINGS: HSBC cuts Santander; DZ Bank likes Meta"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Merck, AstraZeneca Lynparza wins limited label expansion endorsement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-29"", ""headline"": ""27 Largest Biotech Companies in the US"", ""summary"": ""In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in [\u2026]""}, {""date"": ""2023-04-30"", ""headline"": ""GSK struggles to make investors believe its growth story"", ""summary"": ""Industry watchers say UK-listed rival AstraZeneca has a stronger pipeline and benefits from its oncology expertise""}]",{}
16,2023-04-30,72.74234771728516,2023-05-07,74.77896881103516,0.027997736637060067,U3,"[{""date"": ""2023-04-29"", ""headline"": ""27 Largest Biotech Companies in the US"", ""summary"": ""In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in [\u2026]""}, {""date"": ""2023-04-30"", ""headline"": ""GSK struggles to make investors believe its growth story"", ""summary"": ""Industry watchers say UK-listed rival AstraZeneca has a stronger pipeline and benefits from its oncology expertise""}, {""date"": ""2023-05-01"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""SVB Securities Remains a Buy on AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""AstraZeneca \""disappointed\"" with US ODAC's guidance on Lynparza"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""AstraZeneca (AZN) Presents at the 2023 American Association for Cancer Research (AACR) - Slideshow"", ""summary"": ""The following slide deck was published by AstraZeneca PLC in conjunction with this event.""}, {""date"": ""2023-05-02"", ""headline"": ""IN BRIEF: AstraZeneca Chair Michel Demare buys GBP230,000 in shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-02"", ""headline"": ""AstraZeneca says disappointed with FDA Lynparza vote outcome"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-02"", ""headline"": ""AstraZeneca bemoans ODAC judgement on use of Lynparza drug for cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""WHO meeting is set to decide whether to end COVID emergency"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""ADRs End Mostly Lower; Sernova Gains on AstraZeneca Collaboration"", ""summary"": ""By Sabela Ojea International stocks trading in New York closed mostly lower Wednesday. The S&P/BNY Mellon index of American depositary receipts fell 0.02% to...""}, {""date"": ""2023-05-03"", ""headline"": ""AZN Stock Today: This Options Trade Boosts AstraZeneca Stock Yield To 21% Annualized"", ""summary"": ""AstraZeneca is a group leader that is showing an improving Relative Strength Rating. So, let's look at how a covered call trade on AZN stock might take shape. Income investors can further enhance the yield on the stock through the use of covered calls.""}, {""date"": ""2023-05-03"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rose 1.21% to $74.59 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-03"", ""headline"": ""Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio"", ""summary"": ""Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.""}, {""date"": ""2023-05-03"", ""headline"": ""US approves 1st vaccine for RSV after decades of attempts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.93% to \u00a3118.84 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-03"", ""headline"": ""Sernova Shares Jump With AstraZeneca Collaboration"", ""summary"": ""By Robb M. Stewart Sernova's shares rallied Wednesday after the biotechnology company entered a preclinical research collaboration with AstraZeneca to...""}, {""date"": ""2023-05-03"", ""headline"": ""Sernova, AstraZeneca to Collaborate to Evaluate Potential Therapeutic Cell Applications"", ""summary"": ""By Robb M. Stewart Biotechnology company Sernova said Wednesday it entered a preclinical research collaboration with AstraZeneca to evaluate the use of its...""}, {""date"": ""2023-05-03"", ""headline"": ""VGK: 5 Reasons I Like This European ETF"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""Sernova, AstraZeneca enter collaboration for therapeutic cell applications"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""Fentanyl overdose deaths rose 279%, oxycodone deaths fell in 5 years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR sank 0.28% to $74.38 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-04"", ""headline"": ""Baron Health Care Fund Q1 2023 Shareholder Letter"", ""summary"": ""Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing.""}, {""date"": ""2023-05-04"", ""headline"": ""AstraZeneca falls Thursday, still outperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.29% to \u00a3118.50 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-04"", ""headline"": ""June 23rd Options Now Available For AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""AstraZeneca management to meet with TD Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Ionis Pharma upgraded at Citi after quarterly update"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Q1 2023 Ionis Pharmaceuticals Inc Earnings Call"", ""summary"": ""Q1 2023 Ionis Pharmaceuticals Inc Earnings Call""}, {""date"": ""2023-05-04"", ""headline"": ""Pieris Pharmaceuticals completes safety review for 10 mg dose of elarekibep"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""AstraZeneca chair says increasing CEO`s pay wards of rivals, FT reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Baron International Growth Fund Q1 2023 Quarterly Letter"", ""summary"": ""Baron International Growth Fund gained 3.75% (Institutional Shares) during the first quarter of 2023. Click here to read the full fund letter.""}, {""date"": ""2023-05-04"", ""headline"": ""AstraZeneca chair says it is paying CEO enough to ward off US rivals"", ""summary"": ""The new chair of AstraZeneca believes the drugmaker has extinguished the threat of chief executive Pascal Soriot quitting for lucrative roles in the US, saying that the benefit of increasing his pay in recent years outweighed the criticism from some shareholders.  Under Soriot, who has led AstraZeneca for more than a decade, the group has become the most valuable company on the London market, with a market capitalisation of \u00a3185bn.  Sales of its innovative cancer drugs has helped propel the group to three times the size of UK rival GSK.""}, {""date"": ""2023-05-05"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.20% to $75.27 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-05"", ""headline"": ""AstraZeneca rises Friday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.61% to \u00a3119.22 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-05-05"", ""headline"": ""WHO ends global public health emergency status for COVID-19"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""FibroGen stock falls ~10% after roxadustat fails phase 3 trial for anemia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""FibroGen announces MATTERHORN study did not meet primary efficacy endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-06"", ""headline"": ""GSK: Add This Cheap Chip Play To Your Portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-06"", ""headline"": ""3 Low-Volatility Stocks for a Stable Investment Strategy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
17,2023-05-07,74.77896881103516,2023-05-14,74.24250030517578,-0.007174055946331914,D1,"[{""date"": ""2023-05-07"", ""headline"": ""AstraZeneca, Merck`s Koselugo gets approval in China for rare genetic disorder in kids"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-08"", ""headline"": ""AstraZeneca`s Farxiga gets FDA approval to reduce risk of death due to heart failure"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-08"", ""headline"": ""AstraZeneca Farxiga gets FDA approval to reduce risk of death due to heart failure"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-08"", ""headline"": ""AstraZeneca Gets Broader Approval for Heart Failure Treatment in US"", ""summary"": ""By Christian Moess Laursen AstraZeneca said Tuesday that its Farxiga treatment has been approved in the U.S for use on patients with heart failure. The...""}, {""date"": ""2023-05-08"", ""headline"": ""AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-08"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.08% higher to $75.33 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-08"", ""headline"": ""The 7 Best Mutual Funds to Invest in for May 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-08"", ""headline"": ""AstraZeneca reports Koselugo approved in China for inoperable PN in NF1 patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""AstraZeneca's Ultomiris approved in EU for autoimmune disease NMOSD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""AstraZeneca`s Ultomiris gets expanded approval in EU for rare nervous system disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""AstraZeneca Ultomiris gets expanded approval in EU for rare nervous system disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""15 Biggest Immunotherapy Companies in the World"", ""summary"": ""In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power [\u2026]""}, {""date"": ""2023-05-09"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR slumped 0.33% to $75.08 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-09"", ""headline"": ""FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients"", ""summary"": ""WILMINGTON, Del., May 09, 2023--AstraZeneca\u2019s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.1 FARXIGA was previously approved in the US for adults with HF with reduced ejection fraction (HFrEF).""}, {""date"": ""2023-05-09"", ""headline"": ""AstraZeneca outperforms market despite losses on the day"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.07% to \u00a3119.14 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-09"", ""headline"": ""AstraZeneca put volume heavy and directionally bearish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""GLOBAL BROKER RATINGS: Peel Hunt says 'buy' IAG; RBC lifts Intertek"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""AstraZeneca says Farxiga extended in U.S. to reduce risk of cardiovascular death"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""LONDON BROKER RATINGS: RBC raises Intertek; Davy likes Greencoat UK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""TOP NEWS: AstraZeneca's Farxiga approved in US to treat heart failure"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-10"", ""headline"": ""Unusual Call Option Trade in Astrazeneca plc - ADR (AZN)  Worth $261.13K"", ""summary"": """"}, {""date"": ""2023-05-10"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR shed 0.28% to $74.87 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-10"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.79% to \u00a3118.20 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-10"", ""headline"": ""AstraZeneca`s Ultomiris approved in EU for adults with NMOSD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-11"", ""headline"": ""Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript"", ""summary"": ""Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript May 10, 2023 Operator: Good day, ladies and gentlemen. And welcome to the Pieris Pharmaceuticals to host First Quarter 2023 Investor Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host Tom Bures, CFO. Sir, the floor is [\u2026]""}, {""date"": ""2023-05-11"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR sank 0.19% to $74.73 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-11"", ""headline"": ""Top Healthcare Stocks for May 2023"", ""summary"": ""Top healthcare stocks include Azenta Inc. for best value, ShockWave Medical for fastest growth, and Viking Therapeutics for most momentum.""}, {""date"": ""2023-05-11"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.88% to \u00a3119.24 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-11"", ""headline"": ""June 30th Options Now Available For AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-12"", ""headline"": ""Cancer therapies spending set to surge through end of decade"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-12"", ""headline"": ""25 Best US Cities for People With Allergies"", ""summary"": ""In this article, we will take a look at the 25 best US cities for people with allergies. If you want to see more cities in this selection, go to the 5 Best US Cities for People With Allergies. According to Allied Market Research, the market for allergy treatments was valued at $24.6 billion in [\u2026]""}, {""date"": ""2023-05-12"", ""headline"": ""Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns"", ""summary"": ""Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. The results could stoke Sanofi stock.""}, {""date"": ""2023-05-12"", ""headline"": ""Directors\u2019 Deals: AstraZeneca chair bets on upward momentum"", ""summary"": ""AstraZeneca is the jewel in the FTSE 100\u2019s crown.  The pharmaceutical group now has a market capitalisation of \u00a3182bn.  This places it firmly ahead of Shell, the index\u2019s second-largest constituent, with a market cap of \u00a3161bn.""}, {""date"": ""2023-05-12"", ""headline"": ""AstraZeneca PLC ADR remains steady Friday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR were unchanged Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index...""}, {""date"": ""2023-05-12"", ""headline"": ""Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody"", ""summary"": ""The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have revealed data from a real-world trial of their candidate nirsevimab, a long-acting antibody. In November, nirsevimab was approved in Europe, dubbed Beyfortus, to prevent RSV-LRTD in newborns and infants during their first RSV season. The phase 3 HARMONIE study recruited over 8,000 infants 12 months and younger. Infants who received a single dose of the a""}, {""date"": ""2023-05-12"", ""headline"": ""Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates"", ""summary"": ""Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.""}, {""date"": ""2023-05-12"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.72% to \u00a3120.10 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-12"", ""headline"": ""LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-12"", ""headline"": ""LaNova Medicines reports global exclusive LM-305 license pact with AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-12"", ""headline"": ""Capital One biotech analysts to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-12"", ""headline"": ""Celcuity gedatolisib combo shows promise in phase 1b trial in breast cancer patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-13"", ""headline"": ""How The Pharmaceutical Industry Is Using AI"", ""summary"": ""Industry-leading pharmaceutical firms are adopting AI to drive value for the future of their enterprise. Several companies in the PPH ETF are currently integrating AI into their operations.""}, {""date"": ""2023-05-14"", ""headline"": ""Is AstraZeneca Stock a Buy for Growth Investors?"", ""summary"": ""Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark.  This is why I'd advise most investors to consider only the most dominant and established pharmaceutical companies for their portfolios.  British drugmaker AstraZeneca (NASDAQ: AZN) is one such company.""}]",{}
18,2023-05-14,74.24250030517578,2023-05-21,74.3021011352539,0.0008027858683790079,U1,"[{""date"": ""2023-05-13"", ""headline"": ""How The Pharmaceutical Industry Is Using AI"", ""summary"": ""Industry-leading pharmaceutical firms are adopting AI to drive value for the future of their enterprise. Several companies in the PPH ETF are currently integrating AI into their operations.""}, {""date"": ""2023-05-14"", ""headline"": ""Is AstraZeneca Stock a Buy for Growth Investors?"", ""summary"": ""Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark.  This is why I'd advise most investors to consider only the most dominant and established pharmaceutical companies for their portfolios.  British drugmaker AstraZeneca (NASDAQ: AZN) is one such company.""}, {""date"": ""2023-05-15"", ""headline"": ""AI Meets Biotech: Transforming the Drug Development Process"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.35% higher to $74.99 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-15"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.08% to \u00a3120.00 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-16"", ""headline"": ""AstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In Trial"", ""summary"": ""By Christian Moess Laursen AstraZeneca said Wednesday that trial results showed that its Tagrisso drug in combination with chemotherapy demonstrated strong...""}, {""date"": ""2023-05-16"", ""headline"": ""Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites"", ""summary"": ""Pieris' expanding Elarekibep trial finally has active/completed sites. Read more to see my thoughts on PIRS stock and why it is a Buy.""}, {""date"": ""2023-05-16"", ""headline"": ""Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?"", ""summary"": ""We continue our coverage of AstraZeneca with a 'hold' rating for the next 12 months. Demand for some AZN innovative drugs is high, click for our view.""}, {""date"": ""2023-05-16"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.39% higher to $75.28 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-16"", ""headline"": ""UPDATE 1-AstraZeneca to leave leading U.S. drug lobby group"", ""summary"": ""AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.  AstraZeneca decided not to continue its membership after a recent assessment of whether it was \""the most productive and effective use of (company) resources\"", a spokesperson for the British drugmaker said in an emailed statement.  PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023.""}, {""date"": ""2023-05-16"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.58% to \u00a3120.70 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-05-16"", ""headline"": ""AstraZeneca to leave leading U.S. drug lobby group"", ""summary"": ""LONDON (Reuters) -AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.  AstraZeneca decided not to continue its membership after a recent assessment of whether it was \""the most productive and effective use of (company) resources\"", a spokesperson for the British drugmaker said in an emailed statement.  PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023.""}, {""date"": ""2023-05-16"", ""headline"": ""AstraZeneca PLC (LON:AZN) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?"", ""summary"": ""AstraZeneca's (LON:AZN) stock is up by 4.2% over the past three months. However, the company's financials look a bit...""}, {""date"": ""2023-05-16"", ""headline"": ""AstraZeneca to exit leading U.S. drug industry group PhRMA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""WHO recommends updating COVID shots to add XBB.1 variants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slumped 0.77% to $74.70 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-17"", ""headline"": ""AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer"", ""summary"": ""AstraZeneca Plc (NASDAQ: AZN) has reported topline data from the Phase 3 FLAURA2 trial of Tagrisso (osimertinib) in combination with chemotherapy for locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The results showed that Tagrisso plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Tagrisso alone. Related: Ast""}, {""date"": ""2023-05-17"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares dropped 1.21% to \u00a3119.24 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-05-17"", ""headline"": ""TAGRISSO\u00ae (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial"", ""summary"": ""WILMINGTON, Del., May 17, 2023--Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca\u2019s TAGRISSO\u00ae (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).""}, {""date"": ""2023-05-17"", ""headline"": ""AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial"", ""summary"": ""The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday.  The drug maker said patients on the combined treatment showed a meaningful improvement in progression-free survival, or how long a patient lives without the disease getting worse after treatment, than patients given only Tagrisso.  The trial was on patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.""}, {""date"": ""2023-05-17"", ""headline"": ""AstraZeneca announces Tagrisso combination demonstrates statistical significance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""AstraZeneca's Tagrisso plus chemotherapy effective against lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""AstraZeneca Tagrisso chemo combo cuts risk of lung cancer progression in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""The 7 Next Trillion-Dollar Companies to Invest in Now"", ""summary"": ""In the last decade, few companies have touched the magic trillion-dollar valuation. Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), and Alphabet (NASDAQ:GOOG, NASDAQ: GOOGL) are the names worth mentioning. While these businesses will continue to create value, I am more interested in finding the next trillion-dollar companies. An interesting point to note is that most of the trillion-dollar valuation companies in the last decade were from the technology sector. Of course, there are potential opportuni""}, {""date"": ""2023-05-18"", ""headline"": ""AstraZeneca PLC ADR underperforms Thursday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 0.66% to $74.21 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-18"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.45% to \u00a3119.78 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-05-18"", ""headline"": ""Baron Health Care Fund Reduced AstraZeneca PLC (AZN) on Competition Concerns"", ""summary"": ""Baron Funds, an investment management company, released its \u201cBaron Health Care Fund\u201d first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell [\u2026]""}, {""date"": ""2023-05-18"", ""headline"": ""FDA advisers back RSV vaccine for pregnant women that protects their newborns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Supreme Court rules against Amgen in Rapatha patent dispute with Sanofi/ Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Unusually active option classes on open May 18th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""FibroGen stock rises after roxadustat matches Sepo in Chinese trial for anemia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Revvity Announces New License Agreement for Next-Generation Base Editing Technology"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Revvity licenses gene editing tech to AstraZeneca for cancer, immune-mediated therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Revvity announces new license agreement with AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-19"", ""headline"": ""An AstraZeneca executive said the quiet part about China out loud"", ""summary"": ""AstraZeneca has big business in China. The British pharmaceutical company is the biggest drugmaker in the country, where it makes 13% of its revenue.""}, {""date"": ""2023-05-19"", ""headline"": ""AstraZeneca PLC ADR rises Friday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.78% higher to $74.79 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-19"", ""headline"": ""Olema Oncology: Best Contrarian Oncology Play For 2023"", ""summary"": ""Olema, clinical-stage biopharma, targeting ER+ breast cancer, has promising clinical data and a solid cash position. Click here to read why OLMA stock is a buy.""}, {""date"": ""2023-05-19"", ""headline"": ""DeSantis Vs. Disney, Alibaba Spinoffs Cloud Business, Apple Bans Internal ChatGPT Use: Today's Top Stories"", ""summary"": ""Bloomberg Alibaba's Cloud Business Spinoff - What's Going On With Alibaba Stock Friday Alibaba Group Holding Limited's (NYSE: BABA) move to fully spin out a potentially transformative $12 billion cloud business has fueled speculation of it succumbing to market or political realities. Analysts value the cloud business at upwards of $30 billion, a prime beneficiary of a post-ChatGPT frenzy mirroring the success of Amazon.Com Inc's (NASDAQ: AMZN) cloud unit Amazon Web Services. Alibaba splurged ten""}, {""date"": ""2023-05-19"", ""headline"": ""Why Astrazeneca (AZN) is a Great Dividend Stock Right Now"", ""summary"": ""Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.""}, {""date"": ""2023-05-19"", ""headline"": ""3 Undervalued Pharma Stocks to Buy for High Total Returns"", ""summary"": ""Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors. After an extended bull market, there tends to be a price and time correction phase in various sectors. One secret to successful investing is to identify sectors that have been depressed for an extended period. Stocks in this sector tend to be undervalued, and once sentiments reverse, the rally can be massive. My focus in this column is on undervalued pharma stocks to buy. To""}, {""date"": ""2023-05-19"", ""headline"": ""AstraZeneca's China Executive Seeks Loyalty to \""Love the Communist Party\"" In China"", ""summary"": ""During an event held in the city of Wuxi to commemorate its 30th year in China, AstraZeneca Plc's (NASDAQ: AZN) China president, Wang Lei, said the company will seek to be a patriotic company in China that \""loves the Communist Party.\"" Wang, who also holds the position of global executive vice president, commented at the event, Reuters reported citing a person familiar with the matter and photos shared. Also Read: One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps. A""}, {""date"": ""2023-05-19"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.27% to \u00a3120.10 Friday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-19"", ""headline"": ""Astra China head says company seeks to `love the Communist Party,` Reuters says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-19"", ""headline"": ""AstraZeneca's China boss says drugmaker will seek to \""love the Communist Party\"""", ""summary"": ""Global drugmaker AstraZeneca will seek to be a patriotic company in China that \""loves the Communist Party\"", its China president said at an event on Friday.  Wang Lei, who is also the company's global executive vice president, made the comments at an event in the eastern city of Wuxi which the firm organised to celebrate its 30th year in China, according to a person familiar with the matter and photos shared with Reuters.  While many local companies have in recent years publicly pledged allegiance to the ruling Chinese Communist Party as President Xi Jinping strengthened the party's role throughout Chinese society and its economy, such messaging is still unusual from foreign companies.""}, {""date"": ""2023-05-21"", ""headline"": ""Billions of dollars at stake as FDA shortcut allows half-proven drugs - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-21"", ""headline"": ""Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal"", ""summary"": ""Shanghai\u00e2\u0080\u0099s LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million plus royalties on sales. Read more here...""}]",{}
19,2023-05-21,74.3021011352539,2023-05-28,72.04690551757812,-0.030351707195609423,D4,"[{""date"": ""2023-05-21"", ""headline"": ""IN BRIEF: AstraZeneca hires LSEG CFO Anna Manz as non-exec director"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-21"", ""headline"": ""Billions of dollars at stake as FDA shortcut allows half-proven drugs - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-21"", ""headline"": ""Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal"", ""summary"": ""Shanghai\u00e2\u0080\u0099s LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million plus royalties on sales. Read more here...""}, {""date"": ""2023-05-22"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR shed 0.45% to $74.45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-05-22"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.22% to \u00a3120.36 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-22"", ""headline"": ""Pfizer Yielding 4.5% Is Getting Added To My Dividend Harvesting Portfolio And Maybe The Main Account"", ""summary"": ""Pfizer has fallen through the $40 level and looks very enticing as its dividend yield sits at 4.5%. See why I added PFE stock to my portfolio.""}, {""date"": ""2023-05-23"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-23"", ""headline"": ""New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD"", ""summary"": ""WILMINGTON, Del., May 23, 2023--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE\u00ae (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease) is associated with a decreased risk of future exacerbations by 24% vs. delaying treatment by one to six months, and by 34% vs. delaying treatment six months to o""}, {""date"": ""2023-05-23"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR sank 0.51% to $74.07 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-05-23"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-23"", ""headline"": ""AstraZeneca falls Tuesday, still outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.02% to \u00a3120.34 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE...""}, {""date"": ""2023-05-23"", ""headline"": ""Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-24"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-24"", ""headline"": ""AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter"", ""summary"": ""Innoviva Inc's (NASDAQ: INVA) affiliate Entasis Therapeutics Inc received FDA approval for Xacduro (sulbactam and durlobactam for injection), co-packaged as a treatment for hospital-acquired pneumonia. The approval covers patients 18 years and older for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by difficult-to-treat bacteria strains known as Acinetobacter baumannii-calcoaceticus complex. Innoviva acquired Entasis Therapeutics in May 2022 for $2.20 per sha""}, {""date"": ""2023-05-24"", ""headline"": ""As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""AstraZeneca's Ultomiris gets approval in Japan for expanded use in rare nervous system disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""AstraZeneca Ultomiris gets approval in Japan for expanded use in rare nervous system disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""AstraZeneca's Imfinzi plus Lynparza effective for endometrial cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""LONDON BRIEFING: UK retail sales up; Hunt \""comfortable\"" with recession"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""AstraZeneca: Think Medium-To-Long Term"", ""summary"": ""AstraZeneca's price has moved sideways in the past month, after showing good progress for some time. See why AZN stock is still a buy for me.""}, {""date"": ""2023-05-25"", ""headline"": ""AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023"", ""summary"": ""WILMINGTON, Del., May 25, 2023--AstraZeneca advances its ambition to revolutionize cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6, 2023.""}, {""date"": ""2023-05-26"", ""headline"": ""12 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain"", ""summary"": ""In this article, we discuss 12 best growth stocks to buy and hold in 2023 according to billionaire Rajiv Jain. If you want to see more stocks in this selection, check out 5 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain. Bloomberg reported on May 23 that Rajiv Jain, [\u2026]""}, {""date"": ""2023-05-26"", ""headline"": ""Health authorities to target next COVID shot to new strain, WSJ says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""IMFINZI\u00ae (durvalumab) plus LYNPARZA\u00ae (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy"", ""summary"": ""WILMINGTON, Del., May 26, 2023--Positive high-level results from the DUO-E Phase III trial showed IMFINZI\u00ae (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA\u00ae (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cance""}, {""date"": ""2023-05-26"", ""headline"": ""TOP NEWS: AstraZeneca's Ultomiris wins another approval in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Unusually active option classes on open May 26th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""TD Cowen pharma/biotech analysts hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Stocks facing most buy and sell pressure into Russell rebalancing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""AstraZeneca price target lowered to $80 from $85 at Argus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""IN THE KNOW: AstraZeneca's DUO-E positive, but \""mature OS\"" data needed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""AstraZeneca announces results from Imfinzi plus Lynparza trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""AstraZeneca announces high-level results from DUO-E Phase III trial on Imfinzi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Elon Musk's Neuralink gets FDA nod to start human trial of brain implant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""AstraZeneca says Ultomiris approved in Japan for prevention of NMOSD relapses"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""AstraZeneca's Imfinzi, Lynparza cuts risk of uterus cancer progression in phase 3 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""AstraZeneca Imfinzi, Lynparza cuts risk of uterus cancer progression in phase 3 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-28"", ""headline"": ""Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years"", ""summary"": ""Shares of AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK) have both more than doubled over the last five years.  With a $228 billion market capitalization, AstraZeneca is the sixth-largest pharmaceutical company in the world and the second-biggest international-based drugmaker behind Novartis (NYSE: NVS).  As you'd guess would be the case for a major player in the pharmaceutical industry, the British drugmaker possesses a remarkable product portfolio.""}]",{}
20,2023-05-28,72.04690551757812,2023-06-04,72.116455078125,0.000965337234781094,U1,"[{""date"": ""2023-05-28"", ""headline"": ""Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years"", ""summary"": ""Shares of AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK) have both more than doubled over the last five years.  With a $228 billion market capitalization, AstraZeneca is the sixth-largest pharmaceutical company in the world and the second-biggest international-based drugmaker behind Novartis (NYSE: NVS).  As you'd guess would be the case for a major player in the pharmaceutical industry, the British drugmaker possesses a remarkable product portfolio.""}, {""date"": ""2023-05-29"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-29"", ""headline"": ""Nestle hires LSEG's Anna Manz as CFO as Rogers ends eight-year term"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-29"", ""headline"": ""AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal"", ""summary"": ""AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.""}, {""date"": ""2023-05-30"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""BioLight announces joint cooperation agreement with AstraZeneca's Alexion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec\u2019s 3D Spheroid Screening Platform, KIYA-PredictTM"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""Catalyst Pharmaceuticals appoints Thompson to board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""Bolt Biotherapeutics and AstraZeneca Rare Disease partner in retinal disease R&D"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-31"", ""headline"": ""AstraZeneca PLC ADR underperforms Thursday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-31"", ""headline"": ""TOP NEWS: AstraZeneca discontinues brazikumab; Lynparza wins approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-31"", ""headline"": ""LONDON BRIEFING: Higher open as US debt limit bill passes House"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-31"", ""headline"": ""AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program"", ""summary"": ""By Anthony O. Goriainoff AstraZeneca said Thursday that it was discontinuing the brazikumab inflammatory bowel disease development program after reviewing...""}, {""date"": ""2023-05-31"", ""headline"": ""AstraZeneca halts bowel disease drug program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-31"", ""headline"": ""AstraZeneca/Merck's Lynparza gains expanded prostate cancer indication"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Cantor Fitzgerald biotech to hold analyst/industry dinner meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""AstraZeneca's IMFINZI plus chemo improved pathologic response in Phase III trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Germany Is Cooling. 3 Stocks to Put Your Money In."", ""summary"": ""Germany\u2019s industrial machine, diminished or not, still offers attractive names like Siemens, SAP, and Deutsche Telekom.""}, {""date"": ""2023-06-01"", ""headline"": ""AstraZeneca (AZN) Discontinues Brazikumab Development"", ""summary"": ""AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.""}, {""date"": ""2023-06-01"", ""headline"": ""Lexicon Pharmaceuticals Secures Key FDA Approval, But Heavy Lifting Remains"", ""summary"": ""Lexicon Pharmaceuticals received FDA approval to market its heart failure drug Inpefa. Read why I think LXRX remains as a high-risk proposition for investors.""}, {""date"": ""2023-06-01"", ""headline"": ""LYNPARZA\u00ae (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer"", ""summary"": ""WILMINGTON, Del., June 01, 2023--AstraZeneca and Merck & Co., Inc\u2019s, known as MSD outside the US and Canada, LYNPARZA\u00ae (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).""}, {""date"": ""2023-06-01"", ""headline"": ""Merck and Astra's Lynparza prostate cancer treatment gets US approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""UPDATE 1-AstraZeneca to stop developing Crohn's disease drug"", ""summary"": ""British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.  The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and \""the context of a competitive landscape\"".  AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.""}, {""date"": ""2023-06-01"", ""headline"": ""AstraZeneca, Merck announce LYNPARZA + abiraterone approved for BRCAm cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Merck and AstraZeneca's Lynparza prostate cancer combination approved by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""AstraZeneca halts AbbVie-partnered bowel disease drug program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""AstraZeneca discontinues brazikumab IBD development program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""IMFINZI\u00ae (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial"", ""summary"": ""WILMINGTON, Del., June 02, 2023--Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) neoadjuvant (before surgery) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response (pCR) versus neoadjuvant chemotherapy alone fo""}, {""date"": ""2023-06-02"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.34% to $72.59 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-02"", ""headline"": ""Top Research Reports for Exxon Mobil, AstraZeneca & Netflix"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), AstraZeneca PLC (AZN) and Netflix, Inc. (NFLX).""}, {""date"": ""2023-06-02"", ""headline"": ""FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer"", ""summary"": ""Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.""}, {""date"": ""2023-06-02"", ""headline"": ""Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study"", ""summary"": ""Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.""}, {""date"": ""2023-06-02"", ""headline"": ""Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies"", ""summary"": ""FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer""}, {""date"": ""2023-06-02"", ""headline"": ""Here's Why Astrazeneca (AZN) is a Strong Value Stock"", ""summary"": ""Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.""}, {""date"": ""2023-06-02"", ""headline"": ""AstraZeneca sees positive results for Imfinzi in gastric cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers"", ""summary"": ""By Michael Susin AstraZeneca said late Friday that interim analysis of the phase III study regarding its Imfinzi drug together with chemotherapy...""}, {""date"": ""2023-06-02"", ""headline"": ""AstraZeneca rises Friday, still underperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.67% to \u00a3117.48 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-02"", ""headline"": ""AstraZeneca says Imfinzi plus chemotherapy showed clinical benefit in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""3 Nasdaq 100 Stocks That Are Surefire Buys in June"", ""summary"": ""These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer.""}, {""date"": ""2023-06-02"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""Oppenheimer biotech analyst to hold a reception"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""AstraZeneca's Imfinzi shows positive response in gastric cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-03"", ""headline"": ""LYNPARZA\u00ae (olaparib) and IMFINZI\u00ae (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial"", ""summary"": ""WILMINGTON, Del., June 03, 2023--Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA\u00ae (olaparib), IMFINZI\u00ae (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutation""}, {""date"": ""2023-06-03"", ""headline"": ""AstraZeneca interim analysis of DUO-O trial shows statistically significant PFS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-03"", ""headline"": ""SVB Securities Sticks to Their Buy Rating for AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients"", ""summary"": ""AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.  The drug has regulatory approvals across multiple geographies for certain patients with so-called non small cell lung cancer (NSCLC) who have a mutation of the EGFR gene.  The latest data, presented at the American Society of Clinical Oncology (ASCO) meeting, establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer, said Susan Galbraith, executive VP of oncology R&D at AstraZeneca in a statement.""}, {""date"": ""2023-06-04"", ""headline"": ""TAGRISSO\u00ae achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial"", ""summary"": ""WILMINGTON, Del., June 04, 2023--Positive results from the ADAURA Phase III trial showed AstraZeneca\u2019s TAGRISSO\u00ae (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.""}, {""date"": ""2023-06-04"", ""headline"": ""AstraZeneca\u2019s cancer pill Tagrisso halves mortality risk in lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Wall Street Breakfast: The Week Ahead"", ""summary"": ""Investors head into next week with the debt ceiling crisis resolved for the near term.""}, {""date"": ""2023-06-04"", ""headline"": ""AstraZeneca says TAGRISSO achieved 'unprecedent' survival in EGFRm"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""AstraZeneca defies geopolitics to bet on China"", ""summary"": ""AstraZeneca\u2019s chief executive returned from a recent trip to China exuberant about an \u201cexplosion\u201d of biotech companies in the country and the potential for his business to deliver drugs discovered there to the world.  Pascal Soriot said the market was \u201ccompletely open\u201d for pharma investment.  \u201cIt\u2019s hard to not be impressed by the progress that has been made in China over the last few years,\u201d he added on a press call in April.""}]",{}
21,2023-06-04,72.116455078125,2023-06-11,73.57686614990234,0.020250732931828885,U3,"[{""date"": ""2023-06-04"", ""headline"": ""AstraZeneca to Stop Intracranial Hemorrhage Drug Trial After Criteria Met"", ""summary"": ""By Elena Vardon AstraZeneca said Monday that a phase four trial for its Andexxa drug for patients experiencing intracranial haemorrhage will be stopped early...""}, {""date"": ""2023-06-04"", ""headline"": ""GLOBAL BRIEFING: Saudi Arabia to cut oil output to boost prices"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients"", ""summary"": ""AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.  The drug has regulatory approvals across multiple geographies for certain patients with so-called non small cell lung cancer (NSCLC) who have a mutation of the EGFR gene.  The latest data, presented at the American Society of Clinical Oncology (ASCO) meeting, establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer, said Susan Galbraith, executive VP of oncology R&D at AstraZeneca in a statement.""}, {""date"": ""2023-06-04"", ""headline"": ""TAGRISSO\u00ae achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial"", ""summary"": ""WILMINGTON, Del., June 04, 2023--Positive results from the ADAURA Phase III trial showed AstraZeneca\u2019s TAGRISSO\u00ae (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.""}, {""date"": ""2023-06-04"", ""headline"": ""AstraZeneca\u2019s cancer pill Tagrisso halves mortality risk in lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Wall Street Breakfast: The Week Ahead"", ""summary"": ""Investors head into next week with the debt ceiling crisis resolved for the near term.""}, {""date"": ""2023-06-04"", ""headline"": ""AstraZeneca says TAGRISSO achieved 'unprecedent' survival in EGFRm"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""AstraZeneca defies geopolitics to bet on China"", ""summary"": ""AstraZeneca\u2019s chief executive returned from a recent trip to China exuberant about an \u201cexplosion\u201d of biotech companies in the country and the potential for his business to deliver drugs discovered there to the world.  Pascal Soriot said the market was \u201ccompletely open\u201d for pharma investment.  \u201cIt\u2019s hard to not be impressed by the progress that has been made in China over the last few years,\u201d he added on a press call in April.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.84% higher to $73.20 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal"", ""summary"": ""At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients"", ""summary"": ""AstraZeneca plc's (NASDAQ: AZN) Tagrisso (osimertinib) cuts the risk of death by 51% in patients with a certain form of lung cancer diagnosed early enough to remove their tumor surgically, trial data showed. Data from the ADAURA Phase 3 trial showed Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small ce""}, {""date"": ""2023-06-05"", ""headline"": ""Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term"", ""summary"": ""Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.""}, {""date"": ""2023-06-05"", ""headline"": ""$100 Invested In AstraZeneca 10 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial"", ""summary"": ""WILMINGTON, Del., June 05, 2023--Updated results from the TROPION-Lung02 Phase Ib trial showed, with additional enrolment and follow-up from the initial presentation, that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum-based chemotherapy demonstrated promising clinical activity and no new safety signals in both previously untreated or pretreated patients with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterat""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.39% to \u00a3117.94 Monday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-06-05"", ""headline"": ""ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors"", ""summary"": ""WILMINGTON, Del., June 05, 2023--Positive results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses across a broad range of HER2-expressing advanced solid tumors in previously treated patients.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca and Daiichi Sankyo report progress in cancer drug trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca PLC (LON:AZN) is largely controlled by institutional shareholders who own 87% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, AstraZeneca's stock price might be vulnerable to their...""}, {""date"": ""2023-06-05"", ""headline"": ""ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care"", ""summary"": ""WILMINGTON, Del., June 05, 2023--ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of ANDEXXA (andexanet alfa) in patients on oral FXa inhibitor treatment including apixaban and rivaroxaban experiencing an intracranial hemorrhage, will be stopped early.1 The decision is based on achieving pre-specified stopping criteria of superior hemostatic efficacy, the ability to limit the expansion of a potentially life-threatening bleed in the brain, versus usual care.1,2""}, {""date"": ""2023-06-05"", ""headline"": ""Stocks Mixed, Week Ahead, OPEC Cuts, Palo Alto Networks Joins S&P 500, AstraZeneca Lung Cancer Trial - 5 Things To Know"", ""summary"": ""Stock futures edge higher as jobs report, debt deal boost global markets; Week Ahead: inflation data, Treasury bond sales in focus; Saudi Arabia agrees steep production cuts as OPEC seeks to 'stabilize' global markets; Palo Alto Networks leaps on S&P 500 inclusion, DISH Networks slumps and AstraZeneca unveils 'unprecedented' data from late-stage lung cancer trial.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial"", ""summary"": ""By Elena Vardon AstraZeneca said Monday that the phase II trial for its cancer drug Enhertu showed clinically meaningful and durable responses across...""}, {""date"": ""2023-06-05"", ""headline"": ""Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""ENHERTU\u00ae Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""At BIO 2023, Canada Showcases Multiple Strengths as a Biopharma Powerhouse"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca announces updates results from TROPION-Lung02 Phase Ib trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca says Enhertu showed ORR of 37.1% in DESTINY-PanTumor02 Phase 2 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca reports interim analysis from DESTINY-PanTumor02 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca announces ANNEXA-I trial will be stopped early"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca says Andexxa trial stopped early after hitting pre-specified target"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Cantor Fitzgerald biotech to hold analyst/industry dinner meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""AstraZeneca stops Andexxa trial early, Tagrisso reduces death risk"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""This Is What Whales Are Betting On AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Genomic Vision Provides Strategy Update"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.27% higher to $73.40 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-06-06"", ""headline"": ""UPDATE 1-US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapy"", ""summary"": ""The U.S. Food and Drug Administration's staff reviewers on Tuesday raised no new concerns on Sanofi and partner AstraZeneca's experimental therapy to prevent respiratory syncytial virus (RSV) infections in infants.  The RSV prevention antibody, nirsevimab, showed an overall favorable safety profile in clinical trials, FDA staff said in documents published ahead of the health regulator's advisory committee meeting on Thursday.""}, {""date"": ""2023-06-06"", ""headline"": ""AstraZeneca rises Tuesday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.32% to \u00a3118.32 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-06"", ""headline"": ""ASCO"", ""summary"": ""The following slide deck was published by AstraZeneca PLC in conjunction with this event.""}, {""date"": ""2023-06-06"", ""headline"": ""AstraZeneca PLC (AZN) ASCO Investor Event"", ""summary"": ""AstraZeneca PLC (NASDAQ:NASDAQ:AZN) ASCO Investor Event June 5, 2023 7:00 PM ETCorporateParticipantsAndy Barnett - VP Global Head of IRRoy Herbst - Deputy Director, Yale Cancer CenterPascal...""}, {""date"": ""2023-06-07"", ""headline"": ""FDA panel back approval of AstraZeneca, Sanofi RSV drug, Bloomberg says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-07"", ""headline"": ""Iberdrola plans to invest EUR4.00 billion in digitalisation by 2030"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-07"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR slid 0.12% to $73.31 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-06-07"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.66% to \u00a3117.54 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-07"", ""headline"": ""Zentalis price target raised to $50 from $45 at Stifel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""LONDON BRIEFING: Network International agrees to GBP2.2 billion buyout"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""AstraZeneca Says Nirsevimab Recommended for RSV Prevention in Infants by FDA Body"", ""summary"": ""By Joe Hoppe AstraZeneca said Friday that its nirsevimab antibody has been recommended for the prevention of respiratory syncytial virus, a lower respiratory...""}, {""date"": ""2023-06-08"", ""headline"": ""AstraZeneca Reaches Agreement With Quell Therapeutics for Treg Cell Therapies"", ""summary"": ""By Anthony O. Goriainoff AstraZeneca said Friday that it has reached an agreement to develop, manufacture and commercialize engineered T-regulatory, or Treg,...""}, {""date"": ""2023-06-08"", ""headline"": ""AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""UPDATE 3-US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy"", ""summary"": ""The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.  The advisers voted unanimously in favor of using the antibody, nirsevimab, in newborns and infants to prevent infections in their first RSV season.  In a separate 19-2 vote, the panel backed the therapy's use in children aged up to two years who are vulnerable to severe illness through their second RSV season.""}, {""date"": ""2023-06-08"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rose 1.28% to $74.25 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-08"", ""headline"": ""FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection"", ""summary"": ""Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi and AstraZeneca to...""}, {""date"": ""2023-06-08"", ""headline"": ""FDA advisors recommend AstraZeneca, Sanofi antibody to protect babies from RSV"", ""summary"": ""If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV. ""}, {""date"": ""2023-06-08"", ""headline"": ""Top Healthcare Stocks for June 2023"", ""summary"": ""Top healthcare stocks include Theravance Biopharma for best value, Dr Reddy's Laboratories for fastest growth, and Viking Therapeutics for most momentum.""}, {""date"": ""2023-06-08"", ""headline"": ""AstraZeneca falls Thursday, still outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.03% to \u00a3117.50 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-06-08"", ""headline"": ""AZN July 28th Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""Unusually active option classes on open June 8th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""AstraZeneca, Sanofi win FDA advisory committee backing for RSV therapy nirsevimab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""AstraZeneca/Sanofi's RSV drug recommended by FDA AdCom"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody"", ""summary"": ""The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.""}, {""date"": ""2023-06-09"", ""headline"": ""New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control"", ""summary"": ""Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies evaluating crovalimab compared to eculizumab, a current standard of care in paroxysmal nocturnal hemoglobinuria (PNH), were presented at the European Hematology Association Hybrid Congress. In the COMMODORE 2 study, 79.3% of participants randomized to be treated with crovalimab achieved hemolysis control from week five to week 25 compared with 79.0% with AstraZeneca Plc's (NASDAQ: AZN) Soliris (eculizum""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 0.26% to $74.06 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-06-09"", ""headline"": ""Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia's AI Technology Stirs Concern: Today's Top Stories"", ""summary"": ""Financial Times Privacy Breach Risk in Nvidia's AI Technology Stirs Concern Among Researchers Researchers found that an Nvidia Corp (NASDAQ: NVDA) artificial intelligence software feature is susceptible to manipulation leading to the compromise of private information. Robust Intelligence analysts found that the \""NeMo Framework,\"" which allows developers to work with a range of large language models, could easily break through so-called safety guardrails. After using the Nvidia system on their own""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder"", ""summary"": ""AstraZeneca Plc (NASDAQ: AZN) released data from the Phase 3 ALPHA trial of danicopan as an add-on to the standard of care for paroxysmal nocturnal hemoglobinuria (PNH). The data showed that danicopan as an add-on to the standard of care C5 inhibitor therapy Ultomiris (ravulizumab) or Soliris (eculizumab) demonstrated a statistically significant and clinically meaningful increase in hemoglobin levels and maintained disease control in PNH patients, compared to placebo plus established C5 inhibito""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes"", ""summary"": ""AstraZeneca plc (NASDAQ: AZN) has entered into a collaboration, exclusive option, and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies for Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications. Under the terms of the agreement, Quell\u2019s proprietary toolbox of Treg cell engineering modules, including its Foxp3 Phenotype Lock, will be leveraged to develop autologous multi-modular Treg cell therapy candidates for major autoim""}, {""date"": ""2023-06-09"", ""headline"": ""Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon"", ""summary"": ""The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The committee also voted 19 to 2 in support of nirsevimab's favorable benefit-risk profile for children up to 24 months of age who remain vulnerable to""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca outperforms market despite losses on the day"", ""summary"": ""AstraZeneca PLC shares inched down 0.32% to \u00a3117.12 Friday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca (NASDAQ:AZN), Sanofi RSV Antibody Wins FDA Advisors\u2019 Nod"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca in pact with Quell Therapeutics for Treg cell therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""UK cell therapy start-up agrees AstraZeneca partnership worth up to $2bn"", ""summary"": ""One of the most promising UK biotech start-ups, Quell Therapeutics, has signed a research collaboration and licensing deal with AstraZeneca to develop treatments for two autoimmune diseases.  The pharma giant will pay Quell $85mn upfront and up to $2bn more if it meets various development and commercialisation milestones over the next few years.  The technology developed by Quell allows the manipulation of a patient\u2019s immune response by genetically engineering \u201cregulatory T-cells\u201d or Tregs.""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca announces Treg cell therapy agreement with Quell Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""AstraZeneca reports danicopan met primary endpoint in Phase 3 ALPHA trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""US FDA committee recommends Sanofi's RSV disease treatment in infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""TOP NEWS: AstraZeneca hails deal with Quell; positive danicopan data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-10"", ""headline"": ""AI Meets Biotech: Transforming the Drug Development Process"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
22,2023-06-11,73.57686614990234,2023-06-18,74.72930145263672,0.01566301152846683,U2,"[{""date"": ""2023-06-11"", ""headline"": ""AstraZeneca breast cancer drug capivasertib gets priority review in US"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-11"", ""headline"": ""Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""AstraZeneca wins approval in China for Soliris in myasthenia gravis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""AstraZeneca's Soliris Treatment Approved in China for Adults With gMG"", ""summary"": ""By Joe Hoppe AstraZeneca said Tuesday that its Soliris disease treatment has been approved in China for adults with refractory generalized myasthenia gravis,...""}, {""date"": ""2023-06-12"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $73.85, moving -0.28% from the previous trading session.""}, {""date"": ""2023-06-12"", ""headline"": ""AstraZeneca PLC ADR underperforms Monday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.28% to $73.85 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-12"", ""headline"": ""AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies"", ""summary"": ""AstraZeneca (AZN) enters into a collaboration agreement with Quell Therapeutics to co-develop novel cell therapy options in major autoimmune indications for an upfront payment of $85 million.""}, {""date"": ""2023-06-12"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC advanced 1.01% to \u00a3118.30 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-12"", ""headline"": ""Capivasertib in combination with FASLODEX\u00ae (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer"", ""summary"": ""WILMINGTON, Del., June 12, 2023--AstraZeneca\u2019s New Drug Application (NDA) for capivasertib in combination with FASLODEX\u00ae (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen.""}, {""date"": ""2023-06-12"", ""headline"": ""AstraZeneca (AZN) Receives a Buy from Bank of America Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""AstraZeneca announces FDA acceptance, priority review for capivasertib NDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""AstraZeneca's capivasertib-Faslodex combination granted Priority Review in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca put volume heavy and directionally bearish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""Astrazeneca (AZN) Gains But Lags Market: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $74.13, moving +0.38% from the previous trading session.""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.38% higher to $74.13 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review"", ""summary"": ""The FDA grants priority review status to AstraZeneca's (AZN) capivasertib/Faslodex combination for the treatment of adult patients with HR-positive, HER2-negative locally advanced breast cancer.""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.76% to \u00a3117.40 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites"", ""summary"": ""WILMINGTON, Del., June 13, 2023--In a first-of-its-kind collaboration, AstraZeneca is partnering with Vanguard Renewables to deliver renewable natural gas to all its U.S. sites.""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca turns to cows to cut U.S. carbon footprint"", ""summary"": ""Drugmaker AstraZeneca is switching to biogas produced from cow manure and food waste in the United States, it said on Tuesday, in a deal to cut its carbon emissions there.  The Anglo-Swedish drugmaker said the long-term agreement with Massachusetts-based Vanguard Renewables would enable it to transition to biogas from natural gas and cut its emissions across its U.S. research and manufacturing sites.  \""Doing the right thing costs a little bit more, but it is not punitive,\"" said Pascal Soriot, chief executive of AstraZeneca, which makes 26 medicines in the U.S.""}, {""date"": ""2023-06-13"", ""headline"": ""Top 20 Most Profitable Pharmaceutical Companies In The World"", ""summary"": ""In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading [\u2026]""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca to decarbonize its U.S. footprint by turning cow manure into renewable natural gas"", ""summary"": ""In a first for the pharma sector, AstraZeneca will tap renewable natural gas for its U.S. manufacturing sites by the end of 2026.""}, {""date"": ""2023-06-13"", ""headline"": ""Unusually active option classes on open June 13th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca announces partnership with Vanguard Renewables"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""AstraZeneca reports Soliris approved in China for adults with refractory gMG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""Pharma chiefs warn red tape and NHS levy risk Britain missing out on billions"", ""summary"": ""Britain risks missing out on billions of pounds of pharmaceutical investment because bosses are struggling with red tape and a sky-high NHS levy, an industry group has warned.""}, {""date"": ""2023-06-14"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 1.83% to $72.77 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-14"", ""headline"": ""U.K. stocks continue winning streak, climb for third session"", ""summary"": ""U.K. stocks finished higher Wednesday, with the FTSE 100 Index increasing 0.10% at 7,602.74. Among FTSE 100 constituents, medical equipment/supplies company...""}, {""date"": ""2023-06-14"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC shed 1.96% to \u00a3115.10 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-15"", ""headline"": ""FDA panel recommends updated COVID-19 vaccines targeting XBB.1.5 subvariant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-15"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rose 2.54% to $74.62 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-15"", ""headline"": ""LONDON MARKET CLOSE: Europe mixed after ECB hike and hawkish Fed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-15"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rose 1.53% to \u00a3116.86 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-06-16"", ""headline"": ""Biologic drugs will lead European pharmas to surpass US counterparts in sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.80% higher to $75.22 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-16"", ""headline"": ""2 Best Biotech Stocks to Buy Right Now"", ""summary"": ""When done right, investing in pharmaceutical companies can be a lucrative endeavor.  This is because as long as there are diseases and infections, medicines and vaccines will always remain in high demand.  Dating back to Astra's founding in 1913 in Sweden, AstraZeneca (NASDAQ: AZN) has more than a century of corporate history.""}, {""date"": ""2023-06-16"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.87% to \u00a3117.88 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-16"", ""headline"": ""Unusually active option classes on open June 16th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-18"", ""headline"": ""AstraZeneca planning China business spin off -FT"", ""summary"": ""The company would seek to be a patriotic company in China that \""loves the Communist Party\"", its China president said in May. Last year, the country accounted for 13% of AstraZeneca's total sales, and the company is China's biggest drugmaker.  The spin off could protect AstraZeneca from tensions between China and other global powers, while the company retained control of the business, the FT's report said.  AstraZeneca said it did not comment on \""rumours or speculations around future strategy or M&A.\""""}, {""date"": ""2023-06-18"", ""headline"": ""AstraZeneca drafts plan to spin off China business amid tensions"", ""summary"": ""Anglo-Swedish drugmaker views listing a separate unit in Hong Kong as potential shelter from global strife""}, {""date"": ""2023-06-18"", ""headline"": ""How HS2 haunts ambitious plans for Britain\u2019s golden triangle"", ""summary"": ""The rivalry between Oxford and Cambridge stretches back centuries, with each university town famously dismissing their opposite as \u201cthe other place\u201d.""}, {""date"": ""2023-06-18"", ""headline"": ""Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas"", ""summary"": ""San Diego-Shanghai company Cullgen will collaborate with Japan's Astellas Pharma to discover multiple innovative protein degraders in a deal worth up to $1.9 billion. Read more here...""}]",{}
23,2023-06-18,74.72930145263672,2023-06-25,71.64952087402344,-0.0412124898633669,D5,"[{""date"": ""2023-06-18"", ""headline"": ""AstraZeneca weighs China unit spinoff amid geopolitical risks - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-18"", ""headline"": ""LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-18"", ""headline"": ""AZN Stock: China Business Spin-Off in the Works; Politics at Play"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-18"", ""headline"": ""Why is AstraZeneca (NASDAQ:AZN) Mulling Spin-Off of China Business?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-18"", ""headline"": ""PRESS: AstraZeneca drafts plan to spin-off in China - FT"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-18"", ""headline"": ""LONDON MARKET EARLY CALL: Stocks to fall but pound rises ahead of BoE"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-18"", ""headline"": ""AstraZeneca planning China business spin off -FT"", ""summary"": ""The company would seek to be a patriotic company in China that \""loves the Communist Party\"", its China president said in May. Last year, the country accounted for 13% of AstraZeneca's total sales, and the company is China's biggest drugmaker.  The spin off could protect AstraZeneca from tensions between China and other global powers, while the company retained control of the business, the FT's report said.  AstraZeneca said it did not comment on \""rumours or speculations around future strategy or M&A.\""""}, {""date"": ""2023-06-18"", ""headline"": ""AstraZeneca drafts plan to spin off China business amid tensions"", ""summary"": ""Anglo-Swedish drugmaker views listing a separate unit in Hong Kong as potential shelter from global strife""}, {""date"": ""2023-06-18"", ""headline"": ""How HS2 haunts ambitious plans for Britain\u2019s golden triangle"", ""summary"": ""The rivalry between Oxford and Cambridge stretches back centuries, with each university town famously dismissing their opposite as \u201cthe other place\u201d.""}, {""date"": ""2023-06-18"", ""headline"": ""Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas"", ""summary"": ""San Diego-Shanghai company Cullgen will collaborate with Japan's Astellas Pharma to discover multiple innovative protein degraders in a deal worth up to $1.9 billion. Read more here...""}, {""date"": ""2023-06-19"", ""headline"": ""AstraZeneca plots to sell AI drug unit to the Chinese"", ""summary"": ""AstraZeneca\u2019s pioneering artificial intelligence (AI) research centre could fall into foreign ownership under reported plans for the drugs giant to spin off and separately list its Chinese division.""}, {""date"": ""2023-06-19"", ""headline"": ""AstraZeneca/China: break-up deal would reflect necessity not choice"", ""summary"": ""China is known for its prowess in gymnastics.  As tensions heighten between the US and China, AstraZeneca may offer its own twist by carving out its Chinese business.  Chief executive Pascal Soriot has pushed AstraZeneca harder and faster into China than any other big foreign drugmaker.""}, {""date"": ""2023-06-19"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""AstraZeneca PLC shares shed 1.20% to \u00a3116.46 Monday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-06-19"", ""headline"": ""AstraZeneca could break out and separately list China business, FT reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-19"", ""headline"": ""LONDON MARKET OPEN: Stocks falter amid weaker outlook for China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-19"", ""headline"": ""AstraZeneca could spin off China business"", ""summary"": ""AstraZeneca is protecting itself from US-China tensions.  Plus, corporate America has poured a lot of money into diversity plans over the past three years, but now it\u2019s pulling back.  US secretary of state Antony Blinken is wrapping up a trip to China.""}, {""date"": ""2023-06-20"", ""headline"": ""Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""In the latest trading session, Astrazeneca (AZN) closed at $73.95, marking a -1.69% move from the previous day.""}, {""date"": ""2023-06-20"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slid 1.69% to $73.95 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-06-20"", ""headline"": ""AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business"", ""summary"": ""AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.""}, {""date"": ""2023-06-20"", ""headline"": ""Spotify to Launch New Expensive Subscription Plan, Chinese Vendors Bypass US Embargo to Supply Nvidia AI Chips, Eddie Wu To Succeed Daniel Zhang As Alibaba's CEO: Today's Top Stories"", ""summary"": ""Bloomberg Spotify to Launch New Expensive Subscription Plan, 'Supremium,' Amid Competition with Apple and Amazon Spotify Technology S.A. (NYSE: SPOT) is eying a more expensive subscription option likely to include high-fidelity audio to drive more revenue and appease investors. Dubbed \""Supremium,\"" the new tier will be Spotify's most expensive plan and likely offer a HiFi feature it first announced it was working on in 2021. To augment its current \""Premium\"" tier, Spotify will offer subscribers ex""}, {""date"": ""2023-06-20"", ""headline"": ""AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions"", ""summary"": ""European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is considered an option amid mounting geopolitical tensions. Last month, during an event held in Wuxi to commemorate its 30th year in China, AstraZeneca's China president, Wang Lei, said the company will seek to be a patriotic company in China that \""loves the Communist Party.\"" In 2022, China accounted for 13% of the company's overall sales. The s""}, {""date"": ""2023-06-20"", ""headline"": ""AstraZeneca call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-20"", ""headline"": ""AstraZeneca outperforms market despite losses on the day"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.09% to \u00a3116.36 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-20"", ""headline"": ""AstraZeneca: What's Next? (Rating Downgrade)"", ""summary"": ""AstraZeneca is considering spinning off its China operations and listing a separate division in Hong Kong or Shanghai. Read why we're neutral on AZN stock.""}, {""date"": ""2023-06-20"", ""headline"": ""Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court "", ""summary"": ""The lawsuits are the opening salvo in a historic and potentially decisive battle over Medicare's efforts to bring rising drug prices under control. ""}, {""date"": ""2023-06-21"", ""headline"": ""SandboxAQ to launch 'AQBioSim' division to focus on A.I.-assisted drug development"", ""summary"": ""Jack Hidary, SandboxAQ CEO, joins 'Last Call' to discuss the use case for A.I. in the healthcare industry and how the technology is being utilized to develop life saving drugs.""}, {""date"": ""2023-06-21"", ""headline"": ""FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer"", ""summary"": ""Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing standard of care for treating HRR gene-mutated mCRPC.""}, {""date"": ""2023-06-21"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR shed 0.77% to $73.38 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-21"", ""headline"": ""$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-21"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.43% to \u00a3115.86 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-21"", ""headline"": ""What Does AstraZeneca's Debt Look Like?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-21"", ""headline"": ""Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-21"", ""headline"": ""Pieris sinks 60% as AstraZeneca halts mid-stage trial for Asthma candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-21"", ""headline"": ""Pieris Pharma Shares Halted as Partner Discontinues Asthma Treatment Trial"", ""summary"": ""By Adriano Marchese Pieris Pharmaceuticals shares were halted in premarket trading after its partner AstraZeneca decided to discontinue and cease dosing in...""}, {""date"": ""2023-06-22"", ""headline"": ""Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-22"", ""headline"": ""Is AstraZeneca a Top Stock to Buy Right Now?"", ""summary"": ""The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead.""}, {""date"": ""2023-06-22"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.78% higher to $73.95 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-06-22"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.12% to \u00a3116.00 Thursday, on what proved to be an all-around rough trading session for the stock market, with the FTSE...""}, {""date"": ""2023-06-22"", ""headline"": ""Interesting AZN Put And Call Options For August 4th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-22"", ""headline"": ""European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-22"", ""headline"": ""Novo Nordisk falls after safety signal linked to weight loss drug class"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slid 2.47% to $72.12 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-06-23"", ""headline"": ""Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate"", ""summary"": ""Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.""}, {""date"": ""2023-06-23"", ""headline"": ""This Is What Whales Are Betting On AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""IN THE KNOW: GSK inks Zantac settlement but \""not a full stop\"" on saga"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC shed 1.53% to \u00a3114.22 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-06-23"", ""headline"": ""Unusually active option classes on open June 23rd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-25"", ""headline"": ""What is behind big pharma's underperformance?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-25"", ""headline"": ""Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company"", ""summary"": ""The biotech world had a busy week. Click to read about the latest Deals and Financings & Trials and Approvals in biotech.""}]",{}
24,2023-06-25,71.64952087402344,2023-07-02,71.10311126708984,-0.0076261446031762326,D1,"[{""date"": ""2023-06-25"", ""headline"": ""EU committee recommends expanded approval for AstraZeneca's Soliris"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-25"", ""headline"": ""First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-25"", ""headline"": ""Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-25"", ""headline"": ""What is behind big pharma's underperformance?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-25"", ""headline"": ""Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company"", ""summary"": ""The biotech world had a busy week. Click to read about the latest Deals and Financings & Trials and Approvals in biotech.""}, {""date"": ""2023-06-26"", ""headline"": ""AstraZeneca's diabetes combination treatment approved in China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""AstraZeneca put volume heavy and directionally bearish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $71.73, moving -0.54% from the previous trading session.""}, {""date"": ""2023-06-26"", ""headline"": ""AstraZeneca PLC ADR falls Monday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR sank 0.54% to $71.73 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-06-26"", ""headline"": ""AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease"", ""summary"": ""The European Union has recommended for marketing authorization of AstraZeneca Plc's (NASDAQ: AZN) Soliris (eculizumab) for expanded use in refractory generalized myasthenia gravis (gMG) in children and adolescents. gMG is a rare, chronic autoimmune neuromuscular disease causing severe weakness and loss of muscle function. Soliris was first approved in the EU in 2017 for certain adults with gMG and is also approved for certain adults with gMG in the U.S., China, and Japan. If approved, Soliris wo""}, {""date"": ""2023-06-26"", ""headline"": ""Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Amazon targets Ohio for big AWS operations expansion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slid 1.14% to \u00a3112.92 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-06-26"", ""headline"": ""Interesting AZN Put Options For August 18th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""AstraZeneca's Soliris recommended for EU approval by CHMP for children with gMG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Innate Pharma announces first patient dosed in MATISSE trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""AstraZeneca Unusual Options Activity For June 28"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed at $71.67 in the latest trading session, marking a -0.08% move from the prior day.""}, {""date"": ""2023-06-27"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR sank 0.08% to $71.67 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-27"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.90% to \u00a3111.90 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-06-27"", ""headline"": ""Price Over Earnings Overview: AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""AIM ImmunoTech announces approval in the Netherlands to begin Phase 1b/2 study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""Largest borrow rate increases among liquid names"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""AstraZeneca says Xigduo XR approved in China for adults with type-2 diabetes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.99% to $70.96 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-28"", ""headline"": ""How to Find Strong Medical Stocks Slated for Positive Earnings Surprises"", ""summary"": ""Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.""}, {""date"": ""2023-06-28"", ""headline"": ""AstraZeneca rises Wednesday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.39% to \u00a3112.34 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-06-28"", ""headline"": ""Genprex jumps ~15% on third FDA fast track tag for lead asset"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""IN BRIEF: AstraZeneca invests USD400 million in reforestation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health"", ""summary"": ""CAMBRIDGE, United Kingdom, June 28, 2023--Expansion of AZ Forest for climate action and human health""}, {""date"": ""2023-06-28"", ""headline"": ""AstraZeneca announces $400M investment in AZ Forest program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""AstraZeneca PLC ADR underperforms Thursday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.16% to $70.85 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-29"", ""headline"": ""IMFINZI\u00ae (durvalumab) plus IMJUDO\u00ae (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial"", ""summary"": ""WILMINGTON, Del., June 29, 2023--Updated results from the HIMALAYA Phase III trial showed AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) plus IMJUDO\u00ae (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.""}, {""date"": ""2023-06-29"", ""headline"": ""AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.02% to \u00a3112.36 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-06-29"", ""headline"": ""SEC charges five individuals with insider trading before Alexion-Portola merger"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""AstraZeneca Sees Positive Phase 3 Trial Data for Imfinzi Cancer Treatment"", ""summary"": ""By Chris Wack AstraZeneca said a Phase III trial showed its Imfinzi durvalumab plus Imjudo demonstrated a sustained, clinically meaningful overall survival...""}, {""date"": ""2023-06-29"", ""headline"": ""AstraZeneca's Advanced Liver Cancer Treatment Data Shows Improved Survival Rates"", ""summary"": ""By Michael Susin AstraZeneca said Thursday that phase III studies showed that Imfinzi plus Imjudo provided a sustained and clinically meaningful overall...""}, {""date"": ""2023-06-29"", ""headline"": ""AstraZeneca: Imfinzi + Imjudo demonstrate meaningful OS benefit for HCC patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""AstraZeneca says Imfinzi/Imjudo show sustained OS benefit in HIMALAYA trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-30"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.02% to $71.57 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-06-30"", ""headline"": ""AstraZeneca rises Friday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.36% to \u00a3112.76 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-06-30"", ""headline"": ""Medicare revises guidance on drug price negotiations amid lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-01"", ""headline"": ""4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip"", ""summary"": ""It's been a wild two years for Wall Street.  After rocketing to record-closing highs in 2021, all three major stock indexes stumbled into a bear market last year.  The innovation-focused Nasdaq Composite (NASDAQINDEX: ^IXIC) was hardest hit, with the index shedding a third of its value.""}]","{""assetTurnoverTTM"": 0.4635, ""bookValue"": 37392, ""cashRatio"": 0.21474881516587677, ""currentRatio"": 0.8659, ""ebitPerShare"": 1.5744, ""eps"": 1.1654, ""ev"": 247059.2315, ""fcfMargin"": 0.1082, ""fcfPerShareTTM"": 4.2332, ""grossMargin"": 0.8314, ""inventoryTurnoverTTM"": 1.4625, ""longtermDebtTotalAsset"": 0.252, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.6506, ""netDebtToTotalCapital"": 0.3596, ""netDebtToTotalEquity"": 0.6465, ""netMargin"": 0.1593, ""operatingMargin"": 0.2151, ""payoutRatioTTM"": 0.8481, ""pb"": 5.9608, ""peTTM"": 36.1709, ""pfcfTTM"": 33.9712, ""pretaxMargin"": 0.1829, ""psTTM"": 5.0105, ""quickRatio"": 0.6744, ""receivablesTurnoverTTM"": 4.4484, ""roaTTM"": 0.0642, ""roeTTM"": 0.1696, ""roicTTM"": 0.0929, ""rotcTTM"": 0.1108, ""salesPerShare"": 7.3179, ""sgaToSale"": 0.1686, ""totalDebtToEquity"": 0.798, ""totalDebtToTotalAsset"": 0.3091, ""totalDebtToTotalCapital"": 0.4438, ""totalRatio"": 1.6321, ""period"": ""2023-06-30""}"
25,2023-07-02,71.10311126708984,2023-07-09,64.42694854736328,-0.09389410112657948,D5+,"[{""date"": ""2023-07-02"", ""headline"": ""TOP NEWS: AstraZeneca, Daiichi hail datopotamab lung cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-02"", ""headline"": ""AstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer Patients"", ""summary"": ""By Anthony O. Goriainoff AstraZeneca said Monday that its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell...""}, {""date"": ""2023-07-02"", ""headline"": ""Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-02"", ""headline"": ""Europe stocks close slightly lower after strong first half; mining stocks up 2%"", ""summary"": ""European stock markets closed slightly lower on Monday, shortly after ending the first half of the year 8.8% higher.""}, {""date"": ""2023-07-03"", ""headline"": ""Europe stocks close slightly higher as investors await earnings season; OMV shares up 7%"", ""summary"": ""European markets closed slightly higher Tuesday, with investors in a cautious mood ahead of data releases and the start of second-quarter earnings season.""}, {""date"": ""2023-07-03"", ""headline"": ""These Were Monday's 2 Stock Movers That Investors Cared About the Most"", ""summary"": ""Modest gains came for the Nasdaq Composite (NASDAQINDEX: ^IXIC), Dow Jones Industrial Average (DJINDICES: ^DJI), and S&P 500 (SNPINDEX: ^GSPC) alike, as a favorable summer sentiment among many investors continued to build momentum.  Coinbase Global (NASDAQ: COIN) got a big boost as institutional investors look to have the U.S. Securities and Exchange Commission grant approval for some interesting new investments.""}, {""date"": ""2023-07-03"", ""headline"": ""ADRs End Mostly Higher; AstraZeneca, Novartis Trade Actively"", ""summary"": ""By Denny Jacob International stocks trading in New York closed mostly higher on Monday. The S&P/BNY Mellon index of American depositary receipts edged up...""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca: Today's Hit On Lung Cancer Data - Justified Or Overblown?"", ""summary"": ""AstraZeneca stock took a hit today after the company released data from a key lung cancer study. See whether today's selloff in AZN was justified.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca Stock Is Sinking. A Cancer Drug Showed Disappointing Results."", ""summary"": ""American depositary receipts of AstraZeneca were falling Monday after the drugmaker reported disappointing results from a Phase 3 trial of a lung- cancer drug.""}, {""date"": ""2023-07-03"", ""headline"": ""Stocks to Watch Monday: Tesla, Apple, Nio, AstraZeneca"", ""summary"": ""**\u2197\ufe0f** [**Tesla (TSLA)**](https://www.wsj.com/market-data/quotes/TSLA): The electric carmaker's stock rose 6.5% premarket after the company posted [a record quarter for sales.](https://www.wsj.com/articles/tesla-deliveries-to-show-whether-price-cuts-are-paying-off-2f2aac93) Other U.""}, {""date"": ""2023-07-03"", ""headline"": ""Health Care Slips as AstraZeneca Slides -- Health Care Roundup"", ""summary"": ""Health-care companies fell amid development setbacks for some major drugmakers. AstraZeneca and Daiichi Sankyo shares plunged after the British drugmaker and...""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment"", ""summary"": ""AstraZeneca and Daiichi Sankyo reported mixed results Monday from a final-phase study of their lung cancer treatment, and AZN stock tumbled.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca Stock Sinks as Cancer Drug Results Disappoint Investors"", ""summary"": ""'For the dual primary endpoint of overall survival (OS), the data were not mature,' AstraZeneca said in its news release.""}, {""date"": ""2023-07-03"", ""headline"": ""Tesla, Rivian rise; Apple, AstraZeneca fall, Monday, 7/3/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""Midday movers: Tesla, AstraZeneca, Carnival Corp. and more"", ""summary"": ""Investing.com -- Stocks are rising in light trading on a shortened market day in the U.S. session. Here are the market movers for July 3.""}, {""date"": ""2023-07-03"", ""headline"": ""What You Missed On Wall Street On Monday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca drug hits PFS, but no 'clinically meaningful,' says Credit Suisse"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""European Stocks Rise, AstraZeneca Drops After Lung-Cancer Trial Update"", ""summary"": ""European stock markets were mostly in the green on Monday, despite eurozone data suggesting a decline in manufacturing activity in June.  London-listed pharmaceutical company AstraZeneca was among the biggest decliners as the results of a study on a lung-cancer treatment disappointed investors.  AstraZeneca (ticker: AZN) was down nearly 6% in London after it reported results for its datopotamab deruxtecan treatment in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial.""}, {""date"": ""2023-07-03"", ""headline"": ""European stocks decrease for first time in four days"", ""summary"": ""European stocks fell Monday, as the Stoxx Europe 600 index closed down 0.21% to 460.98. The German DAX weakened 0.41% to 16,081.04, the French CAC 40 index...""}, {""date"": ""2023-07-03"", ""headline"": ""LONDON MARKET CLOSE: Blue chips lose early shine as US treads water"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""U.K. stocks drop Monday"", ""summary"": ""U.K. stocks finished down Monday, with the FTSE 100 Index decreasing 0.06% at 7,527.26. Among FTSE 100 constituents, biotechnology company AstraZeneca PLC...""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slipped 8.00% to \u00a3103.74 Monday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca Losses Leave The FTSE In The Red To Start July"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial"", ""summary"": ""WILMINGTON, Del., July 03, 2023--Positive high-level results from the TROPION-Lung01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy.""}, {""date"": ""2023-07-03"", ""headline"": ""Stocks making the biggest moves midday: Tesla, Rivian, XPeng and more"", ""summary"": ""These are the stocks posting the largest moves in midday trading. ""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca Stock (NASDAQ:AZN) Dives as Phase Three Data Disappoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AZN Crosses Below Key Moving Average Level"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca reports mixed Phase 3 data for lung cancer drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""Video: Nasdaq 100 Movers: AZN, TSLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca 'glossing over' patient deaths in trial 'shameful,' Feuerstein says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca shares fall after cancer drug trial disappoints investors"", ""summary"": ""AstraZeneca failed to meet investor expectations for a new lung cancer drug, despite announcing positive results showing a statistically significant improvement over chemotherapy.  Shares in the Anglo-Swedish drugmaker fell 5 per cent on Monday morning after it published the first results from its phase 3 trial for datopotamab deruxtecan, which it is developing with Daiichi Sankyo.  Investors were hoping that the drug would become as successful as Enhertu, another cancer treatment AstraZeneca developed with the Japanese group, and the companies have been investing heavily in trials for different types of cancer.""}, {""date"": ""2023-07-03"", ""headline"": ""Unusually active option classes on open July 3rd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca shares drop as lung cancer trial update lags expectations"", ""summary"": ""AstraZeneca said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped.  The drug, datopotamab deruxtecan, which is being jointly developed with Japan's Daiichi Sankyo, was shown to prolong progression-free survival compared with standard chemotherapy in patients whose non-small cell lung cancer had returned after one or two prior treatment attempts, AstraZeneca said.  The British drugmaker also said some trial participants had died of interstitial lung disease, or scarring of lung tissue, but added that the drug's safety profile was in line with observations during previous clinical trials.""}, {""date"": ""2023-07-03"", ""headline"": ""Tesla, XPeng, Nio rise premarket; AstraZeneca, AMC Entertainment fall"", ""summary"": ""Investing.com -- U.S. futures inched lower at the start of a holiday-shortened week that includes the release of some key economic data, including the monthly employment report.""}, {""date"": ""2023-07-03"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""Stocks making the biggest moves in the premarket: Tesla, Apple, AstraZeneca and more"", ""summary"": ""These are the stocks posting the largest moves in premarket trading. ""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca Drops on Concern Over Lung Cancer Trial"", ""summary"": ""(Bloomberg) -- AstraZeneca Plc shares fell as results from a high-level study of a new cancer medicine raised concern the drug might not work as well as anticipated.Most Read from BloombergTesla and BYD Post Record Sales on Surge in Electric-Car DemandIt\u2019s Getting a Lot Harder to Chase the Stock Rally From Here OnFrench Riots Begin to Abate Even as Economic Costs MountSingapore\u2019s Star Banker Creates a Succession Dilemma for DBSThe drug helped patients with the most common form of lung cancer liv""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca Lung Cancer Treatment Meets Dual Primary Endpoint in First Phase 3 Trial Results"", ""summary"": ""By Ben Glickman AstraZeneca said its treatment for lung cancer met one of its dual primary endpoints in the first batch of results for a Phase 3 trial. The...""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca shares dip after lung cancer drug trial update 'disappoints' hopes"", ""summary"": ""Investing.com -- AstraZeneca (LON:AZN) has announced that its experimental precision drug has shown improvement in slowing the progression of lung cancer in a late-stage trial, however, shares slipped on Monday after analysts noted that the findings disappointed expectations.""}, {""date"": ""2023-07-03"", ""headline"": ""AZN and VBIV among pre-market losers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""LONDON MARKET MIDDAY: Miners and oil majors lead FTSE 100 march"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""Russia and Saudi Arabia cut oil supplies in effort to bolster prices"", ""summary"": ""Oil prices have pushed higher as Saudi Arabia and Russia announced twin moves to cut supplies.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca (NASDAQ: AZN) Slumps Over Concerns about Lung Cancer Drug Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca says TROPION-Lung01 Phase 3 trial met dual primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""AstraZeneca shares slump after Phase 3 lung cancer drug study"", ""summary"": ""AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors.""}, {""date"": ""2023-07-03"", ""headline"": ""Tesla shares rally on delivery numbers, AstraZeneca stock slumps on drug trial, and other stocks on the move"", ""summary"": ""Tesla and AstraZeneca stock head in opposite directions.""}, {""date"": ""2023-07-03"", ""headline"": ""These Stocks Are Moving the Most Today: Tesla, AstraZeneca, and More"", ""summary"": ""Stocks closed in the green Monday\u00a0to start off the shortened holiday week.""}, {""date"": ""2023-07-03"", ""headline"": ""LONDON MARKET OPEN: Stocks start second half in green amid PMIs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""How a Swedish start-up reignited the search for an Alzheimer\u2019s drug"", ""summary"": ""A decade ago a large part of Big Pharma gave up on one of humanity\u2019s cruellest diseases. But then a new treatment showed promise""}, {""date"": ""2023-07-04"", ""headline"": ""Biotech Blues: Stay Balanced Through July Earnings Season"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""Europe stocks set for lower open as economic gloom returns; Fed minutes due"", ""summary"": ""European markets were set to dip at the open amid concerns over the economic outlook. ""}, {""date"": ""2023-07-04"", ""headline"": ""AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results"", ""summary"": ""While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.""}, {""date"": ""2023-07-04"", ""headline"": ""U.K. stocks continue losing streak, fall for second day"", ""summary"": ""U.K. stocks finished lower Tuesday, with the FTSE 100 Index dropping 0.10% at 7,519.72. Of the FTSE 100 constituents, major international banks company...""}, {""date"": ""2023-07-04"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC rallied 1.99% to \u00a3105.80 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-07-04"", ""headline"": ""LONDON MARKET CLOSE: Tepid close after quiet day with US market closed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""LONDON MARKET MIDDAY: Stocks higher amid US holiday-thinned trade"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""GLOBAL BROKER RATINGS: Deutsche Bank cuts Astrazeneca to 'hold'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""AstraZeneca downgraded to Hold from Buy at Deutsche Bank"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""AstraZeneca selloff on lung cancer data overdone, says Berenberg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""LONDON BROKER RATINGS: Dunelm, AstraZeneca and Persimmon cut"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Liquidia Technologies (LQDA) and AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""Moderna announces China investment as country opens doors to foreign pharma"", ""summary"": ""China signals a warmer welcome for Western pharma giants just as Treasury Secretary Janey Yellen leaves for Beijing.""}, {""date"": ""2023-07-05"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 2.77% to $67.06 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-07-05"", ""headline"": ""AstraZeneca, Moderna Stocks Rise"", ""summary"": ""Two large drugmakers are advancing in early trading Wednesday. + AstraZeneca's New-York listed ADR rose 2.6% shortly after the open; shares in the drugmaker sold off Monday after it reported mixed results in a trial for an experimental cancer drug.""}, {""date"": ""2023-07-05"", ""headline"": ""U.K. stocks weaken for third day"", ""summary"": ""U.K. stocks fell Wednesday, as the FTSE 100 Index finished down 1.03% at 7,442.10. Among FTSE 100 constituents, food retail company Ocado Group PLC saw the...""}, {""date"": ""2023-07-05"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.38% to \u00a3106.20 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE...""}, {""date"": ""2023-07-05"", ""headline"": ""Moderna strikes deal to develop mRNA drugs in China "", ""summary"": ""The deal is the biotech company's first agreement with China after the Asian nation repeatedly refused to accept mRNA vaccines from U.S.-based manufacturers. ""}, {""date"": ""2023-07-05"", ""headline"": ""Stocks making the biggest moves in the premarket: Rivian, UPS, Coinbase and more"", ""summary"": ""These are the stocks posting the largest moves premarket.""}, {""date"": ""2023-07-05"", ""headline"": ""GLOBAL BROKER RATINGS: Kepler Cheuvreux cuts Deutsche Boerse to 'hold'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""AstraZeneca weakness a buying opportunity, says TD Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""LONDON BROKER RATINGS: UBS likes Pearson; Liberum cuts Naked Wine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-06"", ""headline"": ""A Look Into AstraZeneca's Debt"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-06"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 2.46% to $65.41 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-07-06"", ""headline"": ""Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine"", ""summary"": ""Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.""}, {""date"": ""2023-07-06"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""AstraZeneca PLC shares slipped 2.75% to \u00a3103.28 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-07-06"", ""headline"": ""Interesting AZN Put And Call Options For November 17th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-07"", ""headline"": ""Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed at $64.85 in the latest trading session, marking a -0.86% move from the prior day.""}, {""date"": ""2023-07-07"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR shed 0.86% to $64.85 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-07-07"", ""headline"": ""Top Analyst Reports for BHP Group, AstraZeneca & Boeing"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including BHP Group Limited (BHP), AstraZeneca PLC (AZN) and The Boeing Company (BA).""}, {""date"": ""2023-07-07"", ""headline"": ""Here's Why Astrazeneca (AZN) is a Strong Value Stock"", ""summary"": ""Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.""}, {""date"": ""2023-07-07"", ""headline"": ""U.K. stocks extend negative streak for fifth day"", ""summary"": ""U.K. stocks finished down Friday, with the FTSE 100 Index falling 0.32% at 7,256.94. Of the FTSE 100 constituents, publishing company RELX PLC saw the...""}, {""date"": ""2023-07-07"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""AstraZeneca PLC shares slipped 2.11% to \u00a3101.10 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-07-07"", ""headline"": ""LONDON MARKET CLOSE: FTSE 100 ends rough week in tepid fashion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Goldman Sachs sees rays of hope in underperforming health sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4635, ""bookValue"": 37392, ""cashRatio"": 0.21474881516587677, ""currentRatio"": 0.8659, ""ebitPerShare"": 1.5744, ""eps"": 1.1654, ""ev"": 247059.2315, ""fcfMargin"": 0.1082, ""fcfPerShareTTM"": 4.2332, ""grossMargin"": 0.8314, ""inventoryTurnoverTTM"": 1.4625, ""longtermDebtTotalAsset"": 0.252, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.6506, ""netDebtToTotalCapital"": 0.3596, ""netDebtToTotalEquity"": 0.6465, ""netMargin"": 0.1593, ""operatingMargin"": 0.2151, ""payoutRatioTTM"": 0.8481, ""pb"": 5.9608, ""peTTM"": 36.1709, ""pfcfTTM"": 33.9712, ""pretaxMargin"": 0.1829, ""psTTM"": 5.0105, ""quickRatio"": 0.6744, ""receivablesTurnoverTTM"": 4.4484, ""roaTTM"": 0.0642, ""roeTTM"": 0.1696, ""roicTTM"": 0.0929, ""rotcTTM"": 0.1108, ""salesPerShare"": 7.3179, ""sgaToSale"": 0.1686, ""totalDebtToEquity"": 0.798, ""totalDebtToTotalAsset"": 0.3091, ""totalDebtToTotalCapital"": 0.4438, ""totalRatio"": 1.6321, ""period"": ""2023-06-30""}"
26,2023-07-09,64.42694854736328,2023-07-16,66.94043731689453,0.03901300350556669,U4,"[{""date"": ""2023-07-09"", ""headline"": ""B. Riley biotechnology analysts to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Goldman Sachs sees rays of hope in underperforming health sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-10"", ""headline"": ""The Zacks Analyst Blog Highlights BHP Group, AstraZeneca, The Boeing, Diageo and General Mills"", ""summary"": ""BHP Group, AstraZeneca, The Boeing, Diageo and General Mills are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-07-10"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.69% to \u00a3101.80 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-07-10"", ""headline"": ""Ionis Pharmaceuticals announces 'positive' results from Phase 3 NEURO-TTRansform"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""LONDON MARKET OPEN: FTSE 100 higher as UK banks pass BoE stress tests"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""LONDON BRIEFING: UK banks pass stress test; Wetherspoon trades well"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed at $64.86 in the latest trading session, marking a -0.51% move from the prior day.""}, {""date"": ""2023-07-11"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.51% to $64.86 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-07-11"", ""headline"": ""Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study"", ""summary"": ""Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).""}, {""date"": ""2023-07-11"", ""headline"": ""AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""2023-07-11"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.96% to \u00a3100.82 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-07-11"", ""headline"": ""50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography \u2013 Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""This Is What Whales Are Betting On AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rose 2.48% to $66.47 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-07-12"", ""headline"": ""AstraZeneca rises Wednesday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC rose 1.65% to \u00a3102.48 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-07-12"", ""headline"": ""IN THE KNOW: UBS backs AstraZeneca despite underwhelming Dato-DXd data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""Astra, Daiichi get China approval for Enhertu breast cancer treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""LianBio announces clinical supply agreement with AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""GLOBAL BROKER RATINGS: Raymond James cuts Activision to market perform"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""AstraZeneca's Enhertu approved in China for HER2-low metastatic breast cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""AstraZeneca upgraded to Buy from Neutral at UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""LONDON BROKER RATINGS: UBS raises AstraZeneca; RBC cuts Bunzl"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""LONDON MARKET OPEN: Stocks mixed ahead of US bank earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""AstraZeneca initiated with a Buy at HSBC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rose 1.87% to $67.71 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-07-13"", ""headline"": ""10 Buyable Inflation-Busting July Dividend Stocks"", ""summary"": ""Top 10 Inflation-Busting Dividend stocks boasted net gains from 21.29% to 52.44% per YCharts forward-looking data 7/11/23. Read more to see my exclusive lists.""}, {""date"": ""2023-07-13"", ""headline"": ""Nvidia Just Confirmed an Emerging AI Boom in Biotech"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.80% to \u00a3103.30 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-07-13"", ""headline"": ""AstraZeneca price target lowered to 12,600 GBp from 13,200 GBp at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""AZN September 1st Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""PepsiCo, Walt Disney, Delta rise premarket; Carvana, Coinbase SoFi fall"", ""summary"": ""Investing.com -- U.S. futures traded higher Thursday, continuing the recent positive sentiment ahead of the latest data on producer prices, with investors looking for more clues guiding future Federal Reserve monetary policy.""}, {""date"": ""2023-07-14"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 0.49% to $67.38 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-07-14"", ""headline"": ""More Challenges Await AbbVie Following A Disappointing Quarter"", ""summary"": ""AbbVie Inc., one of the leaders in the global immunology market, will release its financial report for the second quarter of 2023. Click here to read more.""}, {""date"": ""2023-07-14"", ""headline"": ""AstraZeneca outperforms market despite losses on the day"", ""summary"": ""AstraZeneca PLC shares inched down 0.06% to \u00a3103.24 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-07-14"", ""headline"": ""LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-15"", ""headline"": ""Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool"", ""summary"": ""Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval. Find out why RNLX stock is a Strong Buy.""}, {""date"": ""2023-07-16"", ""headline"": ""Buy/Sell: Wall Street's top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-16"", ""headline"": ""HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4635, ""bookValue"": 37392, ""cashRatio"": 0.21474881516587677, ""currentRatio"": 0.8659, ""ebitPerShare"": 1.5744, ""eps"": 1.1654, ""ev"": 247059.2315, ""fcfMargin"": 0.1082, ""fcfPerShareTTM"": 4.2332, ""grossMargin"": 0.8314, ""inventoryTurnoverTTM"": 1.4625, ""longtermDebtTotalAsset"": 0.252, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.6506, ""netDebtToTotalCapital"": 0.3596, ""netDebtToTotalEquity"": 0.6465, ""netMargin"": 0.1593, ""operatingMargin"": 0.2151, ""payoutRatioTTM"": 0.8481, ""pb"": 5.9608, ""peTTM"": 36.1709, ""pfcfTTM"": 33.9712, ""pretaxMargin"": 0.1829, ""psTTM"": 5.0105, ""quickRatio"": 0.6744, ""receivablesTurnoverTTM"": 4.4484, ""roaTTM"": 0.0642, ""roeTTM"": 0.1696, ""roicTTM"": 0.0929, ""rotcTTM"": 0.1108, ""salesPerShare"": 7.3179, ""sgaToSale"": 0.1686, ""totalDebtToEquity"": 0.798, ""totalDebtToTotalAsset"": 0.3091, ""totalDebtToTotalCapital"": 0.4438, ""totalRatio"": 1.6321, ""period"": ""2023-06-30""}"
27,2023-07-16,66.94043731689453,2023-07-23,68.88765716552734,0.029088842658955505,U3,"[{""date"": ""2023-07-15"", ""headline"": ""Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool"", ""summary"": ""Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval. Find out why RNLX stock is a Strong Buy.""}, {""date"": ""2023-07-16"", ""headline"": ""AstraZeneca's nirsevimab approved as RSV treatment for babies, infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-16"", ""headline"": ""Buy/Sell: Wall Street's top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-16"", ""headline"": ""HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""AstraZeneca (NASDAQ:AZN) and Sanofi Secure FDA Green Light"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""Rishi Sunak to meet bosses at inaugural Business Council gathering"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Astrazeneca (AZN) closed at $67.05, marking a -0.49% move from the previous day.""}, {""date"": ""2023-07-17"", ""headline"": ""FDA Approves First RSV Drug to Protect All Infants From Virus"", ""summary"": ""While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S.""}, {""date"": ""2023-07-17"", ""headline"": ""US FDA approves AstraZeneca and Sanofi's Beyfortus for RSV in infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""Newly approved RSV drug for infants provides all-season protection with 1 shot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""FDA approves Sanofi and AstraZeneca infant RSV vaccine"", ""summary"": ""The U.S. Food and Drug Administration on Monday approved a Sanofi and AstraZeneca PLC respiratory syncytial virus vaccine for newborns and infants. The RSV...""}, {""date"": ""2023-07-17"", ""headline"": ""FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV"", ""summary"": ""RSV is the leading cause of hospitalization among children less than a year old, according to scientists.""}, {""date"": ""2023-07-17"", ""headline"": ""New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold season"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""Sanofi, AstraZeneca confirm FDA approves Beyfortus for RSV disease in infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""FDA approves AstraZeneca's Beyfortus for prevention of RSV in neonates, infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""3 Doomed Biotech Stocks Destined for Disaster"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""AstraZeneca PLC ADR falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Why Pieris Pharmaceuticals Shares Shooting Higher Today?"", ""summary"": ""Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company provided a strategic update. The company says the update follows recent events that have impacted its inhaled respiratory franchise, including AstraZeneca Plc's (NASDAQ: AZN) discontinuation of enrollment of the Phase 2a study for elarekibep. AstraZeneca has now informed the company of its decision to terminate the parties' R&D collaboration agreement, hand back elarekibep, and discontinue the remaining discove""}, {""date"": ""2023-07-18"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.42% to $66.77 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-07-18"", ""headline"": ""Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants"", ""summary"": ""Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.""}, {""date"": ""2023-07-18"", ""headline"": ""AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants"", ""summary"": ""The FDA approved AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA\u2019s (NASDAQ: SNY) Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants. The approval covers newborns and infants during or entering their first RSV season and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus was approved in the European Union in November 2022 to prevent RSV LRTD in""}, {""date"": ""2023-07-18"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.78% to \u00a3102.80 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-07-18"", ""headline"": ""Pieris Pharma to Cut 70% of Workforce, Explore Strategic Options"", ""summary"": ""By Ben Glickman Pieris Pharmaceuticals said Tuesday it would cut about 70% of its workforce and explore strategic options after AstraZeneca terminated a...""}, {""date"": ""2023-07-18"", ""headline"": ""NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Pieris Pharmaceuticals announces restructuring, to reduce workforce by 70%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""The Tech Stock Rally Has Reached a Critical Moment. Watch Tesla, Netflix Earnings."", ""summary"": ""AT&T hit by report about lead on cables, Eli Lilly\u2019s Alzheimer\u2019s drug shows promise in latest trial, and other news to start your day.""}, {""date"": ""2023-07-19"", ""headline"": ""Pieris lays off most staff after AstraZeneca pulls out of partnership"", ""summary"": ""Pieris has also begun the process of exploring strategic alternatives. That could include a merger or acquisition or an asset sale.""}, {""date"": ""2023-07-19"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.17% to $67.55 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-07-19"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares advanced 2.16% to \u00a3105.02 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-07-20"", ""headline"": ""Earnings week ahead: Microsoft, Google, Meta, Boeing, Coca-Cola and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""SK Chemicals' Shares Climb After AstraZeneca Deal"", ""summary"": ""By Kwanwoo Jun SK Chemicals' shares climbed Friday after it won a contract with biopharmaceuticals giant AstraZeneca. Shares of the South Korean...""}, {""date"": ""2023-07-20"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR advanced 1.50% to $68.56 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-07-20"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC rallied 1.85% to \u00a3106.96 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-07-21"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.14% to $69.34 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-07-21"", ""headline"": ""Sanofi expects infant RSV shot to roll out before respiratory virus season this fall"", ""summary"": ""Sanofi said it is working with a CDC panel to include Beyfortus on the childhood immunization schedule and the Vaccines for Children Program.""}, {""date"": ""2023-07-21"", ""headline"": ""AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?"", ""summary"": ""AbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for the declining Humira sales following the loss of U.S. exclusivity.""}, {""date"": ""2023-07-21"", ""headline"": ""Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody"", ""summary"": ""FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.""}, {""date"": ""2023-07-21"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.69% to \u00a3107.70 Friday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-07-21"", ""headline"": ""The Bristol-Myers Squibb Phenomenon: A Game Changer In The Pharmaceutical Industry"", ""summary"": ""On July 27, 2023, Bristol-Myers Squibb will release its financial report for the second quarter of 2023. Read more to see a detailed analysis on BMY stock.""}, {""date"": ""2023-07-21"", ""headline"": ""Pfizer price target lowered to $42 from $43 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-23"", ""headline"": ""Big Pharma Bets Big on China"", ""summary"": ""China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere.""}, {""date"": ""2023-07-23"", ""headline"": ""4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys"", ""summary"": ""Barron\u00e2\u0080\u0099s Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies. Read more here.""}]",{}
28,2023-07-23,68.88765716552734,2023-07-30,70.86467742919922,0.028699194384291138,U3,"[{""date"": ""2023-07-23"", ""headline"": ""Big Pharma Bets Big on China"", ""summary"": ""China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere.""}, {""date"": ""2023-07-23"", ""headline"": ""4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys"", ""summary"": ""Barron\u00e2\u0080\u0099s Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies. Read more here.""}, {""date"": ""2023-07-24"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $68.92, moving -0.61% from the previous trading session.""}, {""date"": ""2023-07-24"", ""headline"": ""AstraZeneca PLC ADR falls Monday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.61% to $68.92 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-07-24"", ""headline"": ""AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?"", ""summary"": ""Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs.""}, {""date"": ""2023-07-24"", ""headline"": ""AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""2023-07-24"", ""headline"": ""AstraZeneca rises Monday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.09% to \u00a3107.80 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-07-25"", ""headline"": ""IN BRIEF: OTAQ names interim finance chief with incumbent to move on"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-25"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""ENHERTU\u00ae Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""Merck (MRK) to Report Q2 Earnings: What's in the Cards?"", ""summary"": ""Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q2 earnings.""}, {""date"": ""2023-07-26"", ""headline"": ""UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks "", ""summary"": ""The probe into potentially life-threatening side effects comes as the drugs skyrocket in popularity in the U.S. and draw heightened investor interest.""}, {""date"": ""2023-07-26"", ""headline"": ""Probe over suicide risk linked to weight loss drugs expands to U.K. \u2013 Reuters"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""LIVE: FTSE 100 and European stocks mixed ahead of Fed interest rates decision"", ""summary"": ""A look at how the major markets are performing on Wednesday.""}, {""date"": ""2023-07-27"", ""headline"": ""LONDON MARKET OPEN: StanChart, AstraZeneca lift FTSE 100 into green"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""TOP NEWS: AstraZeneca profit surges as Alexion agrees Pfizer deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""LONDON BRIEFING: NatWest posts interim growth; IAG swings to profit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""AstraZeneca's Alexion to Buy Gene Therapies Portfolio for Up to $1 Bln From Pfizer"", ""summary"": ""By Anthony O. Goriainoff AstraZeneca said Friday that its Alexion division will buy a portfolio of preclinical rare-disease gene therapies from Pfizer for up...""}, {""date"": ""2023-07-27"", ""headline"": ""Europe stocks set for lower open; Bank of Japan jolts markets by easing YCC stance"", ""summary"": ""European stock markets are heading for a lower open Friday after the Bank of Japan rattled markets. ""}, {""date"": ""2023-07-27"", ""headline"": ""AstraZeneca PLC 2Q EPS $1.17"", ""summary"": ""By Joe Hoppe AstraZeneca on Friday reported a significant rise in second-quarter net profit, but missed market forecasts, and backed its full-year guidance....""}, {""date"": ""2023-07-27"", ""headline"": ""LONDON MARKET EARLY CALL: Stocks to fall; yen firms after BoJ move"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Earnings week ahead: Amazon, Apple, Pfizer, Starbucks, Uber and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""GET READY: AstraZeneca, AIB, IAG, Intertek and NatWest at 0700 BST"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""AstraZeneca beats Q2 top and bottom line estimates; reaffirms FY23 outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""GLOBAL BRIEFING: Yen rises as BoJ adjusts yield curve control"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""50 Most Valuable Companies in the World by Market Cap"", ""summary"": ""In this article, we will be taking a look at the 50 most valuable companies in the world by market cap. If you want to skip our detailed analysis of the most valuable industries, you can go directly to 10 Most Valuable Companies in the World by Market Cap. The most valuable companies in the [\u2026]""}, {""date"": ""2023-07-27"", ""headline"": ""IN BRIEF: Astra drug approved while another shows promise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Why AstraZeneca (AZN) Might Surprise This Earnings Season"", ""summary"": ""AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.""}, {""date"": ""2023-07-27"", ""headline"": ""ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial"", ""summary"": ""WILMINGTON, Del., July 27, 2023--High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2-expressing advanced solid tumors, two secondary endpoints of the trial.""}, {""date"": ""2023-07-27"", ""headline"": ""UK earnings, trading statements calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Notable earnings before Friday's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Starpharma: Patience Needed, But A Lot To Like"", ""summary"": ""The news on Starpharma share price is challenging as a significant shareholder exits. Read more about SPHRF here.""}, {""date"": ""2023-07-27"", ""headline"": ""AstraZeneca says Soliris approved in EU for children with refractory gMG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""AstraZeneca: Enhertu showed clinically meaningful PFS, OS in DESTINY-PanTumor02"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca Plc (AZN) Q2 2023 Earnings Call Transcript"", ""summary"": ""Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.  Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca plays up China, downplays patent loss in latest earnings: CFO"", ""summary"": ""AstraZeneca (AZN) reported strong earnings Friday, including $22 billion, or 4% revenue growth, in the first half of the year, and kept its 2023 forecast stable.""}, {""date"": ""2023-07-28"", ""headline"": ""iPhone US Shipments Take A Hit, Does Social Media Algorithm Impact Political Beliefs? Research Reveals Answer, Disney Joins Netflix To Crack Down Password Sharing In India: Today's Top Stories"", ""summary"": ""Bloomberg DoorDash Embraces AI Chatbot to Revolutionize Food Ordering and Gain Competitive Edge DoorDash Inc (NYSE: DASH) has leveraged an artificial intelligence-based chatbot to speed up ordering and help customers find food options. The Uber Technologies Inc (NYSE: UBER) rival is working on a system called DashAI that it's testing in a limited capacity. The technology will help customers to get personalized restaurant recommendations with simple text prompts, adding an edge over its peers. Be""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales"", ""summary"": ""AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca Shares Surge After Revenue Beat"", ""summary"": ""AstraZeneca's shares rose on Friday after it announced the purchase of Pfizer's rare disease portfolio for up to $1 billion and reported better-than-expected financial results on strong sales of its cancer drugs.""}, {""date"": ""2023-07-28"", ""headline"": ""Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III"", ""summary"": ""AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.""}, {""date"": ""2023-07-28"", ""headline"": ""UK economy left behind as US heads for 'immaculate soft landing'"", ""summary"": ""The US economy is poised to make an \u201cimmaculate soft landing\u201d from the inflation crisis leaving the British economy behind.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca beats Q2 earnings estimates, sees strong sales of cancer treatment drugs"", ""summary"": ""Pharma manufacturer AstraZeneca reports a second-quarter earnings beat, offsetting its losses tied to slowing COVID-19 vaccine sales. AstraZeneca CFO Aradhana Sarin joins Yahoo Finance Live to discuss the value of gene therapy treatment for rare diseases, the company's guidance regarding China, and expectations for its cancer treatment drug Dato-DXd. \""What you see this quarter is really a reflection of all the investments we've made in innovation and new products over the decade,\"" Sarin said.""}, {""date"": ""2023-07-28"", ""headline"": ""Compared to Estimates, Astrazeneca (AZN) Q2 Earnings: A Look at Key Metrics"", ""summary"": ""The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca's Covid vaccine sales drop to zero as health officials back safer mRNA jabs"", ""summary"": ""Sales of the Oxford AstraZeneca Covid vaccine have fallen to zero as health officials switch their backing to safer jabs.""}, {""date"": ""2023-07-28"", ""headline"": ""Stocks Surge, Tech Rallies On Strong Earnings, Inflation Softens: What's Driving Markets Friday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca strikes $1 billion deal for Pfizer rare-disease gene therapies"", ""summary"": ""Stock gains 5% after AstraZeneca's second-quarter results top analyst expectations.""}, {""date"": ""2023-07-28"", ""headline"": ""European Stock Futures Surge After ECB Meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Trending tickers: IAG | NatWest | AstraZeneca | Intel"", ""summary"": ""A look at the stocks making headlines on Friday.""}, {""date"": ""2023-07-28"", ""headline"": ""UPDATE 2-AstraZeneca CEO says lung cancer drug trial data 'very encouraging'"", ""summary"": ""AstraZeneca Chief Executive Pascal Soriot said on Friday the company is \""very encouraged\"" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as \""clinically meaningful\"".  The drugmaker's shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan.  Speaking to media on Friday after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca beats estimates with strong cancer and diabetes drug sales"", ""summary"": ""Strong sales of drugs for cancer and diabetes helped AstraZeneca beat expectations in the second quarter, as the drugmaker expands its genomic medicine business with a $1bn deal to buy assets from Pfizer.  Pascal Soriot, AstraZeneca\u2019s chief executive, said eight medicines delivered more than $1bn of revenue in the first half, with each area of the business, except Covid-19 therapies, growing by double digits year-on-year.  \u201cWe look forward to sharing the data with the medical community at an upcoming medical congress and are proceeding to file the data with the US Food and Drug Administration,\u201d he said.""}, {""date"": ""2023-07-28"", ""headline"": ""Unusually active option classes on open July 28th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca CEO says lung cancer drug trial data 'very encouraging'"", ""summary"": ""AstraZeneca Chief Executive Pascal Soriot said on Friday the company is \""very encouraged\"" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as \""clinically meaningful\"".  The drugmaker's shares fell by as much as 8% earlier this month, after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca PLC 2023 Q2 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by AstraZeneca PLC in conjunction with their 2023 Q2 earnings call.""}, {""date"": ""2023-07-28"", ""headline"": ""6 stocks to watch on Friday: Palantir, Chevron, Ford, AstraZeneca and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca (NASDAQ:AZN) Soars on Q2 Beat; Enters Into $1B Gene Therapy Deal with Pfizer (NYSE:PFE)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more "", ""summary"": ""These are the stocks posting the largest moves in premarket trading. ""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca-Ionis deal for eplontersen expands to Latin America"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""UPDATE 1-AstraZeneca to buy Pfizer's rare disease gene therapy portfolio for up to $1 bln"", ""summary"": ""AstraZeneca said on Friday its unit Alexion has agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales.  AstraZeneca bought Alexion in 2021.  It focuses on rare diseases and plans to close the deal in the third quarter, the British drugmaker said.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca to buy Pfizer's rare disease gene therapy portfolio for up to $1 billion"", ""summary"": ""AstraZeneca bought Alexion in 2021.  It focuses on rare diseases and plans to close the deal in the third quarter, the British drugmaker said.  The deal will bring a number of novel adeno-associated virus (AAV) capsids to Alexion and help build on Alexion and AstraZeneca's capabilities in genomic medicine, it said.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca Q2 results beat estimates; COVID vaccine sales dry up"", ""summary"": ""LONDON (Reuters) -AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of COVID-19 vaccine sales.  Shares in the Anglo-Swedish drugmaker, which has a strong line-up of cancer, metabolic and rare disease drugs, rose as much as 4.8%, before settling back to 3.9% by 1052 GMT, making the stock the largest weighted gainer on the FTSE 100.  Sentiment was boosted by Chief Executive Pascal Soriot's positive remarks on the company's data from a key lung cancer trial, an AstraZeneca shareholder and an analyst told Reuters.""}, {""date"": ""2023-07-28"", ""headline"": ""Ionis expands collaboration with AstraZeneca for eplontersen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""UPDATE 3-AstraZeneca Q2 results beat estimates; COVID vaccine sales evaporate"", ""summary"": ""AstraZeneca on Friday delivered better-than-expected profits and sales in the second quarter as a strong performance of its blockbuster cancer drugs helped offset the loss of COVID-19 vaccine sales.  The Anglo-Swedish drugmaker posted an adjusted profit of $2.15 per share, up 25% and exceeding the $1.98 per share expected in company-compiled consensus estimates.  Total revenue in the quarter was $11.4 billion, up 6% and beating company-compiled analyst estimates of $10.97 billion.""}, {""date"": ""2023-07-28"", ""headline"": ""US Stock Futures Signal Rebound On Tech Earnings Support: Analyst Tells Why Fed May Not Start Cutting Rates Anytime Soon"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca unit in $1B deal with Pfizer for gene therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca backs FY23 view of core EPS up high single-to low double-digit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca reports Q2 core EPS $2.15, consensus $1.97"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Alexion to acquire portfolio of rare disease gene therapies from Pfizer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Earnings Scheduled For July 28, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Astrazeneca: Q2 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""European stocks mixed; strong AstraZeneca numbers help U.K. outperform"", ""summary"": ""European stock markets traded in a mixed fashion Friday, as investors digested a week of corporate earnings, important central bank decisions and economic data.  AstraZeneca stock rose 3.5% after the drugmaker delivered better-than-expected profits and sales in the second quarter as a strong performance of its blockbuster cancer drugs helped offset the loss of COVID-19 vaccine sales.""}, {""date"": ""2023-07-28"", ""headline"": ""AstraZeneca Shares Rise After 2Q Revenue, Earnings Beat Market Views -- Update"", ""summary"": ""By Joe Hoppe AstraZeneca shares rose Friday after the company reported a significant rise in second-quarter revenue and earnings per share, ahead of market...""}, {""date"": ""2023-07-29"", ""headline"": ""RSV treatment market to surge past $9B by 2029"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-29"", ""headline"": ""AstraZeneca PLC (NASDAQ:AZN) Q2 2023 Earnings Call Transcript"", ""summary"": ""AstraZeneca PLC (NASDAQ:AZN) Q2 2023 Earnings Call Transcript July 28, 2023 AstraZeneca PLC misses on earnings expectations. Reported EPS is $0.86 EPS, expectations were $0.98. Operator: Good morning to those joining from the UK and the US. Good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome, ladies and [\u2026]""}, {""date"": ""2023-07-29"", ""headline"": ""AstraZeneca: Solid Earnings Report Reinforces Medium To Long-Term Upside"", ""summary"": ""AstraZeneca's H1 2023 results show robust growth, with revenues ex-COVID-19 medicines increasing by 16% YoY. Read more about AZN stock here.""}, {""date"": ""2023-07-29"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Amplifon S.p.A. (GB:0N61), AstraZeneca (GB:AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-30"", ""headline"": ""AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-30"", ""headline"": ""AstraZeneca: Robust Performance And Promising Growth Initiatives"", ""summary"": ""AstraZeneca's Q2 2023 financial performance showed a 6% increase in total revenue. Read more to see what makes me bullish on AZN stock.""}, {""date"": ""2023-07-30"", ""headline"": ""Baron International Growth Fund Q2 2023 Shareholder Letter"", ""summary"": ""Baron International Growth Fund gained 3.45% (Institutional Shares) during the second quarter of 2023. Click here to read the full fund letter.""}]",{}
29,2023-07-30,70.86467742919922,2023-08-06,68.947265625,-0.027057370099721423,D3,"[{""date"": ""2023-07-29"", ""headline"": ""RSV treatment market to surge past $9B by 2029"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-30"", ""headline"": ""AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-30"", ""headline"": ""AstraZeneca: Robust Performance And Promising Growth Initiatives"", ""summary"": ""AstraZeneca's Q2 2023 financial performance showed a 6% increase in total revenue. Read more to see what makes me bullish on AZN stock.""}, {""date"": ""2023-07-30"", ""headline"": ""Baron International Growth Fund Q2 2023 Shareholder Letter"", ""summary"": ""Baron International Growth Fund gained 3.45% (Institutional Shares) during the second quarter of 2023. Click here to read the full fund letter.""}, {""date"": ""2023-07-31"", ""headline"": ""Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""3 Pharma Stocks to Buy for Their Promising Progress"", ""summary"": ""Identifying promising pharma stocks is no small feat in the dynamic and competitive realm of pharmaceuticals. The industry is replete with businesses boasting robust pipelines, each vying for a breakthrough that could potentially revolutionize healthcare. Today\u2019s article sheds light on three high-potential pharma stocks that hold strong promise for the future. These companies are among the cream of the crop regarding R&D pipeline size as of 2023, demonstrating a powerful blend of innovation and""}, {""date"": ""2023-07-31"", ""headline"": ""Viatris launches first generic of AstraZeneca asthma drug Symbicort"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Ionis Pharmacompletes enrollment for Phase 3 CARDIO-TTRansform study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Astrazeneca plc - ADR (AZN) Declares $0.46 Dividend"", ""summary"": """"}, {""date"": ""2023-08-01"", ""headline"": ""GLOBAL BROKER RATINGS: LBBW says 'buy' Vodafone; DZ raises Intel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Zentalis appoints Freeman as Chief Strategy Officer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Sanofi says CDC panel unanimously recommends use of Beyfortus for infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""AstraZeneca, Sanofi RSV treatment Beyfortus endorsed by CDC panel (updated)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""AstraZeneca, Sanofi RSV treatment Beyfortus priced at $495"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""AstraZeneca and Sanofi RSV drug wins support of CDC panel, Bloomberg says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets"", ""summary"": ""Peter Hecht, the co-founder and CEO of embattled biotech Cyclerion Therapeutics Inc. (Nasdaq: CYCN), is heading up a new startup that's effectively a life raft for Cyclerion's research. Elsewhere in the Petri Dish: a $1 billion deal for Pfizer gene therapies, a succession plan for a founder-led biotech organization, and a new Longwood Fund spinout with assets from GSK.""}, {""date"": ""2023-08-02"", ""headline"": ""Stick to U.S. stocks that offer experience over hope, Goldman says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""AstraZeneca PLC ADR outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Sanofi, AstraZeneca RSV Treatment for Infants Gets U.S. CDC Panel Recommendation"", ""summary"": ""By Cecilia Butini Sanofi and AstraZeneca's preventative treatment for respiratory syncytial virus was recommended for use by an independent health expert...""}, {""date"": ""2023-08-03"", ""headline"": ""CDC panel says babies should get new drug that prevents RSV"", ""summary"": ""Infants should get a new drug to protect them against a respiratory virus that sends tens of thousands of American children to the hospital each year, heath...""}, {""date"": ""2023-08-03"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 1.14% to $69.67 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-03"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slipped 1.77% to \u00a3109.00 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-08-03"", ""headline"": ""Infant RSV shot wins backing of CDC advisors, paving way for fall availability"", ""summary"": ""Sanofi has said the companies are prepared to roll the shot out before RSV season this fall and do not foresee any challenges meeting demand. ""}, {""date"": ""2023-08-04"", ""headline"": ""Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""AstraZeneca PLC ADR falls Friday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR sank 0.39% to $69.40 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-08-04"", ""headline"": ""CDC Recommends New Sanofi, AstraZeneca Shot to Prevent RSV in Babies"", ""summary"": ""The Centers for Disease Control and Prevention recommended a new  Sanofi  and  AstraZeneca  injection for all newborns in the U.S. to prevent cases of respiratory syncytial virus, making the drug the latest in a series of tools against the virus to roll out this fall.  Following a meeting of an expert outside advisory committee, which voted unanimously to support use of the medicine, the CDC said late Thursday it recommends routine use of the medicine in babies younger than eight months old.  Sanofi  (ticker: SNY) American depositary receipt was 1.1% higher in early trading, while  AstraZeneca  (AZN) ADR was down 0.2%.""}, {""date"": ""2023-08-04"", ""headline"": ""5 Healthcare Stocks to Buy Now, According to Analysts \u2013 August 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""AstraZeneca rises Friday, still underperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.09% to \u00a3109.10 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-08-04"", ""headline"": ""UK dividends calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""IN BRIEF: Sanofi wins US CDC recommendation for Beyfortus in RSV"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
30,2023-08-06,68.947265625,2023-08-13,70.37000274658203,0.020635149322965285,U3,"[{""date"": ""2023-08-06"", ""headline"": ""AstraZeneca price target raised to 12,700 GBp from 12,600 GBp at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Future Prospects For Johnson & Johnson Following Strong Q2 Performance"", ""summary"": ""Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. Read why JNJ stock is a hold.""}, {""date"": ""2023-08-07"", ""headline"": ""AstraZeneca PLC ADR underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""The AstraZeneca PLC ADR inched 0.76% higher to $69.93 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-07"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.22% to \u00a3108.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-08-07"", ""headline"": ""Nvidia Just Confirmed an Emerging AI Boom in Biotech"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""IN THE KNOW: Wegovy study key share price driver for Novo - Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""What You Missed On Wall Street On Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.79% higher to $70.48 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-08"", ""headline"": ""3 Stocks That Are Still A Buy On China's Recovery Story"", ""summary"": ""China's economic recovery has turned out to be slower than expected. Read why strong domestic consumption indicates that there are still pockets of recovery.""}, {""date"": ""2023-08-08"", ""headline"": ""AstraZeneca inks mRNA vaccine deal with China's CanSino"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC advanced 1.32% to \u00a3110.30 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-08-08"", ""headline"": ""U.K. stocks drop for second session"", ""summary"": ""U.K. stocks dropped Tuesday, as the FTSE 100 Index finished down 0.36% at 7,527.42. Of the FTSE 100 constituents, investment advisors company abrdn PLC saw...""}, {""date"": ""2023-08-08"", ""headline"": ""China's CanSino in mRNA vaccine deal with AstraZeneca"", ""summary"": ""CanSino Biologics has agreed with AstraZeneca to provide \""contract development and manufacturing services\"" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.  In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca.  AstraZeneca did not have an immediate comment on the announcement.""}, {""date"": ""2023-08-08"", ""headline"": ""Is This Blue Chip Dividend Stock a Buy for Growth Investors?"", ""summary"": ""An investor who put $3,000 into AstraZeneca (NASDAQ: AZN) five years ago and reinvested dividends would have $6,200 today.  The same amount put into the S&P 500 would be worth only $5,200 with dividends reinvested.  Let's examine AstraZeneca's fundamentals and valuation to decide.""}, {""date"": ""2023-08-09"", ""headline"": ""Dr. Reddy's launches generic version of Kombiglyze XR in US"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""AstraZeneca declares goes ex-dividend tomorrow"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares advanced 1.38% to \u00a3111.82 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-08-09"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""UK dividends calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""AstraZeneca signs vaccine deal with China\u2019s CanSino"", ""summary"": ""Drugmaker says it is working on new technologies to develop vaccines for infectious diseases where there is \u2018high unmet need\u2019""}, {""date"": ""2023-08-09"", ""headline"": ""UPDATE 1-China's CanSino in mRNA vaccine deal with AstraZeneca"", ""summary"": ""CanSino Biologics has agreed with AstraZeneca to provide \""contract development and manufacturing services\"" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.  In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca.""}, {""date"": ""2023-08-09"", ""headline"": ""Statkraft Strikes Swedish Wind Power Purchase Deal with AstraZeneca"", ""summary"": ""By Dominic Chopping Renewable energy producer Statkraft said it has entered a wind power agreement with AstraZeneca that sees the Anglo-Swedish pharma giant...""}, {""date"": ""2023-08-09"", ""headline"": ""AstraZeneca signs vaccine deal with China's CanSino Biologics, FT reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates"", ""summary"": ""Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.""}, {""date"": ""2023-08-10"", ""headline"": ""These 10 medications are likely targets for Medicare price negotiations this fall"", ""summary"": ""It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.""}, {""date"": ""2023-08-10"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.47% to \u00a3111.62 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-08-10"", ""headline"": ""Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk"", ""summary"": ""Organon & Co. formed via Merck & Co.'s spinout of its Established Brands, reported its Q2 2023 earnings on 8th August. Read more about OGN stock here.""}, {""date"": ""2023-08-10"", ""headline"": ""Q2 2023 Ionis Pharmaceuticals Inc Earnings Call"", ""summary"": ""Q2 2023 Ionis Pharmaceuticals Inc Earnings Call""}, {""date"": ""2023-08-10"", ""headline"": ""LONDON MARKET MIDDAY: FTSE 100 flat, peers and pound up before US data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-11"", ""headline"": ""Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-11"", ""headline"": ""Hutchmed: Attractive Chinese R&D Giant"", ""summary"": ""Hutchmed (China) Limited shows promise for growth with a range of products in clinical trials and collaborations. Click here to read an analysis on HCM stock.""}, {""date"": ""2023-08-11"", ""headline"": ""Is Most-Watched Stock AstraZeneca PLC (AZN) Worth Betting on Now?"", ""summary"": ""Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""2023-08-11"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-13"", ""headline"": ""AstraZeneca (LON:AZN) shareholders have earned a 16% CAGR over the last five years"", ""summary"": ""When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...""}, {""date"": ""2023-08-13"", ""headline"": ""Week In Review: BeiGene And BMS Close BeiGene-Celgene PD-1 Partnership"", ""summary"": ""What are the pivotal collaborations and transformative partnerships reshaping China's biopharma sector this week? Click here to find out. ""}]",{}
31,2023-08-13,70.37000274658203,2023-08-20,68.45999908447266,-0.027142299098491196,D3,"[{""date"": ""2023-08-13"", ""headline"": ""AstraZeneca (LON:AZN) shareholders have earned a 16% CAGR over the last five years"", ""summary"": ""When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...""}, {""date"": ""2023-08-13"", ""headline"": ""Week In Review: BeiGene And BMS Close BeiGene-Celgene PD-1 Partnership"", ""summary"": ""What are the pivotal collaborations and transformative partnerships reshaping China's biopharma sector this week? Click here to find out. ""}, {""date"": ""2023-08-14"", ""headline"": ""China Looks to Attract Foreign Investment as Its Economy Struggles"", ""summary"": ""(Bloomberg) -- China\u2019s latest attempt to reverse the nation\u2019s foreign investment slump includes pledges to offer overseas firms better tax treatment and make it easier for them to obtain visas, as officials try to allay fears about doing business in the world\u2019s second-largest economy. Most Read from BloombergOutsider Milei Upends Argentina\u2019s Election With Primary WinAmerica\u2019s Fastest Growing City Is Embracing \u2018Yellowstone\u2019 ManiaZuckerberg Says \u2018Time to Move On\u2019 From Musk Cage FightRuble Sinks to""}, {""date"": ""2023-08-14"", ""headline"": ""Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics"", ""summary"": ""Coya Therapeutics aims to target inflammation-related diseases, like ALS, with Treg-enhancing therapeutics. Click here to read my analysis of COYA stock.""}, {""date"": ""2023-08-14"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Murphy Canyon to hold meeting on planned buy of interest in AZD1656"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-16"", ""headline"": ""AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030"", ""summary"": ""WILMINGTON, Del., August 16, 2023--AstraZeneca advances its robust lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), September 9-12, 2023.""}, {""date"": ""2023-08-16"", ""headline"": ""Cheaper Alternatives of Weight-Loss Drugs? Chinese Pharma Companies Are Working On a Local Version"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-16"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""TOP NEWS: AstraZeneca hails heart-focused Forxiga approval in China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR sank 0.85% to $69.12 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-17"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.79% to \u00a3107.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE...""}, {""date"": ""2023-08-17"", ""headline"": ""TAKING AIM: Shore impressed by C4X Discovery's promising portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slid 0.95% to $68.46 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-08-18"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slid 1.24% to \u00a3106.58 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-08-18"", ""headline"": ""AstraZeneca call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
32,2023-08-20,68.45999908447266,2023-08-27,68.25,-0.00306747133042673,D1,"[{""date"": ""2023-08-20"", ""headline"": ""AstraZeneca hails new data on Forxiga's impact on heart failure"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Pay for FTSE 100 bosses jumps 16% as wider wages behind inflation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""US approves Pfizer's maternal vaccine to prevent RSV in infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""FDA approves RSV vaccine for moms-to-be to guard their newborns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""FDA approves Pfizer maternal RSV vaccine for infants"", ""summary"": ""Pfizer hopes that its respiratory syncytial virus vaccine will be available to the public by the end of October or the beginning of November. ""}, {""date"": ""2023-08-21"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.61% higher to $68.88 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-21"", ""headline"": ""Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS"", ""summary"": ""UBS believes there is little chance the lawsuits brought on by pharma companies will delay Medicare pricing negotiations.""}, {""date"": ""2023-08-21"", ""headline"": ""5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace"", ""summary"": ""Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.""}, {""date"": ""2023-08-21"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.15% to \u00a3106.74 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-08-21"", ""headline"": ""The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023"", ""summary"": ""There are sectors in the economy that go through an extended period of trending sideways to lower. A good example is the pharmaceutical sector. In the last 10 years, the S&P Pharmaceuticals Select Industry Index has delivered annualized total returns of 2.65%. Furthermore, the index has annualized total returns in the last five years of -2.63%, clearly indicating an extended bear market among pharma stocks. Covid-19 did translate into buying action in selected pharma stocks. However, the interes""}, {""date"": ""2023-08-21"", ""headline"": ""AstraZeneca to present 19 abstracts at upcoming ESC Congress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Daiichi Sankyo and AstraZeneca's Enhertu wins new approval in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""2023-08-22"", ""headline"": ""3 Sorry Pharma Stocks to Sell in August Before It\u2019s Too Late"", ""summary"": ""Pharmaceutical stocks can bring you from rags to riches \u2014 and back to rags again. The truth is the innovative sector can function similarly to a lottery. Not every company can deliver consistent growth and profits, but those who beat the trend will have their shares pop somewhere in the double digits in share appreciation. A few years ago, the advent of the Covid-19 pandemic saw stocks in various industries plummet. Still, pharmaceutical shares began to rise to astronomic levels due to increased""}, {""date"": ""2023-08-22"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.16% to $68.77 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-22"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.22% to \u00a3106.98 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-08-22"", ""headline"": ""Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca"", ""summary"": ""Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article""}, {""date"": ""2023-08-22"", ""headline"": ""FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""3 Big Reasons Why Fed's Powell Can Be Hawkish At Jackson Hole On Aug 25"", ""summary"": ""The annual economic symposium at Jackson Hole is awaited for insights into Fed's next policy actions. Read why I think Powell will likely continue to be hawkish.""}, {""date"": ""2023-08-23"", ""headline"": ""AstraZeneca says Soliris and Lynparza approved in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""AstraZeneca Prostate Cancer, Generalized Myasthenia Gravis Treatments Get Approval in Japan"", ""summary"": ""By Michael Susin AstraZeneca's prostate-cancer treatment Lynparza has been approved in Japan, while Soliris has been approved for expanded use to treat...""}, {""date"": ""2023-08-23"", ""headline"": ""Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition"", ""summary"": ""Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround.""}, {""date"": ""2023-08-23"", ""headline"": ""U.K. Dividend Stocks Portfolio Review: Summer 2023"", ""summary"": ""The UK Dividend Stocks Portfolio invests exclusively in dividend-paying FTSE All-Share stocks, producing over ten years to July-end a total return of 76.8%.""}, {""date"": ""2023-08-23"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.48% higher to $69.10 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-08-23"", ""headline"": ""AstraZeneca facing two London lawsuits over COVID-19 vaccines"", ""summary"": ""AstraZeneca is facing two London lawsuits, including one from the husband of a woman who died after receiving the Anglo-Swedish drugmaker's COVID-19 vaccine, in the first of potentially dozens of cases brought in England.  Britain was the first country to roll out the at-cost AstraZeneca COVID-19 vaccine in early 2021, although it later restricted the use of it among under 40s due to the small risk of blood clots.  Anish Tailor, whose wife Alpa died in March 2021 after receiving her first dose of the vaccine, filed a product liability claim against AstraZeneca at London's High Court on Aug. 4, according to court records.""}, {""date"": ""2023-08-23"", ""headline"": ""AstraZeneca sued in London over adverse events linked to COVID shot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""AstraZeneca rises Wednesday, still underperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.67% to \u00a3107.70 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-08-23"", ""headline"": ""LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""Five metrics for AI trendspotting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""AstraZeneca PLC ADR underperforms Thursday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 1.75% to $67.89 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-24"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.19% to \u00a3107.50 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-08-24"", ""headline"": ""UPDATE: AstraZeneca, Merck & Co say Lynparza approved in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""AZN October 6th Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collab"", ""summary"": ""A Watertown biotech trimmed its pipeline again, setting aside all of its experimental drugs except one. It's the second time the company has cut programs this year. Plus other life sciences news you may have missed.""}, {""date"": ""2023-08-24"", ""headline"": ""Boeing's 737 Deliveries Delay Due To Supplier Spirit Aerosystems, Petco Health and Wellness Stock Tumbles, AstraZeneca Under Legal Lens: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Drugs picked for Medicare price negotiations to be announced on Tuesday \u2013 Politico"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""AstraZeneca Under Legal Lens, Faces Two COVID-19 Vaccine Lawsuits In London"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Merck, AstraZeneca: LYNPARZA/(abi/pred) combination approved in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""AstraZeneca says Soliris approved in Japan for pediatric gMG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""AstraZeneca says Lynparza combo approved in Japan for certain mCRPC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca sues US over drug pricing laws"", ""summary"": ""Covid vaccine maker AstraZeneca has sued the US government over legislation designed to lower prescription drug prices.""}, {""date"": ""2023-08-25"", ""headline"": ""Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases"", ""summary"": ""Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it. And that in turn makes it more difficult for a company to develop and test effective treatments. With so much less known about rare diseases than common ones, scientists may find themselves groping blindly trying to develop drugs and treatments. Rare diseases have less financial incentive as well. Fewer people having a disease means fewer patients that a treatment can be sold to. Th""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.53% higher to $68.25 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca becomes first international company to file Medicare drug pricing suit"", ""summary"": ""AstraZeneca joins as the sixth pharma company, and the first non-US company, to file suit against the Biden Administration over Medicare drug pricing.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan"", ""summary"": ""AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca files lawsuit against U.S. over drug pricing"", ""summary"": ""AstraZeneca (AZN) joins Johnson & Johnson (JNJ), Merck (MRK), and Bristol-Myers (BMY) in a lawsuit against the U.S. Department of Health and Human Services (HHS) over certain provisions on prices found in President Biden's Inflation Reduction Act (IRA). Yahoo Finance Health Care Reporter Anjalee Khemlani joins the Live show to break down the lawsuit and what to expect moving forward.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca sues US government over drug price reforms"", ""summary"": ""Anglo-Swedish group is latest to challenge Medicare\u2019s new power to negotiate prices for a limited number of medicines""}, {""date"": ""2023-08-25"", ""headline"": ""Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation"", ""summary"": ""FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.""}, {""date"": ""2023-08-25"", ""headline"": ""Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.84% to \u00a3106.60 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca sues US over Medicare drug price negotiation plans"", ""summary"": ""The program faces at least seven other court challenges, including from leading industry group PhRMA and drugmakers Johnson & Johnson, Merck & Co, Bristol Myers Squibb and privately-held Boehringer Ingelheim.  The drug price negotiation program is part of President Joe Biden's signature Inflation Reduction Act (IRA).  AstraZeneca said it was filing the legal challenge to \""protect timely access to medicines for orphan indications\"" in the United States.""}, {""date"": ""2023-08-25"", ""headline"": ""UPDATE 2-AstraZeneca sues US over Medicare drug price negotiation plans"", ""summary"": ""AstraZeneca said on Friday it has sued the U.S. government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices.  The British drugmaker, which filed its complaint in a Delaware district court, joins other drugmakers and business groups claiming that the program would restrict the development of new medicines.  The program faces at least seven other court challenges, including from leading industry group PhRMA and drugmakers Johnson & Johnson, Merck & Co, Bristol Myers Squibb and privately-held Boehringer Ingelheim.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients"", ""summary"": ""WILMINGTON, Del., August 25, 2023--To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA). The drug price negotiation provisions of the IRA run headlong into the goals of the Orphan Drug Act (ODA), a federal statute designed to encourage manufacturers to invest in new therapies for rare diseases.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca latest drugmaker to challenge Medicare drug price negotiation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""As Medicare picks 10 drugs for price negotiations, 50 million people stand to benefit \u2014 even if their drugs aren\u2019t on the list"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Affirm, Netflix, AstraZeneca rise premarket; Nordstrom, Hawaiian Electric fall"", ""summary"": ""Investing.com -- U.S. futures traded higher Friday, bouncing after the previous session\u2019s substantial losses ahead of Fed chief Jerome Powell\u2019s key speech at the Jackson Hole gathering.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca Files Legal Challenge to Some Drug-Price Provisions of IRA"", ""summary"": ""By Will Feuer AstraZeneca said it has filed a legal challenge to certain aspects of the drug price negotiation provisions of the Inflation Reduction Act,...""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca files challenge to aspects of Inflation Reduction Act"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-26"", ""headline"": ""Ken Fisher\u2019s Top 15 Healthcare Stock Picks"", ""summary"": ""In this article, we discuss the top 15 healthcare stock picks of Ken Fisher. If you want to skip our detailed discussion about the healthcare industry, head directly to Ken Fisher\u2019s Top 5 Healthcare Stock Picks. The healthcare sector was forever changed by the COVID-19 pandemic. While it highlighted the weaknesses in the global medical [\u2026]""}, {""date"": ""2023-08-27"", ""headline"": ""Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca"", ""summary"": ""WIR China and Poland partner to create a new drug distribution network. Click here to read more about the past week's new deals, financings, and approvals. ""}]",{}
33,2023-08-27,68.25,2023-09-03,68.13999938964844,-0.0016117305546016203,D1,"[{""date"": ""2023-08-27"", ""headline"": ""Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca"", ""summary"": ""WIR China and Poland partner to create a new drug distribution network. Click here to read more about the past week's new deals, financings, and approvals. ""}, {""date"": ""2023-08-28"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Republicans say Medicare drug negotiations will mean fewer new meds"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""10 drugs targeted for Medicare price negotiations as Biden pitches cost reductions"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""See which drugs President Biden is targeting first for Medicare price-lowering talks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.57% higher to $68.64 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-08-28"", ""headline"": ""Oncology Market's Huge Potential Puts These Stocks in Focus"", ""summary"": ""The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.""}, {""date"": ""2023-08-28"", ""headline"": ""Lexicon Pharmaceuticals Underway With Inpefa, But A Lot Of Hard Work"", ""summary"": ""I expect Lexicon Pharmaceuticals to continue to increase its SG&A spending to support Inpefa. Read more to see why LXRX stock is a Buy.""}, {""date"": ""2023-08-29"", ""headline"": ""Expensive Drugs Targeted for First U.S. Price Negotiations"", ""summary"": ""Lower prices would take effect in 2026 depending on the talks between the U.S. and drugmakers and the outcome of industry lawsuits.""}, {""date"": ""2023-08-29"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.73% higher to $69.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-08-29"", ""headline"": ""The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca"", ""summary"": ""Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-08-29"", ""headline"": ""AstraZeneca rises Tuesday, still underperforms market"", ""summary"": ""AstraZeneca PLC shares rallied 1.35% to \u00a3108.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-08-29"", ""headline"": ""Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations"", ""summary"": ""The Biden administration revealed the first 10 drugs that will face the Medicare negotiation process under the Inflation Reduction Act.""}, {""date"": ""2023-08-29"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""White House names first 10 drugs eligible for Medicare price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Biden administration announces first 10 drugs eligible for Medicare price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""IN THE KNOW: US drug pricing an \""important catalyst\"" for AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations"", ""summary"": ""Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications...""}, {""date"": ""2023-08-29"", ""headline"": ""Biden administration unveils first 10 drugs subject to Medicare price negotiations"", ""summary"": ""The announcement of the 10 drugs kicks off a Medicare negotiation process that aims to make costly medications more affordable for older Americans.\u00a0""}, {""date"": ""2023-08-29"", ""headline"": ""Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Biden unveils first 10 drugs subject to Medicare price negotiation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-30"", ""headline"": ""Roche downgraded to Neutral from Buy at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-30"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slid 0.40% to $68.86 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-30"", ""headline"": ""Medicare price negotiation list: What it means for pharma companies"", ""summary"": ""On Tuesday, the Biden administration listed ten drugs subject to Medicare price negotiations. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the list and how this may impact the pharmaceutical companies who profit from these drugs.\u00a0\u00a0 The ten drugs and pharma companies impacted are:\u00a0 Eliquis - Bristol-Myers Squibb (BMY), Pfizer (PFE) Jardiance - Boehringer Ingelheim, Eli Lilly (LLY) Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ) Januvia - Merck (MRK) Farxiga - AstraZeneca (AZN) Entresto - Novartis (NVS) Enbrel - Amgen (AMGN) Imbruvica - Johnson & Johnson (JNJ), AbbVie (ABBV) Stelara - Johnson & Johnson (JNJ) Fiasp, NovoLog - Novo Nordisk (NVO)""}, {""date"": ""2023-08-30"", ""headline"": ""Medicare drug price negotiations may have a muted impact on drugmakers in the near term"", ""summary"": ""Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.\u00a0""}, {""date"": ""2023-08-30"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.65% to \u00a3107.34 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-08-31"", ""headline"": ""Why this S.F. company says Big Pharma deal is big win for patients"", ""summary"": ""It's no picnic for chronic disease patients \u2014 or, really, anyone \u2014 to gather their medical records from multiple doctor offices.  Now the 100-employee, San Francisco-based company, which has raised more than $100 million over nine years, has a new partnership with AstraZeneca plc (NASDAQ: AZN) to expand its platform into cancer.  The company isn't disclosing the value of the deal or how it came together, but it says the information it gathers on behalf of patients ultimately could provide insights that allow paying customers such as AstraZeneca and dozens of other biopharma partners like Genentech Inc. to make better medicines.""}, {""date"": ""2023-08-31"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR shed 1.51% to $67.82 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-08-31"", ""headline"": ""Big Pharma's biggest ally gets trolled on X for attacking Medicare drug pricing list"", ""summary"": ""Drug lobbying firm PhRMA faced backlash on social media for its attempt to call Medicare pricing negotiations unfair.""}, {""date"": ""2023-08-31"", ""headline"": ""Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-31"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.67% to \u00a3106.62 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-08-31"", ""headline"": ""Amazon continues hot streak as analysts eye AWS event in the fall as a potential catalyst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-31"", ""headline"": ""Novo Nordisk: Super Focused Pharma Company For The Long Run"", ""summary"": ""Novo Nordisk is one of the most qualitative big pharma companies globally. Read why I am bullish on NVO stock with the long-term investment horizon here.""}, {""date"": ""2023-08-31"", ""headline"": ""AstraZeneca Enhertu granted Breakthrough Therapy status for two indications"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-31"", ""headline"": ""China's CanSino seeks more vaccine contracts after AstraZenca deal"", ""summary"": ""China's CanSino Biologics , which recently announced a contract manufacturing deal to support AstraZenca's  messenger RNA (mRNA) technology vaccine programme, is in talks with more firms on similar deals, its CEO said, as it seeks new revenue streams to make up for plummeting COVID vaccine demand.  CanSino begun researching mRNA technology in 2018 and has built a facility in Shanghai that can produce up to 200 million doses a year, giving it the capacity to provide similar services to other companies, CanSino's CEO and co-founder Xuefeng Yu told Reuters in an interview.  \""This is the first step,\"" he said, describing the AstraZenca deal announced earlier this month as \""a business model\"".""}, {""date"": ""2023-08-31"", ""headline"": ""ENHERTU\u00ae Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-31"", ""headline"": ""CanSino Biologics on AstraZeneca Deal, Earnings"", ""summary"": ""Xuefeng Yu, Chairman, Co-Founder & CEO at CanSino Biologics, discusses collaboration plans with pharmaceutical companies including AstraZeneca as well as the company's first half results. He speaks with Rishaad Salamat, David Ingles and Yvonne Man on \""Bloomberg Markets Asia\"".""}, {""date"": ""2023-09-01"", ""headline"": ""Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-01"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""The AstraZeneca PLC ADR inched 0.47% higher to $68.14 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-09-01"", ""headline"": ""Judge withdraws from Medicare drug price case after stock ownership is revealed"", ""summary"": ""Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.""}, {""date"": ""2023-09-01"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.36% to \u00a3107.00 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-09-02"", ""headline"": ""Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal"", ""summary"": ""Explore groundbreaking insights on GenFleet and Verastem's innovations in the China biotech landscape. Click here for more with China Bio Today's latest article.""}, {""date"": ""2023-09-02"", ""headline"": ""8 Pharma Stocks Affected by New  Drug Price Negotiation Rules"", ""summary"": ""Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?""}, {""date"": ""2023-09-03"", ""headline"": ""Why is big pharma unmoved despite Medicare pricing threat?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
34,2023-09-03,68.13999938964844,2023-09-10,68.22000122070312,0.0011740803018973622,U1,"[{""date"": ""2023-09-02"", ""headline"": ""Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal"", ""summary"": ""Explore groundbreaking insights on GenFleet and Verastem's innovations in the China biotech landscape. Click here for more with China Bio Today's latest article.""}, {""date"": ""2023-09-03"", ""headline"": ""IN BRIEF: Astra drug gets China okay for chronic lymphocytic leukaemia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-03"", ""headline"": ""AstraZeneca's Calquence approved in China for chronic lymphocytic leukaemia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-03"", ""headline"": ""LONDON BRIEFING: CMC names new CFO; takeover offer for Ergomed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-03"", ""headline"": ""AstraZeneca's Calquence Product Approved in China for Leukaemia Treatment"", ""summary"": ""By Joe Hoppe AstraZeneca said its Calquence product has been approved in China for the treatment of adults with leukaemia. The Anglo-Swedish pharma giant...""}, {""date"": ""2023-09-03"", ""headline"": ""Why is big pharma unmoved despite Medicare pricing threat?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-04"", ""headline"": ""Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock"", ""summary"": ""Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""2023-09-04"", ""headline"": ""AstraZeneca falls Monday, still outperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.09% to \u00a3106.90 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-09-04"", ""headline"": ""LONDON MARKET MIDDAY: Hopes of rate peak, China turnaround lift stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""AstraZeneca Says FDA Has Requested Improvements to Ultomiris's Risk Evaluation"", ""summary"": ""By Michael Susin AstraZeneca said the U.S. Food and Drug Administration has requested modifications to improve its Ultomiris treatment's risk evaluation and...""}, {""date"": ""2023-09-05"", ""headline"": ""Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR sank 0.73% to $67.64 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-09-05"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.43% to \u00a3107.36 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-09-05"", ""headline"": ""Facebook News To Shut Down In Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Astellas withdraws federal lawsuit over Medicare drug pricing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR shed 0.95% to $67.00 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-09-06"", ""headline"": ""AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication"", ""summary"": ""AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.""}, {""date"": ""2023-09-06"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slipped 1.21% to \u00a3106.06 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE...""}, {""date"": ""2023-09-06"", ""headline"": ""Johnson & Johnson succeeds in lung cancer trial for Rybrevant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""FDA Seeks Further Safeguards for AstraZeneca's Ultomiris Therapy, But Efficacy Not in Question"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""AstraZeneca Ultomiris label expansion declined in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""AstraZeneca says FDA issued a complete response letter for Ultomiris sBLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""AstraZeneca working with FDA on Ultomiris risk evaluation changes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rose 2.06% to \u00a3108.24 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-09-08"", ""headline"": ""Pharma Stock Roundup: J&J to End Hypertension Study & Other Regulatory Updates"", ""summary"": ""J&J (JNJ) to end a late-stage study on macitentan for CTEPH. Merck's (MRK) Ebola vaccine gets approval in Europe for use in kids.""}, {""date"": ""2023-09-08"", ""headline"": ""Top Research Reports for Chevron, AstraZeneca & Netflix"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), AstraZeneca PLC (AZN) and Netflix, Inc. (NFLX).""}, {""date"": ""2023-09-08"", ""headline"": ""UK dividends calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Cizzle says meeting to approve sale of AZD1656 interest postponed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""AstraZeneca downgraded to Hold from Buy at Erste Group"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-09"", ""headline"": ""Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-09"", ""headline"": ""4 Top-Tier Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip"", ""summary"": ""In 2022, all three major stock indexes were fully mired in a bear market, with the growth-focused Nasdaq Composite (NASDAQINDEX: ^IXIC) hit hardest.  On a year-to-date basis, as of the closing bell on Sept. 6, the Nasdaq Composite is higher by nearly 33%.  What follows are four top-tier growth stocks you'll regret not buying in the wake of the Nasdaq bear market dip.""}, {""date"": ""2023-09-09"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Rigel (RIGL), AstraZeneca (GB:AZN) and Ipsen (GB:0MH6)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""AstraZeneca participates in a conference call with Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""Daiichi Sankyo, AstraZeneca present initial results from TROPION-Lung04 phase 1b"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
35,2023-09-10,68.22000122070312,2023-09-17,68.2699966430664,0.0007328557823025328,U1,"[{""date"": ""2023-09-09"", ""headline"": ""Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""AstraZeneca stock dips amid report CEO may step down"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""AstraZeneca (NASDAQ:AZN) Slides despite Solid Drug News"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""AstraZeneca (NASDAQ:AZN) Slides Despite Solid Cancer Drug News"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""AstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control Rates"", ""summary"": ""By Anthony O. Goriainoff AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer treatment--with or...""}, {""date"": ""2023-09-10"", ""headline"": ""AstraZeneca says Imfinzi and Tagrisso combinations show good results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""Daiichi Sankyo, AstraZeneca present initial results from TROPION-Lung04 phase 1b"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)"", ""summary"": ""WILMINGTON, Del., September 11, 2023--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca\u2019s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) who were receiving oral corticosteroids (OCS) with or without stable immunosuppressive therapy.""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca says Fasenra therapy meets primary endpoint at trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Qualcomm-Apple Chip Supply Agreement, Report On AstraZeneca CEO's Alleged Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories"", ""summary"": ""Benzinga Qualcomm Announces Chip Supply Agreement With Apple Qualcomm Inc (NASDAQ: QCOM) stock is trading higher Monday after the chip designer forged a deal with Apple Inc (NASDAQ: APPL). Under the deal, Qualcomm will supply Snapdragon 5G Modem\u2011RF Systems for the iPhone maker's smartphone launch in 2024, 2025, and 2026. The agreement eyes a 20% share of chipset supply for smartphone launch in 2026. Vietnam Airlines Eyes Monumental $10 Billion Deal With Boeing In a strategic move that could pote""}, {""date"": ""2023-09-11"", ""headline"": ""Unveiling AstraZeneca PLC (AZN)'s Value: Is It Really Priced Right? A Comprehensive Guide"", ""summary"": ""Exploring the intrinsic value of AstraZeneca PLC (AZN) and its potential for long-term returns""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca Phase 3 Trial for Rare Vasculitis Treatment Meets Primary Endpoint"", ""summary"": ""By Ben Glickman AstraZeneca said Monday that a Phase 3 trial of its treatment for eosinophilic granulomatosis with polyangiitis, a rare form of vasculitis,...""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca seeks to calm CEO speculation after shares drop"", ""summary"": ""LONDON (Reuters) -AstraZeneca appeared to play down speculation about the future of its CEO after its shares fell more than 4% on Monday following a British tabloid report that Pascal Soriot was considering leaving the drugmaker as soon as next year.  AstraZeneca shares closed down 3.2% after earlier touching their lowest since July 19.  Three analysts and one AstraZeneca shareholder told Reuters they attributed the move to the Mail on Sunday report that said Soriot had privately told friends and advisers he may leave the company as soon as next year.""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts"", ""summary"": ""Data released on Monday by AstraZeneca from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's rival treatment, analysts said.  A brief summary from the Phase 3 trial, called FLAURA2, was released in May, and the detailed data was presented on Monday in Singapore at the World Conference on Lung Cancer.  The FLAURA2 trial showed that when adding chemotherapy to Tagrisso, the risk of disease progression or death is reduced by 38% when compared to Tagrisso alone.""}, {""date"": ""2023-09-11"", ""headline"": ""TAGRISSO\u00ae (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial"", ""summary"": ""WILMINGTON, Del., September 11, 2023--Positive results from the FLAURA2 Phase III trial showed AstraZeneca\u2019s TAGRISSO\u00ae (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).""}, {""date"": ""2023-09-11"", ""headline"": ""ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial"", ""summary"": ""WILMINGTON, Del., September 11, 2023--Results from the primary analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) continued to demonstrate strong and durable tumor responses in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca says lung cancer therapy outperformed with chemotherapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca says Fasenra met primary endpoint in MANDARA trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Video: Nasdaq 100 Movers: AZN, TSLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""The Zacks Analyst Blog Highlights Chevron, AstraZeneca, Netflix, Medtronic and Marvell Technology"", ""summary"": ""Chevron, AstraZeneca, Netflix, Medtronic and Marvell Technology are included in this Analyst Blog.""}, {""date"": ""2023-09-11"", ""headline"": ""Unusually active option classes on open September 11th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca announces results from FLAURA2 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca reports 'positive' results from the FLAURA2 Phase III trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca: Enhertu demonstrated strong, durable responses in DESTINY-Lung02"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""UPDATE: AstraZeneca has good results from three cancer drugs in trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""ENHERTU\u00ae Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""AstraZeneca PLC ADR underperforms Monday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo"", ""summary"": ""Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.""}, {""date"": ""2023-09-12"", ""headline"": ""DiaMedica appoints Ambarish Shah, Ph.D. as Chief Technology Officer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""LONDON BRIEFING: Trainline launches buyback as revenue rises 19%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Moderna (NASDAQ:MRNA) Surges after Landing EU Approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""AstraZeneca PLC (LON:AZN) Shares Could Be 36% Below Their Intrinsic Value Estimate"", ""summary"": ""Key Insights The projected fair value for AstraZeneca is UK\u00a3165 based on 2 Stage Free Cash Flow to Equity AstraZeneca...""}, {""date"": ""2023-09-14"", ""headline"": ""AstraZeneca advances UK clean heat and energy efficiencies with \u00a3100m commitment"", ""summary"": ""CAMBRIDGE, United Kingdom, September 14, 2023--AstraZeneca has established the UK's first supply of unsubsidised biomethane with \u00a3100m commitment to power its transition to net zero.""}, {""date"": ""2023-09-14"", ""headline"": ""Primecap Odyssey Funds' 2023 Semiannual Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""AstraZeneca enters 15-year partnership with Future Biogas"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""Astrazeneca (AZN) Gains As Market Dips: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed at $68.27 in the latest trading session, marking a +0.72% move from the prior day.""}, {""date"": ""2023-09-15"", ""headline"": ""UPDATE 1-EU regulator backs AstraZeneca and Daiichi's lung cancer drug"", ""summary"": ""AstraZeneca said on Friday its and Daiichi Sankyo's cancer drug Enhertu was recommended by the European Medicines Agency's human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).  The recommendation is based on the mid-stage data that showed Enhertu reduced the tumour by 49% and the median duration of response by 16.8 months in patients previously treated for lung cancer.""}, {""date"": ""2023-09-15"", ""headline"": ""AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths"", ""summary"": ""AstraZeneca's (AZN) strong revenue growth outperforms AbbVie's (ABBV) declining sales. Click here to read more on the battle of the pharmaceutical behemoths.""}, {""date"": ""2023-09-15"", ""headline"": ""Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know"", ""summary"": ""Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""2023-09-15"", ""headline"": ""AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU"", ""summary"": ""By Christian Moess Laursen AstraZeneca said its lung-cancer drug Enhertu has been recommended for approval in the European Union following positive test...""}, {""date"": ""2023-09-15"", ""headline"": ""ENHERTU\u00ae Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""AstraZeneca says Enhertu recommended for approval in EU by CHMP"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""AstraZeneca participates in a conference call with Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers \u2013 Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-16"", ""headline"": ""10 Best ADR Stocks To Buy Now"", ""summary"": ""In this piece, we will take a look at the ten best ADR stocks to buy now. If you want to skip our introduction to ADRs and the benefits and drawbacks of buying them, then check out 5 Best ADR Stocks To Buy Now. A fundamental tenet of either a business or a financial education [\u2026]""}, {""date"": ""2023-09-16"", ""headline"": ""IXJ: Healthcare Dashboard For September"", ""summary"": ""Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attractive subsector. Read more here.""}, {""date"": ""2023-09-17"", ""headline"": ""The 'tripledemic' threat to be less severe this season"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
36,2023-09-17,68.2699966430664,2023-09-24,67.83000183105469,-0.006444922127536223,D1,"[{""date"": ""2023-09-17"", ""headline"": ""AARP weighs in on Merck case challenging Medicare drug negotiation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-17"", ""headline"": ""Unfair to call my mini-budget tax cuts unfunded, Liz Truss to claim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-17"", ""headline"": ""The 'tripledemic' threat to be less severe this season"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""AstraZeneca PLC ADR falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""AstraZeneca's Rare-Disease Unit Buys Pfizer Portfolio for $1 Bln"", ""summary"": ""By Christian Moess Laursen AstraZeneca's rare-disease unit Alexion has completed a purchase and license agreement for an early-stage rare-disease gene...""}, {""date"": ""2023-09-19"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors despite daily gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""AstraZeneca refused to pay full bonus to US remote worker, lawsuit claims"", ""summary"": ""AstraZeneca Pharmaceuticals LP has been sued in the U.S. by a former senior director who claims the drugmaker refused to pay her nearly $130,000 in promised bonuses and stock options because she worked from home full-time.  Elmarie Bodes, who was AstraZeneca's senior director of business transformation until January, said in the lawsuit filed in South Carolina state court on Tuesday that she was owed a $124,000 performance bonus and $65,000 in stock options.  Instead, AstraZeneca earlier this year cut her payout in half and refused to grant any stock options because she did not come into the office at least three days per week, according to the lawsuit.""}, {""date"": ""2023-09-20"", ""headline"": ""AstraZeneca\u2019s Rare-Disease Unit Buy Pfizer Portfolio for $1 Bln"", ""summary"": ""AstraZeneca\u2019s Alexion unit has completed a purchase and license agreement for an early-stage rare-disease gene therapy portfolio from Pfizer for $1 billion.""}, {""date"": ""2023-09-20"", ""headline"": ""Alexion completes gene therapy purchase and license agreement from Pfizer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""LONDON MARKET OPEN: Stocks slip after central bank rate calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""Pfizer maternal RSV vaccine recommended by CDC advisers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive"", ""summary"": ""By Christian Moess Laursen AstraZeneca said trial results for its breast cancer drug Dato-DXd showed significant improvement for the primary end-point of...""}, {""date"": ""2023-09-21"", ""headline"": ""Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""Pfizer maternal RSV vaccine recommended by CDC advisors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""Astrazeneca (AZN) Stock Moves -1.38%: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed at $67.02 in the latest trading session, marking a -1.38% move from the prior day.""}, {""date"": ""2023-09-21"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""EXPLAINER-What you need to know about RSV and the new vaccines"", ""summary"": ""Expert advisers to U.S. Centers for Disease Control and Prevention (CDC) on Friday recommended Pfizer's respiratory syncytial virus (RSV) vaccine for women in the middle of the third trimester of pregnancy to protect their babies from severe illness.  That Pfizer shot and one developed by GSK in May became the first two RSV vaccines to win U.S. approval, for use in people aged 60 and over to prevent severe illness.""}, {""date"": ""2023-09-22"", ""headline"": ""Stocks to Watch Friday: Alibaba, Activision, Microsoft"", ""summary"": ""**\u2197\ufe0f** [**Microsoft (MSFT)**](https://www.wsj.com/market-data/quotes/MSFT), [**Activision Blizzard (ATVI)**](https://www.wsj.com/market-data/quotes/ATVI): A modified deal by the software giant to buy the videogame publisher was [cleared by the U.""}, {""date"": ""2023-09-22"", ""headline"": ""AstraZeneca ADSs Rise After Reporting Positive Results in Breast Cancer Drug Trial"", ""summary"": ""AstraZeneca ADSs rose after reporting its experimental breast cancer treatment made with Japanese partner Daiichi Sankyo showed positive high-level results in a Phase 3 trial.""}, {""date"": ""2023-09-22"", ""headline"": ""AstraZeneca Stock Rises on Positive Trial Results for Breast Cancer Drug"", ""summary"": ""The drugmaker says the trial demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival.""}, {""date"": ""2023-09-22"", ""headline"": ""AstraZeneca Surges As It Takes A Shot At Gilead's Second-Biggest Cancer Drug"", ""summary"": ""AstraZeneca and Daiichi Sankyo said Friday their breast cancer treatment outperformed chemo in a Phase 3 study, and AZN stock jumped.""}, {""date"": ""2023-09-22"", ""headline"": ""Pfizer maternal RSV vaccine recommended by CDC "", ""summary"": ""New shot aims to protect babies from a leading cause of hospitalization.""}, {""date"": ""2023-09-22"", ""headline"": ""Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial"", ""summary"": ""WILMINGTON, Del., September 22, 2023--Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival (PFS) compared to investigator\u2019s choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated wit""}, {""date"": ""2023-09-22"", ""headline"": ""Scholastic\u2019s stock tumbles on loss, Activision\u2019s shares rise on Microsoft deal news and more moving stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""AstraZeneca, Daiichi post early win in Phase 3 trial for breast cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""AstraZeneca says Dato-DXd showed significant improvement for primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""AstraZeneca says Dato-DXd improved PFS in breast cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Scholastic stock tumbles on loss, Activision share rises on Microsoft deal news and more moving stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Pfizer maternal RSV vaccine recommended by CDC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-24"", ""headline"": ""3 Magnificent Growth Stocks to Buy Right Now"", ""summary"": ""Three Fool.com contributors believe they've identified truly magnificent growth stocks to buy right now.  Here's why they chose AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski\u00a0(AstraZeneca): What makes AstraZeneca a magnificent long-term investment is how broad the business is and the potential it has to generate long-term gains.""}]",{}
37,2023-09-24,67.83000183105469,2023-10-01,67.72000122070312,-0.0016217102665799787,D1,"[{""date"": ""2023-09-24"", ""headline"": ""AstraZeneca upgraded to Buy from Hold at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-24"", ""headline"": ""Daiichi Sankyo Leads Japan Pharma Stocks Higher on Cancer Drug"", ""summary"": ""(Bloomberg) -- Daiichi Sankyo Co. shares jumped by the most in a year after a drug it developed with AstraZeneca Plc showed favorable results in a trial for a common type of breast cancer.Most Read from BloombergChinese Gold Buying Is Driving a Paradigm Shift in BullionStocks Flash Recession Warning as Trouble Spreads to IndustrialsIndia-Canada Clash Should Be a Wakeup CallWells Fargo Preps for Wealth Battle After $1 Billion TurnaroundCorzine Plans to Shut Hedge Fund and Return Capital to Invest""}, {""date"": ""2023-09-24"", ""headline"": ""LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-24"", ""headline"": ""ASTRAZENECA AND INSTITUT KANSER NEGARA PARTNER TO INTRODUCE AI TECHNOLOGY FOR LUNG SCREENING"", ""summary"": ""In conjunction with Institut Kanser Negara's (IKN) 10th anniversary, AstraZeneca announced its collaboration to accelerate digitalisation in healthcare by introducing Artificial Intelligence (AI) x-ray technology into early lung screening at government clinics and hospitals under the Projek Saringan Awal Paru-Paru (SAPU) programme. As a centre of excellence for cancer care in the country, IKN will be the first government institution in the country to implement this AI technology.""}, {""date"": ""2023-09-24"", ""headline"": ""3 Magnificent Growth Stocks to Buy Right Now"", ""summary"": ""Three Fool.com contributors believe they've identified truly magnificent growth stocks to buy right now.  Here's why they chose AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski\u00a0(AstraZeneca): What makes AstraZeneca a magnificent long-term investment is how broad the business is and the potential it has to generate long-term gains.""}, {""date"": ""2023-09-25"", ""headline"": ""New COVID vaccine rollout running into insurance, supply roadblocks"", ""summary"": ""The rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, \""Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance.\"" Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-09-25"", ""headline"": ""FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease"", ""summary"": ""Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.""}, {""date"": ""2023-09-25"", ""headline"": ""AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study"", ""summary"": ""AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.""}, {""date"": ""2023-09-25"", ""headline"": ""AstraZeneca stock upgraded to Buy at Jefferies"", ""summary"": ""Shares of biopharmaceutical giant AstraZeneca (AZN) were upgraded to \""Buy\"" from \""Hold\"" at Jefferies. The analyst says assets outside of the company's oncology pipeline are being overlooked. Yahoo Finance breaks down the stock's reaction. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-09-25"", ""headline"": ""CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns"", ""summary"": ""Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.""}, {""date"": ""2023-09-25"", ""headline"": ""Microsoft upgraded, Nike downgraded: Wall Street's top analyst calls"", ""summary"": ""Microsoft upgraded, Nike downgraded: Wall Street's top analyst calls""}, {""date"": ""2023-09-25"", ""headline"": ""AstraZeneca price target raised to 12,900 GBp from 12,700 GBp at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca"", ""summary"": ""Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-09-25"", ""headline"": ""AstraZeneca upgraded to buy at Jefferies on assets beyond oncology"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""AstraZeneca call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""GLOBAL BROKER RATINGS: Jefferies says 'buy' Astra; MS raises Novartis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""Dow raised at JPMorgan, Rocket upgraded to Hold: 4 big analyst picks"", ""summary"": ""Here is your Pro Recap of the biggest analyst picks you may have missed since Friday: upgrades at Dow, Rocket, AstraZeneca, and Coeur Mining.  Dow (NYSE:DOW) shares rose more than 1% pre-market today after JPMorgan upgraded the company to Overweight from Neutral with a price target of $55.00.""}, {""date"": ""2023-09-25"", ""headline"": ""LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""AstraZeneca PLC ADR outperforms market despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR shed 1.04% to $68.22 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-09-26"", ""headline"": ""AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""2023-09-26"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.27% to \u00a3111.64 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-09-26"", ""headline"": ""Tuesday\u2019s Top Wall Street Analyst Upgrades and Downgrades: AstraZeneca, Bloom Energy, Cleveland-Cliffs, CrowdStrike, Dow, Nike, Urban Outfitters and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has  Game-Changing New Entrant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 0.41% to $67.94 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-09-27"", ""headline"": ""Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""AstraZeneca falls Wednesday, still outperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.41% to \u00a3111.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE...""}, {""date"": ""2023-09-27"", ""headline"": ""Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?"", ""summary"": ""Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.""}, {""date"": ""2023-09-28"", ""headline"": ""Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Astrazeneca (AZN) closed at $67.42, marking a -0.77% move from the previous day.""}, {""date"": ""2023-09-28"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slid 0.77% to $67.42 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-09-28"", ""headline"": ""What to know as fall vaccinations against COVID, flu and RSV get underway"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""AstraZeneca PLC shares slipped 1.01% to \u00a3110.06 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-09-28"", ""headline"": ""UPDATE 1-J&J's lung cancer therapy combo succeeds in late-stage study"", ""summary"": ""Johnson & Johnson said on Thursday its cancer therapy combination met the main goal in a late-stage study testing it as a treatment for patients with a type of lung cancer.  The drugmaker said an interim analysis of data from the study showed a trend \""favoring\"" the combination of its antibody treatment Rybrevant and experimental drug lazertinib, when compared to AstraZeneca's cancer drug osimertinib or Tagrisso.  J&J said it plans to submit data for an upcoming scientific conference, including additional details on certain secondary goals from the study.""}, {""date"": ""2023-09-28"", ""headline"": ""Merck, Bristol Myers, AstraZeneca agree to Medicare drug pricing talks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""AstraZeneca Unusual Options Activity For September 28"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Johnson & Johnson posts Phase 3 win for lung cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.44% higher to $67.72 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-09-29"", ""headline"": ""Ionis, AbbVie, Alnylam draw bullish views at Raymond James"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.87% to \u00a3111.02 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-09-29"", ""headline"": ""As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment\u00a0"", ""summary"": ""A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.""}, {""date"": ""2023-09-29"", ""headline"": ""As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-30"", ""headline"": ""Week In Review: Adlai Nortye Stages $97.5 Million US IPO On NASDAQ"", ""summary"": ""The highlight of this week in review is Adlai Nortye $97.5M US IPO on NASDAQ. Click here to read more about last week's deals and trials in the biotech world.""}, {""date"": ""2023-09-30"", ""headline"": ""20 Best Residency by Investment Programs in 2023"", ""summary"": ""This article will explore the 20 best Residency by Investment programs in 2023. You can skip our comprehensive analysis and proceed directly to the 5 Best Residency by Investment Programs in 2023. In the past few decades, the world has witnessed a remarkable shift in global migration trends, propelled by factors like economic prospects, political [\u2026]""}]","{""assetTurnoverTTM"": 0.4665, ""bookValue"": 37197, ""cashRatio"": 0.17038617601790962, ""currentRatio"": 0.7871, ""ebitPerShare"": 1.2526, ""eps"": 0.8808, ""ev"": 240150.2493, ""fcfMargin"": 0.1945, ""fcfPerShareTTM"": 4.5016, ""grossMargin"": 0.8203, ""inventoryTurnoverTTM"": 1.5794, ""longtermDebtTotalAsset"": 0.2313, ""longtermDebtTotalCapital"": 0.3379, ""longtermDebtTotalEquity"": 0.5975, ""netDebtToTotalCapital"": 0.3604, ""netDebtToTotalEquity"": 0.6373, ""netMargin"": 0.1196, ""operatingMargin"": 0.17, ""payoutRatioTTM"": 0.8967, ""pb"": 5.8189, ""peTTM"": 36.7105, ""pfcfTTM"": 31.0227, ""pretaxMargin"": 0.1438, ""psTTM"": 4.8105, ""quickRatio"": 0.602, ""receivablesTurnoverTTM"": 4.3607, ""roaTTM"": 0.0611, ""roeTTM"": 0.16, ""roicTTM"": 0.0885, ""rotcTTM"": 0.1208, ""salesPerShare"": 7.3667, ""sgaToSale"": 0.1797, ""totalDebtToEquity"": 0.7682, ""totalDebtToTotalAsset"": 0.2974, ""totalDebtToTotalCapital"": 0.4345, ""totalRatio"": 1.6316, ""period"": ""2023-09-30""}"
38,2023-10-01,67.72000122070312,2023-10-08,67.41999816894531,-0.004430050891170101,D1,"[{""date"": ""2023-09-30"", ""headline"": ""Week In Review: Adlai Nortye Stages $97.5 Million US IPO On NASDAQ"", ""summary"": ""The highlight of this week in review is Adlai Nortye $97.5M US IPO on NASDAQ. Click here to read more about last week's deals and trials in the biotech world.""}, {""date"": ""2023-10-01"", ""headline"": ""Drugmakers comply with Medicare pricing talks despite lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""AstraZeneca Pays $425 Mln to Settle Nexium and Prilosec Liability Litigation"", ""summary"": ""By Michael Susin AstraZeneca has agreed to settle product liability litigations related to Nexium and Prilosec in the U.S. by making a payment of $425...""}, {""date"": ""2023-10-02"", ""headline"": ""AstraZeneca PLC ADR underperforms Monday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slipped 1.46% to $66.73 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-02"", ""headline"": ""J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study"", ""summary"": ""J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.""}, {""date"": ""2023-10-02"", ""headline"": ""AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong"", ""summary"": ""AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.""}, {""date"": ""2023-10-02"", ""headline"": ""Big Pharma Can\u2019t Stop the Price-Negotiation Program. What\u2019s Next."", ""summary"": ""A federal judge dealt a blow to hopes for a near-term injunction to halt the federal government plan to let Medicare to pay less for a few expensive medicines.""}, {""date"": ""2023-10-02"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slid 1.37% to \u00a3109.50 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-02"", ""headline"": ""Alexion treatment of transthyretin amyloidosis granted FDA orphan status"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""Medicare Drug Price Negotiation - What Court's Decision Means for Americans"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has  Game-Changing New Entrant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""The 10 pharma companies participating in Medicare price negotiations"", ""summary"": ""Ten pharmaceutical manufacturers are signing the Inflation Reduction Act's Medicare drug price negotiation program. These companies are Bristol Myers Squibb (BMY), AstraZeneca (AZN), Boehringer Ingelheim, Immunex, Janssen Pharmaceuticals, Pharmacyclics, Merck & Company (MRK), Janssen Biotech, Novartis (NVS), and Novo Nordisk (NVO), according to the Biden administration. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-10-03"", ""headline"": ""Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""AstraZeneca outperforms market despite losses on the day"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.38% to \u00a3109.08 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE...""}, {""date"": ""2023-10-03"", ""headline"": ""Drugmakers agree to US government price talks amid pushback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""AstraZeneca pays \u00a3350m to settle heartburn drugs lawsuits"", ""summary"": ""British pharmaceutical giant AstraZeneca has agreed to pay $425m (\u00a3352m) to settle US lawsuits that claimed two of its heartburn drugs caused kidney damage.""}, {""date"": ""2023-10-03"", ""headline"": ""10 U.S. drugmakers agree to participate in price negotiations with Medicare"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""AstraZeneca settles heartburn drug lawsuits for $425mn"", ""summary"": ""AstraZeneca has settled disputes on stomach drugs Nexium and Prilosec for a combined total of $425mn, \u201ceffectively\u201d resolving product liability claims in some US states.  It added that the settlements on the drugs used to treat gastric symptoms would allow it to avoid continued, costly litigation.  In the case of Nexium and Prilosec, thousands of lawsuits have been filed in recent years accusing AstraZeneca of doing too little to warn doctors and patients of the risk of kidney disease from taking the drug.""}, {""date"": ""2023-10-03"", ""headline"": ""'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""AstraZeneca to pay $425M to settle Nexium, Prilosec litigation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Selected drugmakers agree to US government price talks - White House"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Ocean Biomedical announces ability to restore treatment sensitivity Osimertinib"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""UPDATE 2-AstraZeneca to pay $425 mln to end US lawsuits over heartburn drugs"", ""summary"": ""Britain's AstraZeneca said it will pay $425 million to settle lawsuits in the United States that claimed its heartburn drugs Nexium and Prilosec caused chronic kidney disease.  AstraZeneca did not disclose specific terms of the agreement and said in a statement on Tuesday that it continues to believe the claims are without merit and admitted no wrongdoing.  It is the second British drugmaker to reach a settlement in the United States for its heartburn drug after GSK in June agreed to settle a U.S. lawsuit alleging its discontinued treatment Zantac caused cancer.""}, {""date"": ""2023-10-03"", ""headline"": ""AstraZeneca to pay $425 million to end US lawsuits over heartburn drugs"", ""summary"": ""AstraZeneca did not disclose specific terms of the agreement and said in a statement on Tuesday that it continues to believe the claims are without merit and admitted no wrongdoing.  It is the second British drugmaker to reach a settlement in the United States for its heartburn drug after GSK in June agreed to settle a U.S. lawsuit alleging its discontinued treatment Zantac caused cancer.  AstraZeneca said that the agreements effectively resolve all pending claims against it for failing to warn patients about the risk of contracting chronic kidney disease and related issues, bar one in Louisiana, where a trial is scheduled in April.""}, {""date"": ""2023-10-03"", ""headline"": ""AstraZeneca settles Nexium, Prilosec product liability litigations for $425M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""AstraZeneca PLC ADR outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-04"", ""headline"": ""FDA experts recommend changes to flu vaccines"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-04"", ""headline"": ""Astrazeneca (AZN) Advances But Underperforms Market: Key Facts"", ""summary"": ""Astrazeneca (AZN) concluded the recent trading session at $66.62, signifying a +0.54% move from its prior day's close.""}, {""date"": ""2023-10-04"", ""headline"": ""Why Shares of Conduit Pharmaceuticals Are Jumping Wednesday"", ""summary"": ""Shares of Conduit Pharmaceuticals (NASDAQ: CDT) were up more than 17% on Wednesday as of 11:30 a.m., after jumping up as much as 81% in the first hour of trading, leading to a brief halt in trading.  Conduit calls itself a \""disease agnostic life science company.\""  With no major news announced, Wednesday's brief meteoric rise was nearly as surprising as the big fall a day before.""}, {""date"": ""2023-10-04"", ""headline"": ""AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M"", ""summary"": ""AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.""}, {""date"": ""2023-10-04"", ""headline"": ""IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-04"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""November 24th Options Now Available For AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-06"", ""headline"": ""Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today"", ""summary"": ""Astrazeneca (AZN) concluded the recent trading session at $67.42, signifying a +0.81% move from its prior day's close.""}, {""date"": ""2023-10-06"", ""headline"": ""Biotech-Pharma Trade: Buying Opportunities On The Horizon"", ""summary"": ""Concerns over interest rates, pricing erosion, and Medicare's drug price negotiation plan weigh on biotech and pharma sectors. Learn what investors need to know.""}, {""date"": ""2023-10-06"", ""headline"": ""Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates"", ""summary"": ""Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.""}, {""date"": ""2023-10-06"", ""headline"": ""AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity"", ""summary"": ""AstraZeneca is the best performing pharma in terms of five-year share price growth after Eli Lilly and Novo Nordisk. Find out if AZN stock is a buy.""}, {""date"": ""2023-10-06"", ""headline"": ""2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague"", ""summary"": ""Two Nasdaq 100 components stand out as plain-as-day values, while another widely owned Nasdaq 100 stock may find it impossible to meet investors' lofty growth expectations.""}, {""date"": ""2023-10-06"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-08"", ""headline"": ""Ionis announces new results from analysis of exploratory cardiac endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4665, ""bookValue"": 37197, ""cashRatio"": 0.17038617601790962, ""currentRatio"": 0.7871, ""ebitPerShare"": 1.2526, ""eps"": 0.8808, ""ev"": 240150.2493, ""fcfMargin"": 0.1945, ""fcfPerShareTTM"": 4.5016, ""grossMargin"": 0.8203, ""inventoryTurnoverTTM"": 1.5794, ""longtermDebtTotalAsset"": 0.2313, ""longtermDebtTotalCapital"": 0.3379, ""longtermDebtTotalEquity"": 0.5975, ""netDebtToTotalCapital"": 0.3604, ""netDebtToTotalEquity"": 0.6373, ""netMargin"": 0.1196, ""operatingMargin"": 0.17, ""payoutRatioTTM"": 0.8967, ""pb"": 5.8189, ""peTTM"": 36.7105, ""pfcfTTM"": 31.0227, ""pretaxMargin"": 0.1438, ""psTTM"": 4.8105, ""quickRatio"": 0.602, ""receivablesTurnoverTTM"": 4.3607, ""roaTTM"": 0.0611, ""roeTTM"": 0.16, ""roicTTM"": 0.0885, ""rotcTTM"": 0.1208, ""salesPerShare"": 7.3667, ""sgaToSale"": 0.1797, ""totalDebtToEquity"": 0.7682, ""totalDebtToTotalAsset"": 0.2974, ""totalDebtToTotalCapital"": 0.4345, ""totalRatio"": 1.6316, ""period"": ""2023-09-30""}"
39,2023-10-08,67.41999816894531,2023-10-15,67.33000183105469,-0.0013348611737589167,D1,"[{""date"": ""2023-10-08"", ""headline"": ""Ionis announces new results from analysis of exploratory cardiac endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-09"", ""headline"": ""AstraZeneca PLC ADR underperforms Monday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.56% to $67.04 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-09"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.79% to \u00a3108.56 Monday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-09"", ""headline"": ""14 Best Cancer Stocks To Buy Now"", ""summary"": ""In this article, we discuss 14 best cancer stocks to buy. If you want to skip our detailed discussion on the oncology industry, head directly to 5 Best Cancer Stocks To Buy Now. The global oncology landscape continues to evolve, with ongoing efforts to discover, develop, and provide innovative treatments aimed at improving outcomes for [\u2026]""}, {""date"": ""2023-10-10"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.45% to $68.01 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-10"", ""headline"": ""Astrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity"", ""summary"": ""WILMINGTON, Del., October 10, 2023--As the AstraZeneca Foundation celebrates its 30th anniversary, the organization has awarded 12 nonprofit organizations $2,170,318 in grants across eight US states and Washington, D.C., for innovative approaches to address healthcare disparities at the community level, a reflection of AstraZeneca\u2019s broader commitment to advance health equity efforts.""}, {""date"": ""2023-10-10"", ""headline"": ""Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term"", ""summary"": ""The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.""}, {""date"": ""2023-10-10"", ""headline"": ""AstraZeneca rises Tuesday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC rallied 1.12% to \u00a3109.78 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-11"", ""headline"": ""Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX) and AstraZeneca PLC (AZN).""}, {""date"": ""2023-10-11"", ""headline"": ""AstraZeneca PLC ADR remains steady Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR were unchanged Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-10-11"", ""headline"": ""Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts"", ""summary"": ""A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.""}, {""date"": ""2023-10-11"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.31% to \u00a3109.44 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-10-11"", ""headline"": ""AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-11"", ""headline"": ""AstraZeneca announces first data from four pivotal Phase III trials at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Catalyst watch: Tesla earnings, Jerome Powell speech, UAW drama and Baidu event"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Why the Market Dipped But (AZN) Gained Today"", ""summary"": ""Astrazeneca (AZN) concluded the recent trading session at $68.11, signifying a +0.15% move from its prior day's close.""}, {""date"": ""2023-10-12"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.15% higher to $68.11 Thursday, on what proved to be an all-around rough trading session for the stock market, with the...""}, {""date"": ""2023-10-12"", ""headline"": ""The Zacks Analyst Blog UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer"", ""summary"": ""UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer are part of the Zacks Analyst Blog.""}, {""date"": ""2023-10-12"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC advanced 1.61% to \u00a3111.20 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-10-12"", ""headline"": ""Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers"", ""summary"": ""Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data for FPI-2068, a clinical stage bispecific IgG-based targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that co-express EGFR-cMET. Fusion is jointly developing FPI-2068 with AstraZeneca (LSE/STO/Nasdaq: AZN) under the companies' multi-asset collaborati""}, {""date"": ""2023-10-12"", ""headline"": ""Interesting AZN Put And Call Options For December 1st"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Fusion Pharmaceuticals and AstraZeneca's FPI-2068 shows anti-tumor efficacy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge"", ""summary"": ""WILMINGTON, Del., October 12, 2023--AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Company\u2019s strategic R&D centres in either Cambridge, UK, Gaithersburg or Boston, US or Gothenburg, Sweden.""}, {""date"": ""2023-10-13"", ""headline"": ""AstraZeneca PLC ADR falls Friday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR shed 1.15% to $67.33 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-10-13"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""AstraZeneca PLC shares slid 1.31% to \u00a3109.74 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-10-13"", ""headline"": ""3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition"", ""summary"": ""During the pandemic era, several healthcare stocks skyrocketed. The focus was, however, on biopharma companies with an early-mover advantage related to the vaccine against Covid-19. Sentiments have changed drastically in a post-pandemic era with 2023 being a subdued year for healthcare stocks. However, there is no doubt about the point that global healthcare spending will continue to remain in an uptrend. Be it demographics or the threat of new disease outbreaks, healthcare companies will have a""}, {""date"": ""2023-10-13"", ""headline"": ""ClearBridge International Growth EAFE Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""A historically wide divergence between value and growth styles, a function of a durable U.S. economy forcing interest rates higher, negatively impacted Strategy performance.""}, {""date"": ""2023-10-13"", ""headline"": ""Genmab price target raised to $46 from $44 at BTIG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-13"", ""headline"": ""ABBV Stock: Buy for the Yield, Hold for This Other Reason"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-14"", ""headline"": ""20 Countries with the Most COVID-19 Cases in the World in 2023"", ""summary"": ""In this article, we will be analyzing the history of COVID-19 and the counteraction against the pandemic, while covering the 20 countries with the most COVID-19 cases in the world in 2023. If you wish to skip our detailed analysis, you can move directly to the 5 Countries with the Most COVID-19 Cases in the [\u2026]""}, {""date"": ""2023-10-15"", ""headline"": ""Week In Review: Two China Biopharmas Announce Billion Dollar Deals"", ""summary"": ""ChinaBio's latest Week in Review highlight two China biopharmas announcing billion-dollar deals. Click here to read more.""}]","{""assetTurnoverTTM"": 0.4665, ""bookValue"": 37197, ""cashRatio"": 0.17038617601790962, ""currentRatio"": 0.7871, ""ebitPerShare"": 1.2526, ""eps"": 0.8808, ""ev"": 240150.2493, ""fcfMargin"": 0.1945, ""fcfPerShareTTM"": 4.5016, ""grossMargin"": 0.8203, ""inventoryTurnoverTTM"": 1.5794, ""longtermDebtTotalAsset"": 0.2313, ""longtermDebtTotalCapital"": 0.3379, ""longtermDebtTotalEquity"": 0.5975, ""netDebtToTotalCapital"": 0.3604, ""netDebtToTotalEquity"": 0.6373, ""netMargin"": 0.1196, ""operatingMargin"": 0.17, ""payoutRatioTTM"": 0.8967, ""pb"": 5.8189, ""peTTM"": 36.7105, ""pfcfTTM"": 31.0227, ""pretaxMargin"": 0.1438, ""psTTM"": 4.8105, ""quickRatio"": 0.602, ""receivablesTurnoverTTM"": 4.3607, ""roaTTM"": 0.0611, ""roeTTM"": 0.16, ""roicTTM"": 0.0885, ""rotcTTM"": 0.1208, ""salesPerShare"": 7.3667, ""sgaToSale"": 0.1797, ""totalDebtToEquity"": 0.7682, ""totalDebtToTotalAsset"": 0.2974, ""totalDebtToTotalCapital"": 0.4345, ""totalRatio"": 1.6316, ""period"": ""2023-09-30""}"
40,2023-10-15,67.33000183105469,2023-10-22,63.83000183105469,-0.05198277001064466,D5+,"[{""date"": ""2023-10-15"", ""headline"": ""TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-15"", ""headline"": ""Week In Review: Two China Biopharmas Announce Billion Dollar Deals"", ""summary"": ""ChinaBio's latest Week in Review highlight two China biopharmas announcing billion-dollar deals. Click here to read more.""}, {""date"": ""2023-10-16"", ""headline"": ""Johnson & Johnson (NYSE:JNJ) Slips despite Cancer Drug Win"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""J&J lung cancer drug combo had superior progression-free survival in study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""AstraZeneca data removes 'slight overhang' on Gilead, says Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.73% higher to $67.82 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-10-16"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.02% to \u00a3109.72 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-10-16"", ""headline"": ""Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""AstraZeneca call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Understanding AstraZeneca's Position In Pharmaceuticals Industry Compared To Competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""TAGRISSO\u00ae Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer"", ""summary"": ""WILMINGTON, Del., October 16, 2023--AstraZeneca\u2019s supplemental New Drug Application (sNDA) for TAGRISSO\u00ae (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).""}, {""date"": ""2023-10-16"", ""headline"": ""Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""AstraZeneca's Tagrisso gets FDA priority review in lung cancer subtype"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""UPDATE 1-AstraZeneca's Tagrisso-chemo combo given priority review in US"", ""summary"": ""A combination of AstraZeneca's blockbuster cancer drug Tagrisso, with chemotherapy to treat a type of lung cancer, has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA), the British drugmaker said on Monday.  It would be used to treat adults with a type of advanced lung cancer, AstraZeneca said, adding that the decision from the regulator was based on a late-stage trial which extended median progression-free survival (PFS) by nearly nine months.  The FDA grants priority review to applications for medicines that, if approved, would offer significant improvements over available options.""}, {""date"": ""2023-10-16"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AstraZeneca (AZN) and Ultragenyx Pharmaceutical (RARE)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""AstraZeneca says Tagrisso plus chemo sNDA granted Priority Review in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rallied 2.15% to $69.28 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-10-17"", ""headline"": ""AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review"", ""summary"": ""The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.""}, {""date"": ""2023-10-17"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rose 2.72% to \u00a3112.70 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-17"", ""headline"": ""AstraZeneca price target raised to 13,200 GBp from 12,900 GBp at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock"", ""summary"": ""AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.""}, {""date"": ""2023-10-18"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 5.82% to $65.24 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-18"", ""headline"": ""AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""2023-10-18"", ""headline"": ""Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry"", ""summary"": ""NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Me""}, {""date"": ""2023-10-18"", ""headline"": ""AstraZeneca shares fall as lung cancer drug trial data abstract disappoints"", ""summary"": ""The abstract on the drug, datopotamab deruxtecan, was published ahead of the European Society for Medical Oncology's (ESMO) congress that kicks off in Madrid on Friday.  Jefferies analyst Stephen\u00a0Barker said in a note the data was \""worse-than-expected\"", citing that treatment with the drug only improved the time patients with non-small cell lung cancer live without their disease worsening by 0.7 months compared to chemotherapy.  Barker said he was expecting an improvement of 1.5-2 months.""}, {""date"": ""2023-10-18"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares shed 5.84% to \u00a3106.12 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-10-18"", ""headline"": ""SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care"", ""summary"": ""SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca (LSE/STO/Nasdaq: AZN) to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing in""}, {""date"": ""2023-10-18"", ""headline"": ""AstraZeneca drops after Phase 3 data for lung cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""People of African ancestry are poorly represented in genetic studies. A new effort would change that"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Unusually active option classes on open October 18th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Meharry Medical College, partners launch Together for CHANGE initiative"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Sophia Genetics announces collaboration with MSK Cancer Center and AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""AstraZeneca's durvalumab gets orphan designation status in gastric cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""AstraZeneca says Soliris approved in China for treatment of adults with NMOSD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""AstraZeneca drug Solaris approved in China as NMOSD treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""TOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know"", ""summary"": ""The latest trading day saw Astrazeneca (AZN) settling at $64.42, representing a -1.26% change from its previous close.""}, {""date"": ""2023-10-19"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR shed 1.26% to $64.42 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-19"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""AstraZeneca PLC shares slid 1.17% to \u00a3104.88 Thursday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-10-19"", ""headline"": ""NVO, LLY, AZN: 3 \u201cStrong Buy\u201d Stocks to Bet on Weight-Loss Drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""AstraZeneca: Buy This Blue-Chip Bargain For A Richer Retirement"", ""summary"": ""AstraZeneca is a financially sound business, boasting a solidly investment-grade credit rating from S&P. See why I rate AZN stock a strong buy.""}, {""date"": ""2023-10-20"", ""headline"": ""AstraZeneca PLC ADR outperforms market despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.92% to $63.83 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-20"", ""headline"": ""Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term"", ""summary"": ""Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.""}, {""date"": ""2023-10-20"", ""headline"": ""How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings"", ""summary"": ""Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.""}, {""date"": ""2023-10-20"", ""headline"": ""AstraZeneca falls Friday, still outperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.55% to \u00a3104.30 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-20"", ""headline"": ""IMFINZI\u00ae (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone"", ""summary"": ""WILMINGTON, Del., October 20, 2023--Positive results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's IMFINZI\u00ae (durvalumab) in combination with standard-of-care FLOT neoadjuvant chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel given before surgery) demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response (pCR) versus neoadjuvant chemotherapy a""}, {""date"": ""2023-10-20"", ""headline"": ""AstraZeneca celebrates positive results from Imfinzi cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""AstraZeneca reports 'positive' results from interim analysis of MATTERHORN trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-21"", ""headline"": ""Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-21"", ""headline"": ""IMFINZI\u00ae (durvalumab) plus LYNPARZA\u00ae (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer"", ""summary"": ""WILMINGTON, Del., October 21, 2023--Positive results from the primary analysis of the DUO-E Phase III trial showed that IMFINZI\u00ae (durvalumab) plus platinum-based chemotherapy, followed by either IMFINZI monotherapy or IMFINZI plus LYNPARZA\u00ae (olaparib), both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometria""}, {""date"": ""2023-10-21"", ""headline"": ""TAGRISSO\u00ae (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline"", ""summary"": ""WILMINGTON, Del., October 21, 2023--Results from a prespecified exploratory analysis of the FLAURA2 Phase III trial showed AstraZeneca\u2019s TAGRISSO\u00ae (osimertinib) with the addition of chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-free survival (PFS), compared to TAGRISSO alone for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and brain metastases at baseline, representing 40""}, {""date"": ""2023-10-22"", ""headline"": ""Datopotamab deruxtecan plus IMFINZI\u00ae (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial"", ""summary"": ""WILMINGTON, Del., October 22, 2023--Updated results from the BEGONIA Phase Ib/II trial for the cohort of patients treated with datopotamab deruxtecan (Dato-DXd) plus IMFINZI\u00ae (durvalumab) (Arm 7) showed that the combination demonstrated durable tumor responses and no new safety signals in patients with previously untreated advanced or metastatic triple-negative breast cancer (TNBC) with six months additional follow-up from the previous data cut-off.""}, {""date"": ""2023-10-22"", ""headline"": ""Updated results from BEGONIA Phase Ib/II trial presented at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Results from primary analysis of the DUO-E Phase III trial presented at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""AstraZeneca's TAGRISSO plus chemotherapy results presented at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
41,2023-10-22,63.83000183105469,2023-10-29,61.88999938964844,-0.030393269399256018,D4,"[{""date"": ""2023-10-21"", ""headline"": ""Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""TOP NEWS: AstraZeneca says Enhertu approved by European Commission"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""LONDON BRIEFING: Keller expects higher profit; Upland rejects approach"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment"", ""summary"": ""By Michael Susin AstraZeneca said that its drug Enhertu, which it developed in partnership with Daiichi Sankyo, has been approved in the European Union for...""}, {""date"": ""2023-10-22"", ""headline"": ""ENHERTU\u00ae Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Datopotamab deruxtecan plus IMFINZI\u00ae (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial"", ""summary"": ""WILMINGTON, Del., October 22, 2023--Updated results from the BEGONIA Phase Ib/II trial for the cohort of patients treated with datopotamab deruxtecan (Dato-DXd) plus IMFINZI\u00ae (durvalumab) (Arm 7) showed that the combination demonstrated durable tumor responses and no new safety signals in patients with previously untreated advanced or metastatic triple-negative breast cancer (TNBC) with six months additional follow-up from the previous data cut-off.""}, {""date"": ""2023-10-22"", ""headline"": ""Updated results from BEGONIA Phase Ib/II trial presented at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Results from primary analysis of the DUO-E Phase III trial presented at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""AstraZeneca's TAGRISSO plus chemotherapy results presented at ESMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Context Therapeutics (CNTX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial"", ""summary"": ""WILMINGTON, Del., October 23, 2023--Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy.""}, {""date"": ""2023-10-23"", ""headline"": ""ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial"", ""summary"": ""WILMINGTON, Del., October 23, 2023--Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2-expressing advanced solid tumors.""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca hails \u2018clinically meaningful\u2019 cancer drug trial results"", ""summary"": ""AstraZeneca has sought to reassure investors that its plans to replace traditional chemotherapy with a new generation of targeted drugs are on track, as it announced full trial results at a medical congress on Monday.  David Fredrickson, executive vice-president of oncology business at AstraZeneca, said it was a \u201cmassive achievement\u201d in a \u201creally ambitious programme\u201d to be presenting two clinical trials \u2014 in lung cancer and breast cancer \u2014 that showed their new treatment was better than the chemotherapy that doctors have been dependent on for over a decade.  The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo, the Japanese pharmaceutical company, on the development of two key \u201cantibody drug conjugates\u201d, which use antibodies to deliver a chemotherapy payload to a tumour with fewer side effects.""}, {""date"": ""2023-10-23"", ""headline"": ""Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial"", ""summary"": ""WILMINGTON, Del., October 23, 2023--Positive results from the pivotal TROPION-Breast01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to investigator\u2019s choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated with endocrine-based therapy""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca celebrates drug trial results for cancer indications"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""LONDON MARKET CLOSE: Stocks largely down on Middle East hostilities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slid 3.16% to \u00a3101.00 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca PLC's (LON:AZN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?"", ""summary"": ""It is hard to get excited after looking at AstraZeneca's (LON:AZN) recent performance, when its stock has declined 5.6...""}, {""date"": ""2023-10-23"", ""headline"": ""Merck (MRK) to Report Q3 Earnings: What's in the Cards?"", ""summary"": ""Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca to hold a virtual meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""ENHERTU\u00ae Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca: Enhertu demonstrated meaningful survival in Phase II trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca says Dato-DXd improved progression-free survival in NSCLC trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca reports 'positive' results from TROPION-Breast01 Phase III trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?"", ""summary"": ""AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca chief Soriot refutes reports of exit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Why Is LumiraDx (LMDX) Stock Up 323% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""LumiraDx announces tie-up with AstraZeneca and Everton"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Daiichi Sankyo: Positive Long-Term Outlook With High Market Expectations"", ""summary"": ""Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Click here to read my analysis of DSKYF stock.""}, {""date"": ""2023-10-23"", ""headline"": ""AstraZeneca, Daiichi Sankyo's Enhertu approved in EU for certain NSCLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""These 3 healthcare stocks should come to life as boomers live their golden years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""PRESS DIGEST-British Business - Oct 25"", ""summary"": ""The following are the top stories on the business pages of British newspapers.  - AstraZeneca Chief Executive Officer Sir Pascal Soriot committed himself to leading the FTSE 100 drugs company for another five years.  - British furniture and flooring retailer ScS will go private through a deal of almost 100 million pounds ($121.56 million) by its Italian rival Cerezzola Limited, a subsidiary of Italian furniture retailer Poltronesof\u00e0.""}, {""date"": ""2023-10-24"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rose 2.41% to $64.57 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-24"", ""headline"": ""AstraZeneca asks the FDA to let adults give themselves the annual flu vaccine"", ""summary"": ""AstraZeneca is asking the FDA to let adults self-administer its nasal flu vaccine. It would be the first of its kind if the regulatory agency agrees.""}, {""date"": ""2023-10-24"", ""headline"": ""LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rallied 3.35% to \u00a3104.38 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-24"", ""headline"": ""Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data"", ""summary"": ""Ambrx Biopharma Inc.'s selloff after Phase 1/2 ESMO data release presents a buying opportunity for its ADC candidates. Click here for my view of AMAN stock now.""}, {""date"": ""2023-10-24"", ""headline"": ""A new RSV shot for infants is in short supply"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Alexion, AstraZeneca Rare Disease, concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome"", ""summary"": ""Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris (ravulizumab) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and the treatment of adult and paediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. With the LOI in place with the pCPA, individual""}, {""date"": ""2023-10-24"", ""headline"": ""US Food and Drug Administration accepts for review AstraZeneca\u2019s Supplemental Biologics License Application for self-administration of FLUMIST\u00ae QUADRIVALENT (Influenza Vaccine Live, Intranasal)"", ""summary"": ""WILMINGTON, Del., October 24, 2023--AstraZeneca\u2019s Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FLUMIST\u00ae QUADRIVALENT (Influenza Vaccine Live, Intranasal), a needle-free nasal spray, has been accepted for review by the US Food and Drug Administration (FDA). If approved, FLUMIST QUADRIVALENT will be the first flu vaccine available to be self-administered by eligible patients or administered by caregivers, adding an additional op""}, {""date"": ""2023-10-24"", ""headline"": ""Why Is LumiraDx (LMDX) Stock Down 35% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine"", ""summary"": ""AstraZeneca PLC said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-administered flu vaccine. The company...""}, {""date"": ""2023-10-24"", ""headline"": ""FDA accepts AstraZeneca's sBLA for self-administration of flu vaccine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""AstraZeneca sBLA for Flumist Quadrivalent accepted for review by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""AstraZeneca says US accepts self-administered flu vaccine for review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""US FDA accepts AstraZeneca's self-administered flu vaccine for review"", ""summary"": ""AstraZeneca said on Tuesday the U.S. Food and Drug Administration (FDA) has accepted for review the company's application seeking approval for patients or caregivers to administer its nasal flu vaccine.  If approved, the vaccine \u2013 branded as FluMist Quadrivalent \u2013 could become the first self-administered flu vaccine which does not necessitate a healthcare practitioner for administration.  FluMist was first approved by the FDA in 2003.""}, {""date"": ""2023-10-24"", ""headline"": ""AstraZeneca says FDA accepts sBLA for self-administration FluMist Quadrivalent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know"", ""summary"": ""Astrazeneca (AZN) closed at $64.21 in the latest trading session, marking a -0.56% move from the prior day.""}, {""date"": ""2023-10-25"", ""headline"": ""AstraZeneca PLC ADR outperforms market despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slumped 0.56% to $64.21 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-25"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rallied 1.03% to \u00a3105.46 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-10-25"", ""headline"": ""AstraZeneca: An Undervalued Investment Opportunity with Significant Growth Potential in Oncology"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""PRESS: Soriot commits to five more years as AstraZeneca CEO - Times"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Buy Rating for AstraZeneca: Key Data Sets and Tagrisso Monotherapy Continuity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slid 1.25% to $63.41 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-26"", ""headline"": ""Mixed Day for Vaccine Stocks as Terrible News Emerges"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""AstraZeneca PLC shares slid 1.46% to \u00a3103.92 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-10-26"", ""headline"": ""Concurrent use of COVID and flu shots is linked to stroke risk in older adults"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""ClearBridge International Growth ACWI Ex-US Strategy Q3 2023\u00a0 Commentary"", ""summary"": ""During Q3 2023, the ClearBridge International Growth ACWI Ex-US Strategy underperformed its MSCI ACWI Ex-U.S. benchmark. Click here to read the full fund letter.""}, {""date"": ""2023-10-26"", ""headline"": ""ClearBridge International Growth ADR Strategy Q3 2023 Commentary"", ""summary"": ""During Q3 2023, the ClearBridge International Growth ADR Strategy underperformed its MSCI EAFE Index benchmark. Click here to read the full fund letter.""}, {""date"": ""2023-10-27"", ""headline"": ""AstraZeneca PLC ADR falls Friday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 2.40% to $61.89 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-27"", ""headline"": ""Ironwood Pharmaceuticals: The Right Play Now"", ""summary"": ""Ironwood's revenue-generating product is Linzess, which is approved for multiple GI indications. Read more to see our take on IRWD stock and its prospects.""}, {""date"": ""2023-10-27"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""AstraZeneca PLC shares slid 2.58% to \u00a3101.24 Friday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-10-28"", ""headline"": ""3 No-Brainer Stocks to Buy for Under $100 Right Now"", ""summary"": ""Benjamin Franklin would probably be disappointed that the $100 bill that bears his likeness isn't worth what it used to be.  Three Motley Fool contributors think they've found no-brainer stocks to buy for under $100 right now -- and all three stocks are in the healthcare sector.  Here's why they picked AstraZeneca (NASDAQ: AZN), BioNTech (NASDAQ: BNTX), and Novartis (NYSE: NVS).""}, {""date"": ""2023-10-29"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
42,2023-10-29,61.88999938964844,2023-11-05,63.959999084472656,0.033446432626244915,U4,"[{""date"": ""2023-10-29"", ""headline"": ""AstraZeneca price target lowered to 12,500 GBp from 13,300 GBp at Berenberg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""13 Most Undervalued Pharma Stocks To Buy According To Analysts"", ""summary"": ""In this piece, we will take a look at the 13 most undervalued pharmaceutical stocks to buy according to analysts. If you want to skip our overview of the pharma industry, then check out 5 Most Undervalued Pharma Stocks To Buy. The pharmaceutical industry is one of the biggest in the world and one that [\u2026]""}, {""date"": ""2023-10-30"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.70% to $62.94 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-10-30"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.93% to \u00a3102.18 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-30"", ""headline"": ""Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?"", ""summary"": ""Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""2023-10-30"", ""headline"": ""The European healthcare sector is expected to produce higher yields."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""11 Best Immunotherapy Stocks To Buy Now"", ""summary"": ""In this article, we discuss 11 of the best immunotherapy stocks to buy now. If you want to skip our detailed discussion on the cancer and oncology industry, head directly to the 5 Best Immunotherapy Stocks To Buy Now. The global oncology landscape is continually transforming, driven by persistent efforts to explore, create, and deliver [\u2026]""}, {""date"": ""2023-10-30"", ""headline"": ""GLOBAL BROKER RATINGS: Stifel cuts Mercedes and Sanofi to 'hold'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-31"", ""headline"": ""AstraZeneca to Invest $245 Million in Deal With Cellectis"", ""summary"": ""By Ben Otto British drugmaker AstraZeneca plans to invest $245 million in a deal with biotechnology company Cellectis to develop next-generation therapeutics...""}, {""date"": ""2023-10-31"", ""headline"": ""Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know"", ""summary"": ""In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.""}, {""date"": ""2023-10-31"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.46% higher to $63.23 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-10-31"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.31% to \u00a3102.50 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-10-31"", ""headline"": ""Daiichi Sankyo ups revenue and profit, boosts quarterly dividend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.87% higher to $63.78 Wednesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-11-01"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.84% to \u00a3103.36 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-11-01"", ""headline"": ""AMD, Kraft Heinz stocks surge, WeWork and CVS shares sink and other stocks on the move"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""JMP sees AZN deal as 'great option' for Cellectis to close financing overhang"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Health Canada approves Ultomiris for adults with neuromyelitis optica spectrum disorder (NMOSD)"", ""summary"": ""Ultomiris (ravulizumab) has been approved by Health Canada as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1""}, {""date"": ""2023-11-01"", ""headline"": ""Cellectis\u2019 stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca"", ""summary"": ""The U.S.-listed shares of Cellectis S.A. rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company...""}, {""date"": ""2023-11-01"", ""headline"": ""Cellectis Shares Soar Premarket on AstraZeneca Deal"", ""summary"": ""By Colin Kellaher Shares of Cellectis took flight in premarket trading Wednesday after the clinical-stage biotechnology company inked a lucrative research...""}, {""date"": ""2023-11-01"", ""headline"": ""Why Is Cellectis (CLLS) Stock Up 175% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Today\u2019s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on\u00a0Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""AstraZeneca, Cellectis announces collaboration and investment agreement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""AstraZeneca launches collaboration and investment deal with Cellectis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""AstraZeneca to invest $245M in Cellectis to strengthen gene therapy portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Catalyst Watch: Disney earnings, Moderna AI event, Powell IMF speech and Las Vegas strike threat"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.63% higher to $64.18 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-11-02"", ""headline"": ""AstraZeneca rises Thursday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.25% to \u00a3103.62 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-11-02"", ""headline"": ""How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings"", ""summary"": ""Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.""}, {""date"": ""2023-11-02"", ""headline"": ""Pfizer: Value Investment Opportunity After Recent Price Decline"", ""summary"": ""Pfizer still generates significant gross profit and has a strong revenue growth rate. Read why I feel PFE stock presents a value investment opportunity now.""}, {""date"": ""2023-11-03"", ""headline"": ""Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects"", ""summary"": ""Cellectis is preparing to showcase its cell therapy candidates for lymphoma and leukemia at the ASH 2023 conference. Learn more about CLLS stock here.""}, {""date"": ""2023-11-03"", ""headline"": ""AstraZeneca PLC ADR falls Friday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.34% to $63.96 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-03"", ""headline"": ""Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial"", ""summary"": ""WILMINGTON, Del., November 03, 2023--Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), used to assess albuminuria, at 12 weeks compared with dapagliflozin alone.""}, {""date"": ""2023-11-03"", ""headline"": ""AstraZeneca plans next phase of trial on kidney drug combination data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.89% to \u00a3102.70 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-11-03"", ""headline"": ""UK earnings, trading statements calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""AstraZeneca: Zibotentan/dapagliflozin combination shows albuminuria reduction"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Q3 2023 Ionis Pharmaceuticals Inc Earnings Call"", ""summary"": ""Q3 2023 Ionis Pharmaceuticals Inc Earnings Call""}, {""date"": ""2023-11-03"", ""headline"": ""7 Evergreen Stocks for Long-term Wealth Generation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""AstraZeneca's Lokelma lets kidney disease patients maintain therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-04"", ""headline"": ""Baron International Growth Fund Q3 2023 Shareholder Letter"", ""summary"": ""Baron International Growth Fund\u00c2\u00ae (the Fund) declined 6.98% (Institutional Shares) during Q3 2023. Click here to read the full fund letter.""}, {""date"": ""2023-11-05"", ""headline"": ""12 Best Large Cap Stocks To Buy Now"", ""summary"": ""In this piece, we will take a look at the 12 best large cap stocks to buy now. If you want to skip our introduction to the stock market and the different kinds of stocks that can be traded, then read 5 Best Large Cap Stocks To Buy Now. Stocks can be divided and segregated [\u2026]""}, {""date"": ""2023-11-05"", ""headline"": ""Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
43,2023-11-05,63.959999084472656,2023-11-12,63.16999816894531,-0.012351484159403792,D2,"[{""date"": ""2023-11-05"", ""headline"": ""The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman \u2013 and Martin Shkreli"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-05"", ""headline"": ""12 Best Large Cap Stocks To Buy Now"", ""summary"": ""In this piece, we will take a look at the 12 best large cap stocks to buy now. If you want to skip our introduction to the stock market and the different kinds of stocks that can be traded, then read 5 Best Large Cap Stocks To Buy Now. Stocks can be divided and segregated [\u2026]""}, {""date"": ""2023-11-05"", ""headline"": ""Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?"", ""summary"": ""Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the third quarter, partially offset by lower sales of legacy drugs.""}, {""date"": ""2023-11-06"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.14% higher to $64.05 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-11-06"", ""headline"": ""Pharma Stocks Are Bleeding. But These 2 Look Like Bargains."", ""summary"": ""Investors have mostly had one reaction to drugmakers\u2019 earnings this quarter: Slam that big red \u201csell\u201d button, and slam it hard.  The latest no good, very bad earnings season started with  Johnson & Johnson  (ticker: JNJ), which on Oct. 17 raised its full-year guidance and announced third quarter earnings that beat Wall Street estimates.  Bristol-Myers Squibb  (BMY) shares fell 6.4% on Oct. 26 despite an earnings beat.""}, {""date"": ""2023-11-06"", ""headline"": ""Unlocking Q3 Potential of Astrazeneca (AZN): Exploring Wall Street Estimates for Key Metrics"", ""summary"": ""Besides Wall Street's top -and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.""}, {""date"": ""2023-11-06"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.06% to \u00a3102.76 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-11-06"", ""headline"": ""Price Over Earnings Overview: AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Xencor falls after royalty sale to Canada\u2019s OMERS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.69% to $63.61 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-07"", ""headline"": ""International Wide-Moat Stocks On Sale - The November 2023 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks. We are only interested in those targets that are attractively valued in historical comparison. Read more here.""}, {""date"": ""2023-11-07"", ""headline"": ""Q3 2023 FibroGen Inc Earnings Call"", ""summary"": ""Q3 2023 FibroGen Inc Earnings Call""}, {""date"": ""2023-11-07"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.45% to \u00a3102.30 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE...""}, {""date"": ""2023-11-07"", ""headline"": ""AbbVie, GSK, Teva cited as FTC tackles improper Orange Book patents"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""9 Once-In-A Lifetime Blue-Chip Opportunities Yielding As Much As 10%"", ""summary"": ""The UK recession is one of the mildest in history, is expected to end in 6 months, and UK stock earnings are down just 7% and expected to accelerate for three straight years. Read more here.""}, {""date"": ""2023-11-07"", ""headline"": ""Compugen Reports Third Quarter 2023 Results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca announces license agreement with Eccogene for ECC5004"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca (NASDAQ:AZN) Rises on Impressive Q3 Momentum"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca lifts forecast after strong Q3, signs $2B deal for obesity drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca Shares Rise After Guidance Increase"", ""summary"": ""By Ian Walker Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total...""}, {""date"": ""2023-11-08"", ""headline"": ""LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca Agrees on Licensing Deal for Obesity Treatment"", ""summary"": ""By Joe Hoppe AstraZeneca said it has entered an exclusive agreement with Eccogene, licensing the latter's ECC5004 product for treating conditions such as...""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca Raises Core EPS Guidance Despite Profit Miss -- Update"", ""summary"": ""By Ian Walker AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower...""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca PLC 3Q EPS 88c"", ""summary"": ""By Ian Walker AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower...""}, {""date"": ""2023-11-08"", ""headline"": ""LONDON MARKET EARLY CALL: FTSE 100 called lower on tame China data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""GET READY: Taylor Wimpey, AstraZeneca, B&M, Auto Trader at 0700 GMT"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca reports mixed Q3 earnings; raises FY23 outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""GLOBAL BRIEFING: China's economy slips back into deflation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript"", ""summary"": ""Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings Calls. [Operator Instructions]. I\u2019d now like to introduce the first speaker Arthur Stril, Chief Business Officer. You may begin. Arthur Stril: Good morning, and welcome, everyone, to Cellectis third quarter 2023 [\u2026]""}, {""date"": ""2023-11-08"", ""headline"": ""BGY: Going Global For Discounts"", ""summary"": ""BlackRock Enhanced International Dividend Trust provides exposure to international equities, with a focus on dividend-paying companies. Learn more on BGY CEF here.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slid 0.13% to $63.53 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca reports, Li Auto earnings, Tapestry: 3 things to watch"", ""summary"": ""Investing.com -- Stocks wobbled for much of the day on Wednesday, struggling to keep a multi-day rally going as investors continued to absorb earnings reports.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca: Revenue Softening Possible, Profits To Rise"", ""summary"": ""AstraZeneca's continued profit growth coupled with recent price correction make its forward P/E attractive once again. Find out if AZN stock is a buy.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.59% to \u00a3101.70 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE...""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity"", ""summary"": ""WILMINGTON, Del., November 08, 2023--AstraZeneca (AZN) is leveraging its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas (RNG) productivity through a planned expanded collaboration with Vanguard Renewables. With an ambition of achieving a multiple fold increase in productivity, the collaboration aims to accelerate parity with fossil fuel-generated natural gas.""}, {""date"": ""2023-11-08"", ""headline"": ""UK earnings, trading statements calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca Q3 2023 Earnings Preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""AstraZeneca's Outlook, Drug Pipeline Seen in Focus -- Earnings Preview"", ""summary"": ""By Ian Walker AstraZeneca is scheduled to report results for the third quarter of the year on Thursday. Here is what you need to know: SALES: The...""}, {""date"": ""2023-11-09"", ""headline"": ""PRESS DIGEST-British Business - Nov. 10"", ""summary"": ""The following are the top stories on the business pages of British newspapers.  Shell is suing Greenpeace for $2.1 million after activists from Greenpeace occupied one of its vessels to protest against its North Sea oil drilling plans.  Germany has asked Brussels to postpone a set of post-Brexit rules that would in effect impose a 10% tariff on most electric car exports between the UK and the European Union.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript"", ""summary"": ""Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.  Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these working statements.""}, {""date"": ""2023-11-09"", ""headline"": ""Medicare drug price negotiations: AstraZeneca CEO's take"", ""summary"": ""AstraZeneca's Farxiga, a diabetes drug, is one of the ten drugs that Medicare will negotiate prices for, a new process that was implemented under the Inflation Reduction Act (IRA). AstraZeneca (AZN) CEO Pascal Soriot tells Yahoo Finance's Anjalee Khamlani that he would like to see \""a little adjustment\"" to the IRA. \""Our advocacy has been... rather than start the clock when you launch the product, please start the clock when the product loses its orphan drug status as decided by the FDA. So that gives, that would give rare disease products a little bit longer protection and would stimulate development for rare diseases,\"" Soriot says. Click here to watch the full interview on the Yahoo Finance YouTube page or you can watch this full episode of Yahoo Finance Live here.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs"", ""summary"": ""Shares of AZN stock popped Thursday after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene.""}, {""date"": ""2023-11-09"", ""headline"": ""The battle for weight loss drug dominance is heating up. Here's why."", ""summary"": ""AstraZeneca reenters the weight loss drug race with a Chinese partner while Eli Lilly finally gets FDA approval for its drug, Zepbound.""}, {""date"": ""2023-11-09"", ""headline"": ""Petrol garages under fire over rising margins at the pump"", ""summary"": ""Petrol retailers have been accused of \u201ctaking advantage\u201d of drivers at the pumps after a report showed motorists were hit with \u201csignificant increases\u201d in fuel sellers\u2019 margins.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca to develop new weight-loss drug after striking \u00a31.6bn deal"", ""summary"": ""AstraZeneca will develop a new diabetes and weight loss treatment after striking a $2bn (\u00a31.6bn) deal to enter the obesity drug race.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.88% higher to $64.09 Thursday, on what proved to be an all-around rough trading session for the stock market, with the...""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca PLC 2023 Q3 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by AstraZeneca PLC in conjunction with their 2023 Q3 earnings call.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca Strikes a Deal for an Experimental Weight-Loss Drug and Boosts Its Guidance"", ""summary"": ""AstraZeneca raised its guidance on higher demand for its cancer treatments and signed a licensing agreement with Eccogene for the Chinese company's experimental weight-loss pill.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca CFO: Obesity Market Has a Lot of Potential"", ""summary"": ""AstraZeneca CFO Aradhana Sarin discusses the company's third-quarter results and its plans to develop an obesity pill. The treatment developed by closely held Chinese biotech Eccogene is in early-stage clinical tests for diabetes. She speaks with Alix Steel and Guy Johnson on \""Bloomberg Markets.\"" Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com Connect with us on... Twitter: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness/ Instagram: https://www.instagram.com/quicktake/?hl=en""}, {""date"": ""2023-11-09"", ""headline"": ""Jobless Claims Decreased More Than Expected"", ""summary"": ""Jobless Claims Decreased More Than Expected""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost."", ""summary"": ""AstraZeneca has struck a licensing deal worth up to $2 billion for a weight-loss drug. Stockholders are welcoming the move as its shares have lagged behind peers Eli Lilly and Novo Nordisk.""}, {""date"": ""2023-11-09"", ""headline"": ""Pre-Markets Strong on Higher Bond Rates, Mixed Earnings"", ""summary"": ""While this positive sentiment is welcome, we note bond yield rates going higher this morning.""}, {""date"": ""2023-11-09"", ""headline"": ""Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates"", ""summary"": ""The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.""}, {""date"": ""2023-11-09"", ""headline"": ""Walt Disney, Affirm, AMC Entertainment, Twilio rise premarket; Lyft, Tesla fall"", ""summary"": ""Investing.com -- U.S. futures traded in a muted fashion Thursday, as investors awaited a speech by Fed Chair Jerome Powell while digesting more quarterly earnings.""}, {""date"": ""2023-11-09"", ""headline"": ""Father with brain injury sues pharma giant over Covid vaccine \u2018defect\u2019"", ""summary"": ""Jamie Scott, 47, has brought a High Court claim against AstraZeneca over the alleged impact of its jab.""}, {""date"": ""2023-11-09"", ""headline"": ""Traders Hold Breath For Powell's Remarks, Bitcoin's Wild Ride Unleashed: What's Driving Markets Thursday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca stays in GLP-1 drug race with new deal"", ""summary"": ""AstraZeneca is paying $185 million upfront to gain access to an experimental GLP-1 drug from China-based biotech Eccogene.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rose 2.62% to \u00a3104.36 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-11-09"", ""headline"": ""IMFINZI\u00ae (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial"", ""summary"": ""WILMINGTON, Del., November 09, 2023--Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) in combination with transarterial chemoembolization (TACE) and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolization. The trial continues to follow the secondary endpoin""}, {""date"": ""2023-11-09"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Trending tickers: Disney | Arm | Astrazeneca | S4 Capital"", ""summary"": ""The latest investor updates on stocks that are trending on Thursday.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca signs deal for oral weight loss drug and lifts profit outlook"", ""summary"": ""Anglo-Swedish drugmaker\u2019s oncology and rare disease medication sales offset waning demand for Covid jabs""}, {""date"": ""2023-11-09"", ""headline"": ""Auto Trader & AstraZeneca Help FTSE Reverse Early Losses"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""BMO Capital Sticks to Its Buy Rating for AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""6 stocks to watch on Thursday: Take-Two, Grab, Li Auto, Novavax and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""UPDATE 1-China health sector sees better sentiment from anti-graft drive - execs"", ""summary"": ""Business activities in China's healthcare sector are returning from a sudden near freeze that began in July when Beijing kicked off a year-long anti-corruption campaign, two foreign industry executives said.  The campaign targets the bribing of doctors in drug and medical equipment sales and marks a sharp escalation of an anti-corruption drive in the sector that started years ago.  \""We see a recovery in terms of engagements ... we see an improvement in that area,\"" Zafer Unluer, China president of U.S. healthcare company Organon, told Reuters on the sidelines of an industry event in Shanghai.""}, {""date"": ""2023-11-09"", ""headline"": ""UPDATE 2-AstraZeneca raises stakes in obesity drug race with Eccogene deal"", ""summary"": ""AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an experimental oral drug in the field.  The Anglo-Swedish drugmaker said it had struck the deal for ECC5004, a once-daily oral drug that is part of a class of highly promising weight-loss medicines known as GLP-1 receptor agonists currently dominated by Novo Nordisk and Eli Lilly, which have injectable products.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca Raises Core EPS Guidance Despite Profit Miss"", ""summary"": ""AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower third-quarter profit that missed forecasts.""}, {""date"": ""2023-11-09"", ""headline"": ""LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca ups profit outlook and boosts anti-obesity pipeline"", ""summary"": ""LONDON (Reuters) -AstraZeneca raised its annual earnings forecast on Thursday, helped by strong demand for its cancer drugs, and moved to boost its pipeline in the booming anti-obesity market with a deal costing up to $2 billion.  The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations.  For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca: Imfinzi+bevacizumab met primary endpoint for PFS in liver cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Lancashire Holdings declares special dividend after strong year so far"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca succeeds in Phase 3 trial for liver cancer drug combo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Astrazeneca: Q3 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca announces results from EMERALD-1 Phase III trial of Imfinzi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca raises FY core EPS view to up low double digits to low teens"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca reports Q3 core EPS $1.73, consensus 84c"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines"", ""summary"": ""AstraZeneca shares jumped 3% after the Anglo-Swedish drugmaker said it expects its full-year revenues will increase at a higher rate than previously forecast""}, {""date"": ""2023-11-10"", ""headline"": ""AstraZeneca PLC (NASDAQ:AZN) Q3 2023 Earnings Call Transcript"", ""summary"": ""AstraZeneca PLC (NASDAQ:AZN) Q3 2023 Earnings Call Transcript November 9, 2023 AstraZeneca PLC beats earnings expectations. Reported EPS is $0.87, expectations were $0.79. Operator: Good morning to those joining from the U.S. Good afternoon to those in the U.K. and Central Europe and good evening to those listening in Asia. Welcome, ladies and gentlemen to [\u2026]""}, {""date"": ""2023-11-10"", ""headline"": ""AstraZeneca prioritizes US for RSV drug amid surge in cases"", ""summary"": ""AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply.  AstraZeneca CEO Pascal Soriot in an interview at the Reuters office in New York said the U.S. Centers for Disease Control and Prevention (CDC) had been asking for more of the antibody therapy that was co-developed with French drugmaker Sanofi .""}, {""date"": ""2023-11-10"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slipped 1.44% to $63.17 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-10"", ""headline"": ""Wegovy maker to spend \u00a34.9bn on new facilities amid obesity drug race"", ""summary"": ""Wegovy maker Novo Nordisk will spend more than \u00a34.9bn to expand its production in Denmark as it races to meet surging demand for weight-loss drugs.""}, {""date"": ""2023-11-10"", ""headline"": ""AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate"", ""summary"": ""To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.""}, {""date"": ""2023-11-10"", ""headline"": ""AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View"", ""summary"": ""AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.""}, {""date"": ""2023-11-10"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""AstraZeneca PLC shares shed 3.32% to \u00a3100.90 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-11-10"", ""headline"": ""The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Best Stocks to Buy Now, 11/10/2023, According to Top Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""AstraZeneca Receives Buy Rating Amid Mixed Q3 Results and Upbeat 2023 Guidance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-12"", ""headline"": ""Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-12"", ""headline"": ""Eli Lilly expected to add $4.1B U.S. sales from new weight loss drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
44,2023-11-12,63.16999816894531,2023-11-19,64.12999725341797,0.015197073172381392,U2,"[{""date"": ""2023-11-12"", ""headline"": ""LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-12"", ""headline"": ""Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-12"", ""headline"": ""Eli Lilly expected to add $4.1B U.S. sales from new weight loss drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-13"", ""headline"": ""11 Best European Stocks To Buy Now"", ""summary"": ""In this piece, we will take a look at the 11 best European stocks to buy now. If you want to skip our introduction to the European economy and major companies and countries, then take a look at the 5 Best European Stocks To Buy Now. Europe is one of the most developed continents in [\u2026]""}, {""date"": ""2023-11-13"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.84% higher to $63.70 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-11-13"", ""headline"": ""Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise"", ""summary"": ""Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.""}, {""date"": ""2023-11-13"", ""headline"": ""Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""2023-11-13"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rallied 1.57% to \u00a3102.48 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-11-13"", ""headline"": ""Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-13"", ""headline"": ""With 86% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing"", ""summary"": ""Key Insights Significantly high institutional ownership implies AstraZeneca's stock price is sensitive to their trading...""}, {""date"": ""2023-11-14"", ""headline"": ""Cellectis stock jumps on execution of $140M additional investment by AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""Cellectis stock jumps on execution of $140M additional investment with AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""Biggest stock movers today: JD.com, Arcturus Therapeutics and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.83% higher to $64.23 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-14"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.60% to \u00a3101.86 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2023-11-14"", ""headline"": ""Merck: Tracking Well Above The Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""AstraZeneca Targets New Pill as Cheaper Option for Losing a \u2018Bit of Weight\u2019"", ""summary"": ""The U.K.-based drugmaker  AstraZeneca  is jumping into the increasingly crowded race to bring an effective weight-loss pill to market, and it says its late start won\u2019t be a major setback.  AstraZeneca  (ticker: AZN) last week announced a licensing deal with a Chinese biotech for a weight-loss pill still in early-stage trials.  Investors have swooned over the opportunity for record-obliterating sales from the new class of weight loss drugs from  Novo Nordisk  (ticker: NVO) and  Eli Lilly  (LLY), making both the companies among the most valuable in healthcare.""}, {""date"": ""2023-11-14"", ""headline"": ""TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""AstraZeneca says Phase 3 lung cancer trial for new Imfinzi regimen failed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""AstraZeneca reports Imfinzi plus chemotherapy approved in China for BTC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""AstraZeneca says PACIFIC-2 trial did not hit primary PFS endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow."", ""summary"": ""Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.""}, {""date"": ""2023-11-15"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 1.71% to $63.13 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-15"", ""headline"": ""AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails"", ""summary"": ""AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.""}, {""date"": ""2023-11-15"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.94% to \u00a3100.90 Wednesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-11-15"", ""headline"": ""13 Buyable Inflation-Busting November Dividend Stocks"", ""summary"": ""This article is based on five UBS, Kiplinger, and Barron's articles, aimed at finding 'Inflation Busting', stocks since 2022. Read more to see the list.""}, {""date"": ""2023-11-15"", ""headline"": ""Biggest stock movers today: Target, ZIM Integrated Shipping, JD.com, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""UPDATE 2-US FDA approves AstraZeneca's breast cancer drug combination"", ""summary"": ""The U.S. Food and Drug Administration on Thursday approved AstraZeneca's Truqap in combination with an older drug, providing another treatment option for patients with the most common type of breast cancer.  The FDA decision allows use of the drug, chemically known as capivasertib, in combination with the British drugmaker's older cancer treatment faslodex.  The Truqap combination enters a competitive market of breast cancer treatments, which include AstraZeneca-Daiichi Sankyo's Enhertu and Gilead's Trodelvy.""}, {""date"": ""2023-11-16"", ""headline"": ""UPDATE 2-CDC releases 77,000 additional doses of Sanofi-AstraZeneca's RSV drug"", ""summary"": ""The U.S. Centers for Disease Control and Prevention said on Thursday it has released more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus.  The additional doses, which the CDC said will be distributed immediately to physicians and hospitals, will help improve the availability of the drug at a time when a surge in cases of the disease is outpacing supply.  Beyfortus was approved earlier this year to prevent the disease in infants and toddlers.""}, {""date"": ""2023-11-16"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR advanced 1.06% to $63.80 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-16"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.75% to \u00a3101.66 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-11-16"", ""headline"": ""Interesting AZN Put And Call Options For July 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), AstraZeneca (AZN) and Acadia Healthcare (ACHC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""AstraZeneca PLC ADR rises Friday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.52% higher to $64.13 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-17"", ""headline"": ""Penny Stocks To Buy? 4 Under $5 To Watch Right Now"", ""summary"": ""Biotech penny stocks to watch this week.""}, {""date"": ""2023-11-17"", ""headline"": ""AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock"", ""summary"": ""U.K.-based AstraZeneca (NASDAQ: AZN) is now gearing up for the second time to develop a challenger to Novo Nordisk's (NYSE: NVO) Ozempic, its absurdly successful treatment for type 2 diabetes.  If AstraZeneca's bid succeeds, the company will mint yet another blockbuster drug yielding more than $1 billion in sales per year.  Let's go over why this attempt to dethrone Ozempic probably isn't a slam dunk.""}, {""date"": ""2023-11-17"", ""headline"": ""Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use"", ""summary"": ""FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication""}, {""date"": ""2023-11-17"", ""headline"": ""AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer"", ""summary"": ""AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.""}, {""date"": ""2023-11-17"", ""headline"": ""US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""AstraZeneca rises Friday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.92% to \u00a3102.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the FTSE...""}, {""date"": ""2023-11-17"", ""headline"": ""TRUQAP\u2122 (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer"", ""summary"": ""WILMINGTON, Del., November 17, 2023--AstraZeneca\u2019s TRUQAP\u2122 (capivasertib) in combination with fulvestrant has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adj""}, {""date"": ""2023-11-17"", ""headline"": ""AstraZeneca: Growth Is Still A Better Choice"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""AstraZeneca gets FDA nod for breast cancer drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""AstraZeneca announces approval of Truqap plus Faslodex in the U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""IQDG: Finding Dividend Growth In Quality And Forward Earnings"", ""summary"": ""IQDG has outperformed at least four close competitors in 2023 and has the best 5-year dividend growth rate in its group. Explore more details here.""}]",{}
45,2023-11-19,64.12999725341797,2023-11-26,64.5,0.005769573716336129,U1,"[{""date"": ""2023-11-19"", ""headline"": ""AstraZeneca Launches Health-Tech Business Evinova -- Update"", ""summary"": ""By Michael Susin AstraZeneca said it has launched Evinova, a separate health-tech business to offer its knowledge of clinical-trial design and study...""}, {""date"": ""2023-11-19"", ""headline"": ""AstraZeneca Launches Health-Tech Business Evinova to Support Clinical Studies"", ""summary"": ""By Michael Susin AstraZeneca said it has launched Evinova, a separate health-tech business to offer its knowledge of clinical trial design and study...""}, {""date"": ""2023-11-19"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""IQDG: Finding Dividend Growth In Quality And Forward Earnings"", ""summary"": ""IQDG has outperformed at least four close competitors in 2023 and has the best 5-year dividend growth rate in its group. Explore more details here.""}, {""date"": ""2023-11-20"", ""headline"": ""Merck: A Dividend Growth Stock Worth Considering"", ""summary"": ""Merck reports positive quarterly earnings and consistent dividend growth over 12 years. Read why MRK stock is well-positioned for potential future success.""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca PLC ADR falls Monday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.53% to $63.79 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-20"", ""headline"": ""Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand"", ""summary"": ""Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.""}, {""date"": ""2023-11-20"", ""headline"": ""5 Growth Stocks to Buy for 2024"", ""summary"": ""This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here. Was 2023 a good year for growth stocks? At first glance, the answer seems obvious: an undeniable \u201cyes.\u201dInvestorPlace - Stock Market News, Stock Advice & Trading Tips Tech giants like Amazon (NASDAQ:AMZN) and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) have ridden a surge in cloud computing demand this year. Nvidia (NASDAQ:NVDA) is now a trillion-dollar company. And ev""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes"", ""summary"": ""WILMINGTON, Del., November 20, 2023--AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector.""}, {""date"": ""2023-11-20"", ""headline"": ""J&J's Janssen submits FDA application for Rybrevant for cancer form"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS), Guardant Health (GH) and AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""12 European Countries with the Best Quality of Life"", ""summary"": ""In this article, we will look into the 12 European countries with the best quality of life. If you want to skip our detailed analysis, you can go directly to the 5 European Countries with the Best Quality of Life. According to WHO\u2019s definition of quality of life, \u201cQuality of life is a subjective evaluation [\u2026]""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC dropped 1.50% to \u00a3101.06 Monday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-11-20"", ""headline"": ""20 Most Valuable Healthcare Companies in the World"", ""summary"": ""In this article, we will look into the 20 most valuable healthcare companies in the world. If you want to skip our detailed analysis, you can go directly to the 5 Most Valuable Healthcare Companies in the World. Healthcare Services Industry: A Market Analysis According to a report by Verified Market Research, the global healthcare [\u2026]""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca creates digital health unit, with big-name partnerships already in place"", ""summary"": ""Called Evinova, the unit will operate as a separate business within AstraZeneca, which sees digital health solutions as a market primed for growth.""}, {""date"": ""2023-11-20"", ""headline"": ""Top European Ideas through EPS Growth by J.P. Morgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca launches digital solutions business for clinical trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""Top European Ideas through EPS Growth by Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca launches health-tech business Evinova"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca (NASDAQ:AZN) Unveils New AI-Driven Health Solutions Unit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca launches new life sciences tech innovation firm Evinova"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""AstraZeneca announces launch of Evinova, a digital health solutions provider"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.77% higher to $64.28 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-21"", ""headline"": ""Sutro Biopharma Names Jane Chung as Next Operating Chief"", ""summary"": ""By Denny Jacob Sutro Biopharma promoted Jane Chung to president and chief operating officer, effective Dec. 1. The clinical-stage oncology company said...""}, {""date"": ""2023-11-21"", ""headline"": ""Here's Why Astrazeneca (AZN) is a Strong Value Stock"", ""summary"": ""Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.""}, {""date"": ""2023-11-21"", ""headline"": ""AstraZeneca's Koselugo gets orphan drug status"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.85% to \u00a3101.92 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-11-21"", ""headline"": ""Major Milestone Met in AI-Powered Fight Against Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""AstraZeneca's Alexion granted orphan status for glioma treament"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""AstraZeneca Pays Hefty Price For Chinese Weight-Loss Drug"", ""summary"": ""Chinese biotech Eccogene says its small-molecule drug may prove easier to use than rival weight- control therapies.""}, {""date"": ""2023-11-22"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 1.04% to $63.61 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-22"", ""headline"": ""Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant"", ""summary"": ""Weight-loss drugs present an enormous opportunity in the healthcare market.  Wegovy and Mounjaro are some of the top-selling drugs available in that indication, and companies that make them -- Novo Nordisk and Eli Lilly -- have seen their share prices soar this year to levels that have put them among the most valuable healthcare businesses in the world.  There will almost certainly soon be more competition in this highly lucrative market, and one company that may be among those debuting a new weight-loss treatment in the next few years is AstraZeneca (NASDAQ: AZN).""}, {""date"": ""2023-11-22"", ""headline"": ""AstraZeneca fights accusations its Covid-19 jab was \u2018defective\u2019"", ""summary"": ""AstraZeneca is contesting accusations that its Covid-19 jab was \u201cdefective\u201d after the drugmaker was sued for damages by a vaccine recipient who claimed to have suffered from a severe side effect.  The Anglo-Swedish drugmaker, which developed the vaccine with the University of Oxford, has filed its defence in a case brought by Jamie Scott, who claimed he suffered a rare but severe type of blood clot because he took the vaccine.  The lawsuit will be closely watched, in case other vaccine recipients could file more suits.""}, {""date"": ""2023-11-22"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares shed 1.04% to \u00a3100.86 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-11-22"", ""headline"": ""3 No-Brainer Stocks to Buy With $1,000 Right Now"", ""summary"": ""A modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts.""}, {""date"": ""2023-11-22"", ""headline"": ""Cellectis price target lowered to $10 from $12 at Citi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Elephants don\u2019t gallop \u2013 except for AstraZeneca"", ""summary"": ""The late, great investor (and Telegraph Money columnist) Jim Slater famously said that \u201celephants don\u2019t gallop\u201d.""}, {""date"": ""2023-11-23"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-23"", ""headline"": ""IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-24"", ""headline"": ""Novo Nordisk (NVO) to Expand Manufacturing Site in France"", ""summary"": ""Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.""}, {""date"": ""2023-11-24"", ""headline"": ""Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know"", ""summary"": ""Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""2023-11-24"", ""headline"": ""Pneumonia outbreak in China is no reason for alarm: WHO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-25"", ""headline"": ""Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston's Ensem"", ""summary"": ""BeiGene acquiring global rights to a preclinical novel CDK2 inhibitor from Ensem Therapeutics is this week's top. Click here for more exciting biotech news.""}, {""date"": ""2023-11-25"", ""headline"": ""Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston\u2019s Ensem"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-26"", ""headline"": ""12 Best Diabetes Stocks To Buy Now"", ""summary"": ""In this article, we shall discuss the 12 best diabetes stocks to buy now. To skip our detailed analysis of the global diabetes drugs industry in 2023, go directly and see 5 Best Diabetes Stocks to Buy Now. Diabetes is a chronic metabolic disease which is normally characterized by high blood glucose levels, which tend [\u2026]""}, {""date"": ""2023-11-26"", ""headline"": ""15 Best Drug Stocks To Invest In"", ""summary"": ""In this article, we discuss the 15 best drug stocks to invest in. You can skip our detailed analysis of the drug and pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Drug Stocks To Invest In. Healthcare expands on the defensive concept, encompassing a myriad of companies. This [\u2026]""}]",{}
46,2023-11-26,64.5,2023-12-03,64.79000091552734,0.004496138225230206,U1,"[{""date"": ""2023-11-25"", ""headline"": ""Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston's Ensem"", ""summary"": ""BeiGene acquiring global rights to a preclinical novel CDK2 inhibitor from Ensem Therapeutics is this week's top. Click here for more exciting biotech news.""}, {""date"": ""2023-11-26"", ""headline"": ""LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-26"", ""headline"": ""12 Best Diabetes Stocks To Buy Now"", ""summary"": ""In this article, we shall discuss the 12 best diabetes stocks to buy now. To skip our detailed analysis of the global diabetes drugs industry in 2023, go directly and see 5 Best Diabetes Stocks to Buy Now. Diabetes is a chronic metabolic disease which is normally characterized by high blood glucose levels, which tend [\u2026]""}, {""date"": ""2023-11-26"", ""headline"": ""15 Best Drug Stocks To Invest In"", ""summary"": ""In this article, we discuss the 15 best drug stocks to invest in. You can skip our detailed analysis of the drug and pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Drug Stocks To Invest In. Healthcare expands on the defensive concept, encompassing a myriad of companies. This [\u2026]""}, {""date"": ""2023-11-27"", ""headline"": ""Tesla sues Sweden in bid to avoid hit from strikes"", ""summary"": ""Tesla has sued Sweden\u2019s government in an attempt to circumvent strikes crippling its operations in the country.""}, {""date"": ""2023-11-27"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slipped 1.30% to $63.66 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-27"", ""headline"": ""Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan"", ""summary"": ""Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.""}, {""date"": ""2023-11-27"", ""headline"": ""AIO: Some AI Exposure, But Not Exactly An AI Play"", ""summary"": ""Virtus AI & Tech Opportunities Fund adds more tech companies to its portfolio, but performance lags peers due to a unique approach. Click here to read more.""}, {""date"": ""2023-11-27"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slid 2.00% to \u00a399.76 Monday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index...""}, {""date"": ""2023-11-27"", ""headline"": ""Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Do AstraZeneca's (LON:AZN) Earnings Warrant Your Attention?"", ""summary"": ""Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...""}, {""date"": ""2023-11-27"", ""headline"": ""GLOBAL BROKER RATINGS: Entain and Novartis lowered to 'sell'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""15 Hardest Countries to Get Citizenship in Europe"", ""summary"": ""In this article, we will explore the 15 hardest countries to get citizenship in Europe. You can skip our comprehensive analysis and proceed directly to the 5 Hardest Countries to Get Citizenship in Europe. Obtaining citizenship in European countries often entails strict criteria and requirements. Eligibility typically includes a minimum residency period, clean criminal record, [\u2026]""}, {""date"": ""2023-11-28"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slid 0.57% to $63.30 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-11-28"", ""headline"": ""UPDATE 1-White House urges RSV vaccine makers to meet demand"", ""summary"": ""Senior Biden administration officials met with RSV vaccine makers this week to underscore the need for manufacturers such as Sanofi and AstraZeneca to urgently meet demand as winter approaches, the White House said on Tuesday.  At a meeting at the White House on Monday, officials and manufacturers also agreed to plan now to meet next year's demand for the vaccines targeting respiratory syncytial virus, which generally causes mild, cold-like symptoms but can develop into severe illness in infants and older adults.""}, {""date"": ""2023-11-28"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.76% to \u00a399.00 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE...""}, {""date"": ""2023-11-28"", ""headline"": ""AstraZeneca: Strong Buy Recommendation on Robust Growth Prospects and Solid Product Base"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""30 Countries with the Highest Quality of Life Heading into 2024"", ""summary"": ""In this article, we will look into the 30 countries with the highest quality of life heading into 2024. If you want to skip our detailed analysis you can go directly to the 5 Countries with the Highest Quality of Life Heading into 2024. Global Quality of Life: An Analysis Quality of life is a [\u2026]""}, {""date"": ""2023-11-29"", ""headline"": ""3 Best Stocks to Buy Now, 11/30/2023, According to Top Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""17 Best European Countries to Move to from the USA"", ""summary"": ""In this article, we will be navigating through the living conditions across Europe while covering the 17 best European countries to move to from the USA. If you wish to skip our detailed analysis, you can move directly to the 5 Best European Countries to Move to from the USA. Life in Europe: An Overview [\u2026]""}, {""date"": ""2023-11-29"", ""headline"": ""Ajinomoto: Food, Biotech, And Semis All-In-One"", ""summary"": ""Ajinomoto pursues growth in biopharma and semiconductor industries, leveraging its market position, R&D investment, and operational catalysts. Learn more on AJINF stock here.""}, {""date"": ""2023-11-29"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.30% to $64.12 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-11-29"", ""headline"": ""Biogen: LAQEMBI's $10 Billion Potential"", ""summary"": ""Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval. Click here to read why we still rate the BIIB stock as a 'Strong Buy'.""}, {""date"": ""2023-11-29"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares advanced 1.33% to \u00a3100.32 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-11-29"", ""headline"": ""AstraZeneca advances scientific leadership in hematology at ASH 2023"", ""summary"": ""WILMINGTON, Del., November 29, 2023--AstraZeneca will present new clinical and real-world data in multiple hematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting andExposition, December 9 to 12, 2023 in San Diego, CA.""}, {""date"": ""2023-11-30"", ""headline"": ""LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""AstraZeneca pulls plug on anti-hyperkalaemia drug trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""AstraZeneca discontinues two phase III evidence trials for Lokelma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""LONDON BRIEFING: Stocks called higher; UK house prices fall annually"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""EU regulators seeking more info on GLP-1s and suicidal thoughts: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""Best Penny Stocks Today? 3 To Watch Under $4 Now"", ""summary"": ""Penny stocks under $4 to watch now.""}, {""date"": ""2023-11-30"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.73% higher to $64.59 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-11-30"", ""headline"": ""17 Ideal Pre-Crash Recovery December Divi-Dogs"", ""summary"": ""Discover the top pre-crash-recovery stocks of 2023 in financial services, healthcare, and real estate sectors. Click for our top dividend picks in several sectors.""}, {""date"": ""2023-11-30"", ""headline"": ""AbbVie's $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained"", ""summary"": ""AbbVie Inc.'s $10.1B acquisition of ImmunoGen, Inc. diversifies its oncology pipeline and reduces its Humira reliance. Click for my take on the ABBV deal for IMGN.""}, {""date"": ""2023-11-30"", ""headline"": ""Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO\u00ae Technology"", ""summary"": ""Presage Biosciences, a pioneering translational oncology company whose mission is to use CIVO and spatial molecular profiling to understand the complexity of drug response in the tumor microenvironment (TME), has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company. According to the agreement, Presage's platform will be used by AstraZeneca in translational analysis to evaluate several investigational bispecific antibody combinations in samples take""}, {""date"": ""2023-11-30"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.94% to \u00a3101.26 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-12-01"", ""headline"": ""Directors\u2019 Deals: Strategy refresh spurs Unilever directors"", ""summary"": ""Unilever\u2019s new chief executive Hein Schumacher is open about the problems facing the consumer staples giant.  As part of a new action plan, Schumacher said there would be \u201cno major or transformational acquisitions\u201d on his watch.  A pruning has now begun \u2014 Dollar Shave Club, which Unilever acquired for $1bn (\u00a3800mn) in 2016, is being sold.""}, {""date"": ""2023-12-01"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.31% higher to $64.79 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-12-01"", ""headline"": ""AstraZeneca (AZN) to Discontinue Two Studies on Lokelma"", ""summary"": ""Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.""}, {""date"": ""2023-12-01"", ""headline"": ""AstraZeneca rises Friday, still underperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.71% to \u00a3101.98 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-01"", ""headline"": ""Pfizer hits new 52-week low after weight loss setback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-01"", ""headline"": ""Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-01"", ""headline"": ""AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-01"", ""headline"": ""AstraZeneca discontinuing STABILIZE-CKD, DIALIZE-Outcomes trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-02"", ""headline"": ""Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Tang Capital offering $465M for LianBio Plus 80% of any Licenses/Divestments is ChinaBio's lead news this week. Click here to read more.""}, {""date"": ""2023-12-02"", ""headline"": ""Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-03"", ""headline"": ""AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT"", ""summary"": ""The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said.  It did not say what kind of cancer they plan to target.""}, {""date"": ""2023-12-03"", ""headline"": ""UPDATE 1-AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT"", ""summary"": ""Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.  The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said.""}, {""date"": ""2023-12-03"", ""headline"": ""AstraZeneca ties up with AI biologics company to develop cancer drug"", ""summary"": ""AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer, the latest tie-up in fast-expanding efforts to use artificial intelligence for drug discovery.  The collaboration aims to harness Absci\u2019s AI technology for large-scale protein analysis to find a viable oncology therapy \u2014 a leading focus of Anglo-Swedish drugmaker AstraZeneca.  The partnership adds to a flurry of agreements between big pharmaceutical companies and young AI businesses to build novel disease treatments and cut the costs of developing them.""}]",{}
47,2023-12-03,64.79000091552734,2023-12-10,63.25,-0.023769113964594357,D3,"[{""date"": ""2023-12-02"", ""headline"": ""Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Tang Capital offering $465M for LianBio Plus 80% of any Licenses/Divestments is ChinaBio's lead news this week. Click here to read more.""}, {""date"": ""2023-12-03"", ""headline"": ""Correction: AstraZeneca is not scheduled to report earnings tomorrow"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-03"", ""headline"": ""AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT"", ""summary"": ""The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said.  It did not say what kind of cancer they plan to target.""}, {""date"": ""2023-12-03"", ""headline"": ""UPDATE 1-AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT"", ""summary"": ""Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.  The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said.""}, {""date"": ""2023-12-03"", ""headline"": ""AstraZeneca ties up with AI biologics company to develop cancer drug"", ""summary"": ""AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer, the latest tie-up in fast-expanding efforts to use artificial intelligence for drug discovery.  The collaboration aims to harness Absci\u2019s AI technology for large-scale protein analysis to find a viable oncology therapy \u2014 a leading focus of Anglo-Swedish drugmaker AstraZeneca.  The partnership adds to a flurry of agreements between big pharmaceutical companies and young AI businesses to build novel disease treatments and cut the costs of developing them.""}, {""date"": ""2023-12-04"", ""headline"": ""AstraZeneca price target lowered to 13,000 GBp from 14,000 GBp at JPMorgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""QQQ ETF Update, 12/6/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024"", ""summary"": ""Read about Pfizer's challenges in 2023, including decreased demand for COVID-19 vaccines and antiviral products, a destructive tornado, and a weight-loss treatment.""}, {""date"": ""2023-12-04"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.35% higher to $65.02 Monday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-04"", ""headline"": ""Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca"", ""summary"": ""Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.""}, {""date"": ""2023-12-04"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.67% to \u00a3102.66 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-04"", ""headline"": ""Merus falls after updated data for lung cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca"", ""summary"": ""By Chris Wack Absci shares were up 27% at $2.21 after the company entered into a collaboration with AstraZeneca to deliver an AI-designed antibody against an...""}, {""date"": ""2023-12-04"", ""headline"": ""AstraZeneca in pact with Absci to develop cancer drug based on AI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""Absci enters collab with AstraZeneca to advance AI-driven oncology candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""AstraZeneca, Absci tie up on cancer drug, FT reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""Validation data on prognostic test in stage I lung cancer presented at NACLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""International Wide-Moat Stocks On Sale - The December 2023 Heat Map"", ""summary"": ""Historical evidence says that while quality alone is a poor indicator of outperformance when combined with a decent valuation filter. Click here for a detailed analysis.""}, {""date"": ""2023-12-05"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slipped 1.55% to $64.01 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-05"", ""headline"": ""AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""2023-12-05"", ""headline"": ""Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy"", ""summary"": ""Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.""}, {""date"": ""2023-12-05"", ""headline"": ""Pfizer\u2019s Weight-Loss Pill Disappointment Is an Opening for Biotech Rivals"", ""summary"": ""Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.""}, {""date"": ""2023-12-05"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slid 1.19% to \u00a3101.44 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-05"", ""headline"": ""These 3 stocks are Cowen\u2019s best ideas for 2024 including AstraZeneca and Datadog"", ""summary"": ""New Year lists and resolutions are just part of the celebrations \u2013 and that holds true for stock investors, too. Every year, like clockwork, Wall Street\u2019s research firms and analysts will take some time to publish their \u2018top picks\u2019 and \u2018best ideas\u2019 for the coming year. This year, Cowen is obliging us, with its list of the \u2018Best Ideas for 2024,\u2019 and we can dig into their recommendations for some valuable New Year market advice. It\u2019s an interesting list, with stocks from varied sectors, from healt""}, {""date"": ""2023-12-05"", ""headline"": ""GLOBAL BROKER RATINGS: UBS raises Pirelli to 'buy'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""LONDON BROKER RATINGS: Goldman lifts Landsec and British Land"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.66% to $63.59 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-06"", ""headline"": ""Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.14% to \u00a3101.30 Wednesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-12-06"", ""headline"": ""Koselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas"", ""summary"": ""AstraZeneca's Koselugo (selumetinib) is now available in Malaysia as a monotherapy for the treatment of paediatric patients three years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)1. Koselugo, which received regulatory approval earlier this year, is a product approved by the National Pharmaceutical Regulatory Agency (NPRA) for NF1 with inoperable PN.""}, {""date"": ""2023-12-06"", ""headline"": ""Pfizer said to be leaving industry trade group BIO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""White House to back controversial patent ploy to fight drug costs, STAT says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""UPDATE 2-US urges makers of infant RSV shots to meet winter demand"", ""summary"": ""U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week.  The officials on Tuesday met with representatives of Sanofi , AstraZeneca and Thermo Fisher \""and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market,\"" the White House said in a statement.""}, {""date"": ""2023-12-07"", ""headline"": ""FTC warns pharma companies on excessive drug patenting"", ""summary"": ""The Federal Trade Commission (FTC) issued warning letters to several pharmaceutical companies, including AbbVie (ABBV) AstraZeneca (AZN), and Teva (TEVA), over excessive patenting of medications as Medicare negotiates drug costs with the pharma industry. Yahoo Finance Health Reporter Anjalee Khemlani explains the Biden administration's ideas to license patents to lower drug costs for patients. For more expert insight and the latest market action, click\u00a0here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-12-07"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR sank 0.13% to $63.51 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-07"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.32% to \u00a3100.98 Thursday, on what proved to be an all-around rough trading session for the stock market, with the FTSE...""}, {""date"": ""2023-12-07"", ""headline"": ""Gilead Sciences: The Bull Case Is More Powerful Than You Think"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck halts lung cancer trial for Keytruda combo after failure in main goal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-08"", ""headline"": ""AstraZeneca PLC ADR falls Friday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slumped 0.41% to $63.25 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-08"", ""headline"": ""AstraZeneca rises Friday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.24% to \u00a3101.22 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-08"", ""headline"": ""What The Fed Will Do After The November Non-Farm Payrolls Report"", ""summary"": ""The November NFP report showed a lower-than-average job increase, putting pressure on inflation rate. Check out my analysis on November jobs report.""}, {""date"": ""2023-12-09"", ""headline"": ""Week In Review: Abbisko Sells China Rights For CSF-1R Inhibitor To Merck In $605M Deal"", ""summary"": ""Abbisko selling China rights for CSF-1R inhibitor to Germany's Merck in a $605M deal is the headline this week. Click here to read more.""}, {""date"": ""2023-12-10"", ""headline"": ""Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS\u00ae or SOLIRIS\u00ae sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-10"", ""headline"": ""AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?"", ""summary"": ""It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge their drug development efforts -- and AstraZeneca's (NASDAQ: AZN) materials are no different.  Let's probe this issue by looking at the collaboration and acquisition activity that the company is pursuing.  It's no surprise that drugmakers are interested in using AI to accelerate the pace of drug development.""}, {""date"": ""2023-12-10"", ""headline"": ""Is Now the Right Time to Buy AstraZeneca Stock?"", ""summary"": ""The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock.""}, {""date"": ""2023-12-10"", ""headline"": ""Results from 24-week, LTE period of ALPHA Phase III trial presented at ASH"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
48,2023-12-10,63.25,2023-12-17,64.80000305175781,0.024505977102890375,U3,"[{""date"": ""2023-12-09"", ""headline"": ""Week In Review: Abbisko Sells China Rights For CSF-1R Inhibitor To Merck In $605M Deal"", ""summary"": ""Abbisko selling China rights for CSF-1R inhibitor to Germany's Merck in a $605M deal is the headline this week. Click here to read more.""}, {""date"": ""2023-12-10"", ""headline"": ""AstraZeneca says danicopan tests well as blood disorder treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-10"", ""headline"": ""Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS\u00ae or SOLIRIS\u00ae sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis"", ""summary"": ""WILMINGTON, Del., December 11, 2023--Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ULTOMIRIS\u00ae (ravulizumab-cwvz) or SOLIRIS\u00ae (eculizumab) continued to demonstrate clinical benefit for patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH).1""}, {""date"": ""2023-12-10"", ""headline"": ""AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?"", ""summary"": ""It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge their drug development efforts -- and AstraZeneca's (NASDAQ: AZN) materials are no different.  Let's probe this issue by looking at the collaboration and acquisition activity that the company is pursuing.  It's no surprise that drugmakers are interested in using AI to accelerate the pace of drug development.""}, {""date"": ""2023-12-10"", ""headline"": ""Is Now the Right Time to Buy AstraZeneca Stock?"", ""summary"": ""The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock.""}, {""date"": ""2023-12-10"", ""headline"": ""Results from 24-week, LTE period of ALPHA Phase III trial presented at ASH"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Icosavax to be acquired by AstraZeneca for $15.00 per share in cash, CVR"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""AstraZeneca to acquire vaccine maker Icosavax in ~$1.1B deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Icosavax enters agreement to be acquired by AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""AstraZeneca to Buy Icosavax for Up to $1.1 Bln -- Update"", ""summary"": ""By Ian Walker AstraZeneca said it would buy U.S.-based clinical-stage biopharmaceutical company Icosavax for up to $1.1 billion in a deal that expands its...""}, {""date"": ""2023-12-11"", ""headline"": ""Stock market today: Asian shares are mixed ahead of the Fed's decision on interest rates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Stock market today: Wall Street drifts after an inflation report and before the Fed's next decision"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.40% higher to $63.50 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-12-11"", ""headline"": ""AstraZeneca Is Feeling The Weight Of The Market In 2023"", ""summary"": ""AstraZeneca's stock is trading below its April 2022 highs, but AZN is executing well and making right moves to return and stay in growth mode. Read more here.""}, {""date"": ""2023-12-11"", ""headline"": ""AstraZeneca falls Monday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.26% to \u00a3100.96 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-11"", ""headline"": ""Novo Nordisk's unique structure gives it an extra edge \u2014 and risk"", ""summary"": ""Novo Nordisk's corporate structure has a few quirks that investors need to know about.""}, {""date"": ""2023-12-11"", ""headline"": ""AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""30 Largest Pharmaceutical Companies in the World"", ""summary"": ""In this article, we will be taking a look at the 30 largest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 Largest Pharmaceutical Companies in the World. The world\u2019s leading pharmaceutical companies became the center of attention for people all over the world as a [\u2026]""}, {""date"": ""2023-12-12"", ""headline"": ""LLY Down as Patients Regain Weight After Stopping Zepbound"", ""summary"": ""Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.""}, {""date"": ""2023-12-12"", ""headline"": ""Why AstraZeneca Is Buying Icosavax For $1.1 Billion"", ""summary"": ""AstraZeneca agreed to pay $1.1 billion for Icosavax to expand its reach into cutting-edge vaccine technology with Icosavax's innovative vaccine platform.""}, {""date"": ""2023-12-12"", ""headline"": ""AstraZeneca strikes \u00a3880m deal to buy US vaccine maker amid questions over Covid jab"", ""summary"": ""AstraZeneca has struck a deal worth up to \u00a3880m to buy a US vaccine maker as it battles against claims its Covid-19 jab was defective.""}, {""date"": ""2023-12-12"", ""headline"": ""AstraZeneca strikes \u00a3880m deal to buy US vaccine maker amid row over Covid jab"", ""summary"": ""AstraZeneca has struck a deal worth up to \u00a3880m to buy a US vaccine maker as it battles against claims its Covid-19 jab was defective.""}, {""date"": ""2023-12-12"", ""headline"": ""Stocks to Watch Tuesday: Alphabet, Hasbro, Oracle, AstraZeneca"", ""summary"": ""[**Alphabet (GOOGL)**](https://www.wsj.com/market-data/quotes/GOOGL): Google [lost an antitrust case](https://www.wsj.com/tech/google-loses-antitrust-case-brought-by-epic-games-651f5987) over the market power of its app store brought by the videogame maker Epic Games.""}, {""date"": ""2023-12-12"", ""headline"": ""Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock"", ""summary"": ""Tuesday brought favorable inflation data, and bullish investors are looking for stock winners.""}, {""date"": ""2023-12-12"", ""headline"": ""AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B"", ""summary"": ""AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.""}, {""date"": ""2023-12-12"", ""headline"": ""This Vaccine Stock Soars 47% After $1.1 Billion AstraZeneca Deal"", ""summary"": ""AstraZeneca agreed to acquire respiratory vaccine developer Icosavax in a cash deal expected to close in the first quarter of next year.""}, {""date"": ""2023-12-12"", ""headline"": ""Oracle, Hasbro fall; Icosavax, Perion Network rise, Tuesday, 12/12/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Oracle, Hasbro fall; Icosovax, Perion Network rise, Tuesday, 12/12/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.75% to \u00a3101.72 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-12"", ""headline"": ""AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data"", ""summary"": ""WILMINGTON, Del., December 12, 2023--AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform.""}, {""date"": ""2023-12-12"", ""headline"": ""AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B"", ""summary"": ""The deal signals the pharma company\u2019s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.""}, {""date"": ""2023-12-12"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""M & A News: AstraZeneca\u2019s (NASDAQ:AZN) $1.1B Bet on ICVX Sends Shares Soaring"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Trending tickers: Google | AstraZeneca | Hargreaves Lansdown | Broadcom"", ""summary"": ""The latest investor updates on stocks that are trending on Tuesday.""}, {""date"": ""2023-12-12"", ""headline"": ""Biggest stock movers today: Oracle, Workhorse Group, Icosavax and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Health Care Company AstraZeneca Announces Acquisition of Icosavax"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Biggest stock movers today: Oracle, Hasbro, Icosavax and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""AstraZeneca strikes $1bn deal to acquire its first vaccine company"", ""summary"": ""AstraZeneca has agreed to buy its first vaccine company in a deal worth up to $1.1bn, as the pharma group expands the infectious disease division it set up during the coronavirus pandemic.  The Anglo-Swedish drugmaker said on Tuesday that it had struck a deal for Seattle-based Icosavax, which has a potential vaccine for two common respiratory diseases that can cause severe illness in older adults: respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).  If it succeeds in a phase-3 trial, the vaccine candidate, dubbed IVX-A12, would compete with approved RSV shots from GSK and Pfizer, and potentially one from Moderna.""}, {""date"": ""2023-12-12"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""AstraZeneca to Buy Icosavax for Up to $1.1 Bln"", ""summary"": ""AstraZeneca said it would buy U.S.-based Icosavax for up to $1.1 billion in a deal that expands its vaccines and immune therapies late-stage pipeline.""}, {""date"": ""2023-12-12"", ""headline"": ""UPDATE 3-AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal"", ""summary"": ""AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.  Icosavax is developing a combination vaccine candidate targeting RSV and human metapneumovirus (hMPV).  RSV is a leading cause of pneumonia in toddlers and the elderly, while hMPV causes very similar respiratory tract infections.""}, {""date"": ""2023-12-12"", ""headline"": ""Why Is Icosavax (ICVX) Stock Up 46% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""M&A News: AstraZeneca\u2019s (NASDAQ:AZN) $1.1B Bet on ICVX Sends Shares Soaring"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Today\u2019s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on\u00a0Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Icosavax Shares Take Flight on Takeover by AstraZeneca"", ""summary"": ""By Colin Kellaher Shares of Icosavax jumped nearly 50% in premarket trading Tuesday after the vaccine developer agreed to be acquired by pharmaceutical giant...""}, {""date"": ""2023-12-12"", ""headline"": ""Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Market Today: Shift4Payments Surges on Acquisition Buzz, Alteryx in Buyout Talks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Biden administration secures 230K more RSV injections for infants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""AbbVie, AstraZeneca targeted for improper use of drug patents"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR rallied 3.00% to $65.90 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-13"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rallied 2.14% to \u00a3103.90 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-13"", ""headline"": ""AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition"", ""summary"": ""AstraZeneca acquires Icosavax, expanding its respiratory vaccine portfolio and offering potential benefits for both companies. Read here why AZN is a Buy.""}, {""date"": ""2023-12-13"", ""headline"": ""AstraZeneca call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Catalyst Watch: Spotlight on FedEx, Nike, Micron and gold stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.68% higher to $66.35 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-12-14"", ""headline"": ""The Zacks Analyst Blog Highlights Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources"", ""summary"": ""Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-12-14"", ""headline"": ""UPDATE 1-Drugmakers to push 230,000 more RSV infant shots to market, US says"", ""summary"": ""Manufacturers of RSV immunizations will make an additional 230,000 doses available for infants in January, the White House said on Thursday, after U.S. government officials met with suppliers to discuss meeting demand during winter.  Drugmakers and officials from President Joe Biden's administration have been holding meetings aimed at addressing tight supplies of the shot to prevent respiratory syncytial virus (RSV), a leading cause of hospitalization in infants and toddlers.""}, {""date"": ""2023-12-14"", ""headline"": ""Top Analyst Reports for Adobe, AstraZeneca & Intel"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), AstraZeneca PLC (AZN) and Intel Corporation (INTC).""}, {""date"": ""2023-12-14"", ""headline"": ""Biopharmaceutical Stocks: The Rally Has Just Begun"", ""summary"": ""With the recent rise in the XBI ETF, investors may begin to wonder if they 'missed the rally'. Read more to see my analysis.""}, {""date"": ""2023-12-14"", ""headline"": ""AstraZeneca rises Thursday, still underperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.75% to \u00a3104.68 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-12-15"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR slid 2.34% to $64.80 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-12-15"", ""headline"": ""Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More"", ""summary"": ""Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.""}, {""date"": ""2023-12-15"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slipped 2.69% to \u00a3101.86 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-15"", ""headline"": ""LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-15"", ""headline"": ""PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
49,2023-12-17,64.80000305175781,2023-12-24,66.29000091552734,0.02299379311108085,U3,"[{""date"": ""2023-12-18"", ""headline"": ""Compugen spikes after deal with Gilead for anti-tumor drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Compugen spikes 180% on $848M deal with Gilead for anti-tumor drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider"", ""summary"": ""In the most recent trading session, Astrazeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day.""}, {""date"": ""2023-12-18"", ""headline"": ""AstraZeneca PLC ADR rises Monday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rose 1.77% to $65.95 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-12-18"", ""headline"": ""11 Best European Dividend Stocks to Buy"", ""summary"": ""In this article, we will take a detailed look at the 11 Best European Dividend Stocks to Buy. For a quick overview of such stocks, read our article 5 Best European Dividend Stocks to Buy. European equities were laggards when compared to US stocks in 2023 as economic activity in the Eurozone continues to contract. In December, the Eurozone [\u2026]""}, {""date"": ""2023-12-18"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""AstraZeneca PLC shares rose 1.67% to \u00a3103.56 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-18"", ""headline"": ""XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector"", ""summary"": ""XLV comprises major healthcare industry players and offers a convenient and cost-effective way to invest in the sector. Find out my analysis of XLV ETF.""}, {""date"": ""2023-12-18"", ""headline"": ""13 Most Profitable Pharmaceutical Stocks Now"", ""summary"": ""In this article, we discuss the 13 most profitable pharmaceutical stocks to buy. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read the 5 Most Profitable Pharmaceutical Stocks Now. The healthcare sector encompasses a diverse range of companies, spanning pharmaceuticals, medical equipment and device [\u2026]""}, {""date"": ""2023-12-18"", ""headline"": ""Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Dividend Stocks: 4 To Choose for 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR sank 0.08% to $65.90 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-19"", ""headline"": ""13 Most Promising Healthcare Stocks According to Analysts"", ""summary"": ""In this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to [\u2026]""}, {""date"": ""2023-12-19"", ""headline"": ""Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka"", ""summary"": ""Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.""}, {""date"": ""2023-12-19"", ""headline"": ""5 Top Healthcare Stocks to Buy Now, According to Analysts \u2013 December 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer"", ""summary"": ""Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The""}, {""date"": ""2023-12-19"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.10% to \u00a3103.46 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2023-12-19"", ""headline"": ""Compugen stock rockets 160% on Gilead development deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Why Is Compugen (CGEN) Stock Up 189% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Compugen eligible to receive $10M payment upon dosing of AstraZeneca trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-20"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-20"", ""headline"": ""J&J submits sBLA to FDA for Rybrevant combo in non-small cell lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-20"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, still outperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 0.18% to $65.78 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-20"", ""headline"": ""QQQ ETF Update, 12/20/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-20"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC advanced 1.33% to \u00a3104.84 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-12-20"", ""headline"": ""COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""AstraZeneca, Ionis get US FDA nod for Wainua in \""important milestone\"""", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""LONDON BRIEFING: UK on brink of recession as economy contracts in Q3"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""Ionis Stock (NASDAQ:IONS) Advances as FDA Approves its Nerve Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""WAINUA\u2122 (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis"", ""summary"": ""WILMINGTON, Del., December 22, 2023--AstraZeneca and Ionis\u2019 WAINUA\u2122 (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.1 WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.2-4""}, {""date"": ""2023-12-21"", ""headline"": ""UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug"", ""summary"": ""The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.  The drug, branded as Wainua, is approved for patients with polyneuropathy, or nerve damage caused by hereditary transthyretin amyloidosis (ATTR-PN), which affects an estimated 40,000 patients globally.  Transthyretin amyloidosis is a progressive condition characterized by the build-up of abnormal protein deposits in the body's organs and tissues.""}, {""date"": ""2023-12-21"", ""headline"": ""Ionis, AstraZeneca get FDA approval for rare genetic disease treatment"", ""summary"": ""Ionis Pharmaceuticals and AstraZeneca's Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.""}, {""date"": ""2023-12-21"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.79% higher to $66.30 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-12-21"", ""headline"": ""Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry"", ""summary"": ""Which weight-loss stocks are good buys today?""}, {""date"": ""2023-12-21"", ""headline"": ""5 Biotech Acquisition Targets To Accumulate In 2024"", ""summary"": ""Discover why the current slump in biotech valuations presents a great opportunity for acquisitions. Click here to read what investors need to know.""}, {""date"": ""2023-12-21"", ""headline"": ""AstraZeneca falls Thursday, still outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.04% to \u00a3104.80 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE...""}, {""date"": ""2023-12-21"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""Cytokinetics gains amid report of Novartis, AstraZeneca takeover interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""Cytokinetics seeing 'strong interest' from strategic suitors, Dealreporter says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""AstraZeneca / Ionis' Wainua approved in U.S. for treatment of polyneuropathy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""Doubling Down On Gain Therapeutics"", ""summary"": ""Discover how Gain Therapeutics' physics-based approach to AI drug discovery is revolutionizing biotech investments and reducing financial risks.""}, {""date"": ""2023-12-22"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR slumped 0.02% to $66.29 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-22"", ""headline"": ""Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod"", ""summary"": ""FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.""}, {""date"": ""2023-12-22"", ""headline"": ""Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate"", ""summary"": ""FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.""}, {""date"": ""2023-12-22"", ""headline"": ""These 3 Big Pharma Stocks Are Making Big Plays With AI"", ""summary"": ""Opportunity is in the air with AI, and these pharma giants are seizing the moment.""}, {""date"": ""2023-12-22"", ""headline"": ""AstraZeneca falls Friday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.42% to \u00a3104.36 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2023-12-22"", ""headline"": ""Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""FDA approves AstraZeneca, Ionis drug for ATTRv-PN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""Biotech stocks set for a rebound in 2024, analysts say"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""AlloVir halts Phase 3 studies over efficacy, stock plunges 65%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-22"", ""headline"": ""Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten"", ""summary"": ""Cytokinetics' (CYTK) share price surged on rumors of potential takeover interest from Novartis and AstraZeneca. Read why I am staying on the sidelines.""}, {""date"": ""2023-12-22"", ""headline"": ""Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug"", ""summary"": ""The clearance of Wainua for transthyretin amyloidosis opens up a new front in a long-running commercial battle between Ionis and Alnylam.""}, {""date"": ""2023-12-22"", ""headline"": ""Wall Street Breakfast Podcast: Nike Warns On Soft Sales, Increased Promotions"", ""summary"": ""Retail shocker: Nike warns on soft sales. Cytokinetics soars amid report of Novartis, AstraZeneca takeover interest. Government opens investigation into frequent flyer programs.""}, {""date"": ""2023-12-22"", ""headline"": ""William Blair sees ATTR-PN market as large enough for two players"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
50,2023-12-24,66.29000091552734,2023-12-31,67.3499984741211,0.01599030840178295,U2,"[{""date"": ""2023-12-25"", ""headline"": ""Gracell jumps 61% to $9.97 after AstraZeneca buyout agreement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-25"", ""headline"": ""Biggest stock movers today: Gracell Biotechnologies, MBIA and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-25"", ""headline"": ""AstraZeneca to acquire Gracell in $1.2B transaction"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-25"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-25"", ""headline"": ""Gracell just downgraded at Piper Sandler, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-25"", ""headline"": ""Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-25"", ""headline"": ""5 Top Growth Stocks to Buy Now, According to Analysts \u2013 December 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""TOP NEWS: AstraZeneca buys Gracell to \""enrich\"" cell therapy pipeline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Investor Sentiment Improves; Dow Jumps Over 150 Points"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Why Is Cytokinetics (CYTK) Stock Up 70% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""16 Most Promising Dividend Stocks According to Analysts"", ""summary"": ""In this article, we discuss 16 most promising dividend stocks according to analysts. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Most Promising Dividend Stocks According to Analysts. This year brought a notable shift in the investment scene, where technology stocks surged [\u2026]""}, {""date"": ""2023-12-26"", ""headline"": ""PRESS DIGEST-British Business - Dec 27"", ""summary"": ""The following are the top stories on the business pages of British newspapers.  - AstraZeneca has struck a $1.2 billion deal to buy Gracell Biotechnologies, a Chinese company that creates innovative treatments for cancer and rare autoimmune diseases.  - EasyPark Group, the owner of brands including RingGo and ParkMobile, said customer names, phone numbers, addresses, email addresses and parts of credit card numbers had been taken in a cyberattack but said parking data had not been compromised.""}, {""date"": ""2023-12-26"", ""headline"": ""AstraZeneca PLC ADR rises Tuesday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.32% higher to $66.50 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-12-26"", ""headline"": ""AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals"", ""summary"": ""AstraZeneca  announced Tuesday it would acquire  Gracell Biotechnologies  in a deal valued at up to $1.2 billion.  Gracell is a Chinese biopharmaceutical company that focuses on cancer drug development.  AstraZeneca  said in a press release that it plans on buying the company to further its cell therapy ambitions.""}, {""date"": ""2023-12-26"", ""headline"": ""AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies"", ""summary"": ""AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio. The deal value is $2.00/share (equivalent to $10/ADS ADS of Gracell) plus a non-tradable contingent value right of $0.30/share (equivalent to $1.50/ADS of Gracell) in cash. The proposed acquisition will enrich AstraZeneca's growing pipeline of cell therapies with GC012F, a clinical-stage FasTCAR-enabled BCMA, and CD19 dual-targeting autologou""}, {""date"": ""2023-12-26"", ""headline"": ""Can AstraZeneca's Deal to Buy Gracell Biotechnologies Perk Up Its Price?"", ""summary"": ""AstraZeneca  has announced here on Tuesday that it is going to buy Gracell Biotechnologies  for $1.2 billion.  In this daily bar chart of AZN, below, I can see that prices have been in a downward path since April.  The daily On-Balance-Volume (OBV) line shows us a choppy rise since July as buyers of AZN have been more aggressive than sellers.""}, {""date"": ""2023-12-26"", ""headline"": ""AstraZeneca set to make one of its first acquisitions in China"", ""summary"": ""AstraZeneca is set to make one of its first acquisitions in China, announcing plans to acquire Gracell Biotechnologies for up to $1.2bn to increase its investment in cell therapies for treating cancer.  The Anglo-Swedish drugmaker has been trying to use its status as one of the largest drugmakers in China by sales to hunt for potential deals.""}, {""date"": ""2023-12-26"", ""headline"": ""Biggest stock movers today: Intel, RayzeBio, Nio, Airbnb, Lionsgate and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Crude Oil Rises Over 3%; US Home Prices Increase In October"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""CORRECTED-UPDATE 1-AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 bln deal"", ""summary"": ""AstraZeneca said on Tuesday it will buy China-based Gracell Biotechnologies for up to $1.2 billion as the  Anglo-Swedish pharma company furthers its cell therapy ambitions.  The cash deal aimed at bolstering AstraZeneca's portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.  \""The proposed acquisition of Gracell will complement AstraZeneca's existing capabilities and previous investments in cell therapy, where we have established our presence in CAR-T and T-cell receptor therapies in solid tumours\"", AstraZeneca's Oncology R&D Vice President Susan Galbraith said in a statement.""}, {""date"": ""2023-12-26"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion"", ""summary"": ""AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former\u2019s efforts to grow its cell therapies business.""}, {""date"": ""2023-12-26"", ""headline"": ""M & A News: Bristol-Myers (NYSE:BMY) Snaps Up RayzeBio (NASDAQ:RYZB) for $4.1B"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases"", ""summary"": ""WILMINGTON, Del., December 26, 2023--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition.""}, {""date"": ""2023-12-26"", ""headline"": ""Wall Street Breakfast Podcast: AstraZeneca To Buy Gracell Biotechnologies"", ""summary"": ""AstraZeneca to buy Gracell Biotechnologies for $1.2B. Manchester United agrees to sell 25% stake to Jim Ratcliffe for $1.3B. Nano Dimension offers to buy Stratasys for $16.50 a share.""}, {""date"": ""2023-12-26"", ""headline"": ""US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""Gracell ADSs Take Flight Premarket on $1.2B Takeover by AstraZeneca"", ""summary"": ""By Colin Kellaher American depositary shares of Gracell Biotechnologies surged nearly 60% in premarket trading Tuesday after the clinical-stage...""}, {""date"": ""2023-12-26"", ""headline"": ""JN.1 Omicron strain becomes dominant COVID variant in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Market Today: Pharma and Biotech Deal Values Surge Amid Patent Cliffs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Pharma and biotech deal values spike 35% in 2023: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing"", ""summary"": ""In the most recent trading session, Astrazeneca (AZN) closed at $67.35, indicating a +1.28% shift from the previous trading day.""}, {""date"": ""2023-12-27"", ""headline"": ""Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned"", ""summary"": ""With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE: BM""}, {""date"": ""2023-12-27"", ""headline"": ""AstraZeneca PLC ADR rises Wednesday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR rallied 1.28% to $67.35 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-27"", ""headline"": ""Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win"", ""summary"": ""Gracell Biotechnologies stock price skyrocketed by 360% this year after the AstraZeneca acquisition was announced. Click here for my look at GRCL and AZN stocks.""}, {""date"": ""2023-12-27"", ""headline"": ""AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion"", ""summary"": ""AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.""}, {""date"": ""2023-12-27"", ""headline"": ""AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""2023-12-27"", ""headline"": ""LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""AstraZeneca rises Wednesday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.88% to \u00a3105.28 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-27"", ""headline"": ""Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca"", ""summary"": ""The latest investor updates on stocks that are trending on Wednesday.""}, {""date"": ""2023-12-27"", ""headline"": ""FDA\u2019s new drug approvals for 2023 rise 51% from last year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)"", ""summary"": ""Cytokinetics' share price soared on positive results of aficamten in phase 3 trial, with potential as a best-in-class drug. Click here for my CYTK stock update.""}, {""date"": ""2023-12-27"", ""headline"": ""Cytokinetics may be worth $90+ a share in potential deal amid Phase 3 data - UFP"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Cytokinetics may be worth $90+ in potential acquisition after Phase 3 data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Gracell price target raised by $3 at Wells Fargo, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""What You Missed On Wall Street On Friday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors despite losses on the day"", ""summary"": ""The AstraZeneca PLC ADR shed 0.07% to $67.30 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-12-28"", ""headline"": ""AstraZeneca rises Thursday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.44% to \u00a3105.74 Thursday, on what proved to be an all-around rough trading session for the stock market, with the FTSE...""}, {""date"": ""2023-12-28"", ""headline"": ""Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Buy AstraZeneca Stock. It Looks Much Better Going Into 2024."", ""summary"": ""The Big Pharma mainstay is set to deliver double-digit earnings growth, driven by a diverse portfolio of blockbusters and promising newcomers.""}, {""date"": ""2023-12-28"", ""headline"": ""AstraZeneca looks much better heading into 2024, Barron's says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""CytoSorbents drops as blood purification system fails key trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""The Decline In Global Bond Yields Supports Stock Indices"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-29"", ""headline"": ""Biotech Stocks Were Tanking. The Cure? M&A."", ""summary"": ""Biotech ETFs trailed the S&P 500 a lot as the companies suffered from rising rates. But a wave of deals beginning in October gave new life to the sector.""}, {""date"": ""2023-12-29"", ""headline"": ""Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $67.35, moving +0.07% from the previous trading session.""}, {""date"": ""2023-12-29"", ""headline"": ""2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer"", ""summary"": ""During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. as it continues its efforts to tap pharma innovations from China\u2019s biotech industry. Although this year, Covid-19 stars, namely Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), were left in the dust with their shares tumbling, Wall Street is expecting a rebound as both are making efforts to enhance their cancer treatment businesses. AstraZeneca\u2019s Newes""}, {""date"": ""2023-12-29"", ""headline"": ""AstraZeneca PLC ADR underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""The AstraZeneca PLC ADR inched 0.07% higher to $67.35 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-12-29"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.25% to \u00a3106.00 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2023-12-29"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-31"", ""headline"": ""Week In Review: $1.7B Collaboration Between Elpiscience And Astellas Is Final 2023 Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-31"", ""headline"": ""Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-31"", ""headline"": ""AstraZeneca looking much better going into 2024, Barron's says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
51,2023-12-31,67.3499984741211,2024-01-07,68.37999725341797,0.015293226468188426,U2,"[{""date"": ""2023-12-31"", ""headline"": ""Week In Review: $1.7B Collaboration Between Elpiscience And Astellas Is Final 2023 Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-31"", ""headline"": ""Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-31"", ""headline"": ""AstraZeneca looking much better going into 2024, Barron's says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-01"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors despite daily gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-01"", ""headline"": ""Icosavax just downgraded at Guggenheim, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-01"", ""headline"": ""AstraZeneca, Sanofi RSV infant shot authorized in China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-01"", ""headline"": ""LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-01"", ""headline"": ""AstraZeneca and Sanofi received approval in China for RSV antibody"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-01"", ""headline"": ""LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-01"", ""headline"": ""Fly Intel: Top five weekend stock stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""AstraZeneca PLC ADR underperforms Wednesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""C4X Discovery Shares Rise on AstraZeneca Milestone Payment"", ""summary"": ""By Ian Walker C4X Discovery Holdings shares rose as much as 66% in early trade after the company said it has received a $11 million milestone payment from...""}, {""date"": ""2024-01-02"", ""headline"": ""AstraZeneca just downgraded at Jefferies, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""C4X receives USD11 million from AstraZeneca following NRF2 trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants"", ""summary"": ""Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) Beyfortus (nirsevimab), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season. Beyfortus will be available during the 2024-2025 RSV season. Beyfortus is the first approved preventive option to protect against RSV in a broad infant""}, {""date"": ""2024-01-02"", ""headline"": ""Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca"", ""summary"": ""Allorion Therapeutics (\""Allorion\""), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).""}, {""date"": ""2024-01-02"", ""headline"": ""AstraZeneca (NASDAQ:AZN) Gains on New Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""Biora shares 'reaching a key tipping point,' says H.C. Wainwright"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""AstraZeneca (NASDAQ:AZN) Gains With New Drug Movement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""AstraZeneca, Allorion form pact to advance EGFR inhibitor"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""AstraZeneca signs exclusive option and global license agreement with Allorion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""Biora Therapeutics progresses research collaboration for BioJet platform"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""LONDON MARKET MIDDAY: London stocks make largely soft start to 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""AstraZeneca PLC ADR outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""On This Day: Pelosi is 1st woman elected speaker of the House"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024"", ""summary"": ""I believe that 2024 will be good for equities. Potential rate cuts are a big impending catalyst. However, even with a bullish outlook, I would further strengthen my income portfolio by considering exposure to quality dividend-paying stocks. Of course, there are attractive growth stock stories, but it\u2019s important to limit exposure to growth and penny stocks to 40% to 50% of your total portfolio. Among dividend-paying stocks, the good news is that there are several that trade at a valuation gap. I""}, {""date"": ""2024-01-03"", ""headline"": ""LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""4 Red-Hot Stocks Top Wednesday\u2019s Biggest Wall Street Upgrades and Downgrades"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""GLOBAL BROKER RATINGS: Jefferies raises GSK, cuts AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""IN BRIEF: Nuformix narrows annual loss as develops drug assets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""TAKING AIM: C4X's Astra deal shows value to investors - Shore Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""AstraZeneca PLC ADR falls Friday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""FDA evaluating reports of GLP-1 drugs and negative side effects"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Why the Market Dipped But Astrazeneca (AZN) Gained Today"", ""summary"": ""Astrazeneca (AZN) reachead $68.78 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.""}, {""date"": ""2024-01-04"", ""headline"": ""Masking returns to some U.S. hospitals amid rising COVID, flu cases"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Interesting AZN Put And Call Options For February 23rd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Bullish Two Hundred Day Moving Average Cross - AZN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know"", ""summary"": ""The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close.""}, {""date"": ""2024-01-05"", ""headline"": ""Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk"", ""summary"": ""Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.""}, {""date"": ""2024-01-05"", ""headline"": ""Icosavax CVR Seems Fairly Valued"", ""summary"": ""AstraZeneca plans to acquire Icosavax for $15/share in cash and one non-tradable CVR per share. Learn why I rate ICVX stock a hold.""}, {""date"": ""2024-01-05"", ""headline"": ""Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs"", ""summary"": ""Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.""}, {""date"": ""2024-01-05"", ""headline"": ""Should You Add AstraZeneca PLC (AZN)?"", ""summary"": ""ClearBridge Investments, an investment management company, released its \u201cClearBridge Dividend Strategy\u201d fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The market recovered in 2023 following a sharp decline in 2022, driven by excitement about artificial intelligence and an improving forecast for interest rates. The strategy underperformed the benchmark S&P 500 [\u2026]""}, {""date"": ""2024-01-05"", ""headline"": ""With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Florida wins FDA nod for mass drug imports from Canada (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Florida to become first state to win FDA nod for mass drug imports from Canada: NYT"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-06"", ""headline"": ""4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip"", ""summary"": ""The growth-fueled Nasdaq Composite is 9% below its record high, meaning amazing deals are still hiding in plain sight.""}, {""date"": ""2024-01-07"", ""headline"": ""ClearBridge Dividend Strategy Q4 2023 Portfolio Manager Commentary"", ""summary"": ""The ClearBridge Dividend Strategy underperformed its S&P 500 Index benchmark during Q2 2023. Click here to read the full fund letter.""}]",{}
52,2024-01-07,68.37999725341797,2024-01-14,69.41999816894531,0.0152091394749998,U2,"[{""date"": ""2024-01-07"", ""headline"": ""GSK, Teva, AstraZeneca under Senate probe over asthma inhaler pricing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""ClearBridge Dividend Strategy Q4 2023 Portfolio Manager Commentary"", ""summary"": ""The ClearBridge Dividend Strategy underperformed its S&P 500 Index benchmark during Q2 2023. Click here to read the full fund letter.""}, {""date"": ""2024-01-08"", ""headline"": ""GSK to buy Aiolos Bio for up to $1.4B to expand respiratory portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""AstraZeneca PLC ADR rises Monday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR advanced 1.21% to $69.21 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2024-01-08"", ""headline"": ""Johnson & Johnson: EPS Growth Returns In 2024, JPM Healthcare Conference On Tap"", ""summary"": ""Investors are showing interest in Johnson & Johnson as they move away from glamour growth stocks. Read more to see our analysis on JNJ stock.""}, {""date"": ""2024-01-08"", ""headline"": ""Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer"", ""summary"": ""Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.""}, {""date"": ""2024-01-08"", ""headline"": ""AstraZeneca rises Monday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.13% to \u00a3107.72 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...""}, {""date"": ""2024-01-08"", ""headline"": ""Cytokinetics falls amid no sale announcement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""AstraZeneca put volume heavy and directionally bearish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Compugen to receive $10M milestone payment from AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Zura Bio names Robert Lisicki as COO, Kiran Nistala as CMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Daiichi Sankyo rises on reported FDA filing for cancer drug developed with AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""2024-01-09"", ""headline"": ""International Wide-Moat Stocks On Sale - The January 2024 Heat Map"", ""summary"": ""Based on available data, stocks with wide-moat rating that also fit into 4- or 5-star category deserve to be the subject of further analysis. Read more here.""}, {""date"": ""2024-01-09"", ""headline"": ""AstraZeneca PLC ADR falls Tuesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR sank 0.43% to $68.91 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2024-01-09"", ""headline"": ""AstraZeneca rises Tuesday, outperforms market"", ""summary"": ""Shares of AstraZeneca PLC advanced 1.21% to \u00a3109.02 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2024-01-09"", ""headline"": ""Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""Cytokinetics plunges amid no deal announcement, Novartis backing away (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market"", ""summary"": ""Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.""}, {""date"": ""2024-01-10"", ""headline"": ""AstraZeneca PLC ADR outperforms market on strong trading day"", ""summary"": ""The AstraZeneca PLC ADR inched 0.96% higher to $69.57 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2024-01-10"", ""headline"": ""AIM ImmunoTech announces open enrollment for Phase 1b/2 study of Ampligen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""Absci appoints Sir Pangalos to its board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Here's Why Astrazeneca (AZN) Fell More Than Broader Market"", ""summary"": ""Astrazeneca (AZN) closed at $69.18 in the latest trading session, marking a -0.56% move from the prior day.""}, {""date"": ""2024-01-11"", ""headline"": ""AstraZeneca PLC ADR falls Thursday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR dropped 0.56% to $69.18 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2024-01-11"", ""headline"": ""Leerink Partners Reaffirms Their Buy Rating on AstraZeneca (AZN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""AstraZeneca outperforms market despite losses on the day"", ""summary"": ""Shares of AstraZeneca PLC inched down 0.64% to \u00a3108.30 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE...""}, {""date"": ""2024-01-11"", ""headline"": ""Cytokinetics plunges amid no deal announcement as JPMorgan conf set to end"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Innate Pharma: Worth A Deeper Look"", ""summary"": ""Innate Pharma has strong financial backing and multiple partnerships, making it an attractive investment opportunity. Find out if IPHA stock is a buy.""}, {""date"": ""2024-01-11"", ""headline"": ""Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-12"", ""headline"": ""Astrazeneca (AZN) Laps the Stock Market: Here's Why"", ""summary"": ""In the latest trading session, Astrazeneca (AZN) closed at $69.42, marking a +0.35% move from the previous day.""}, {""date"": ""2024-01-12"", ""headline"": ""AstraZeneca PLC ADR rises Friday, outperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.35% higher to $69.42 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2024-01-12"", ""headline"": ""Why Investors Need to Take Advantage of These 2 Medical Stocks Now"", ""summary"": ""The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.""}, {""date"": ""2024-01-12"", ""headline"": ""AstraZeneca rises Friday, still underperforms market"", ""summary"": ""Shares of AstraZeneca PLC inched up 0.30% to \u00a3108.62 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100...""}, {""date"": ""2024-01-14"", ""headline"": ""First RSV shots, groundbreaking gene therapy among 2024 drugs to watch"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
53,2024-01-14,69.41999816894531,2024-01-21,66.25,-0.04566404858194584,D5,"[{""date"": ""2024-01-14"", ""headline"": ""Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-14"", ""headline"": ""First RSV shots, groundbreaking gene therapy among 2024 drugs to watch"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-15"", ""headline"": ""LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-15"", ""headline"": ""AstraZeneca just downgraded at UBS, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-15"", ""headline"": ""AstraZeneca outperforms market despite losses on the day"", ""summary"": ""AstraZeneca PLC shares inched down 0.09% to \u00a3108.52 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100...""}, {""date"": ""2024-01-15"", ""headline"": ""The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca"", ""summary"": ""Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.""}, {""date"": ""2024-01-16"", ""headline"": ""AstraZeneca PLC ADR underperforms Tuesday when compared to competitors"", ""summary"": ""The AstraZeneca PLC ADR shed 3.10% to $67.27 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2024-01-16"", ""headline"": ""Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio"", ""summary"": ""Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.""}, {""date"": ""2024-01-16"", ""headline"": ""4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn\u2019t One."", ""summary"": ""Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.""}, {""date"": ""2024-01-16"", ""headline"": ""AstraZeneca price target raised by 500 GBp at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-16"", ""headline"": ""AstraZeneca falls Tuesday, underperforms market"", ""summary"": ""Shares of AstraZeneca PLC slipped 1.90% to \u00a3106.46 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100...""}, {""date"": ""2024-01-16"", ""headline"": ""Trending tickers: Apple | Tesla | AstraZeneca | Hugo Boss"", ""summary"": ""The latest investor updates on stocks that are trending on Tuesday.""}, {""date"": ""2024-01-16"", ""headline"": ""LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-16"", ""headline"": ""GLOBAL BROKER RATINGS: UBS says 'buy' Sanofi, but 'sell' AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-16"", ""headline"": ""Sell AstraZeneca, says UBS, which upgrades European rivals including GSK"", ""summary"": ""UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.""}, {""date"": ""2024-01-17"", ""headline"": ""AstraZeneca PLC ADR falls Wednesday, underperforms market"", ""summary"": ""The AstraZeneca PLC ADR slipped 1.52% to $66.25 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...""}, {""date"": ""2024-01-17"", ""headline"": ""AstraZeneca falls Wednesday, underperforms market"", ""summary"": ""AstraZeneca PLC shares slipped 1.88% to \u00a3104.46 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100...""}, {""date"": ""2024-01-17"", ""headline"": ""Check Out What Whales Are Doing With AZN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-17"", ""headline"": ""Pfizer faces setback in Enhertu patent dispute with Daiichi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""AstraZeneca reports positive liver cancer study results for Imfinzi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""AstraZeneca PNH drug gets first regulatory approval in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing"", ""summary"": ""Astrazeneca (AZN) closed the most recent trading day at $66.52, moving +0.41% from the previous trading session.""}, {""date"": ""2024-01-18"", ""headline"": ""AstraZeneca PLC ADR rises Thursday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.41% higher to $66.52 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2024-01-18"", ""headline"": ""Eli Lilly\u2019s Jaypirca to lead BTK inhibitor market for leukemia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""AstraZeneca falls Thursday, underperforms market"", ""summary"": ""AstraZeneca PLC shares inched down 0.13% to \u00a3104.32 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE...""}, {""date"": ""2024-01-18"", ""headline"": ""Medicare drug price negotiations hit critical phase"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Week in Review: Lee\u2019s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today"", ""summary"": ""In the closing of the recent trading day, Astrazeneca (AZN) stood at $66.54, denoting a +0.03% change from the preceding trading day.""}, {""date"": ""2024-01-19"", ""headline"": ""Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN).""}, {""date"": ""2024-01-19"", ""headline"": ""AstraZeneca PLC ADR rises Friday, still underperforms market"", ""summary"": ""The AstraZeneca PLC ADR inched 0.03% higher to $66.54 Friday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2024-01-19"", ""headline"": ""IMFINZI\u00ae (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization"", ""summary"": ""WILMINGTON, Del., January 19, 2024--Positive results from the EMERALD-1 Phase III trial showed AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolization.""}, {""date"": ""2024-01-19"", ""headline"": ""Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?"", ""summary"": ""Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.""}, {""date"": ""2024-01-19"", ""headline"": ""AstraZeneca rises Friday, outperforms market"", ""summary"": ""AstraZeneca PLC shares inched up 0.73% to \u00a3105.08 Friday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100...""}, {""date"": ""2024-01-19"", ""headline"": ""AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled"", ""summary"": """"}, {""date"": ""2024-01-19"", ""headline"": ""AstraZeneca says Imfinzi combo improved survival in carcinoma patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""AstraZeneca reports Voydeya granted regulatory approval in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-21"", ""headline"": ""Week In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure Therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-21"", ""headline"": ""The total return for AstraZeneca (LON:AZN) investors has risen faster than earnings growth over the last five years"", ""summary"": ""Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...""}]",{}
